adalimumab vs etanercept

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriatic Arthritis

Shared mechanism: TNF-alpha · full Psoriatic Arthritis pipeline

adalimumab · Humira

Marketed by AbbVie and partners

Approved in Psoriatic Arthritismonoclonal antibody (fully human IgG1)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT07398651 (registry estimate)

No aligned efficacy figure on record for this race.

etanercept · Enbrel

Marketed by Amgen and partners

Approved in Psoriatic Arthritisfusion protein
Reliable signal

NCT00317499 · Phase 3 · completed

Participants were randomized to etanercept or placebo with quadruple-blinding. Substantially more patients on etanercept achieved a meaningful joint-symptom response than on placebo, a highly significant difference.

Reported efficacy

Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 (Baseline and week 24): ACR20 response at week 24 (primary endpoint), SEAM-PsA: etanercept monotherapy 60.9% vs methotrexate monotherapy 50.7% (P=0.029); etanercept+methotrexate combination 65.0% vs methotrexate monotherapy 50.7% (P=0.005) (met)

Result source: NCT02376790

Results for Psoriatic Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumabetanercept
ACR20—Not posted · NCT0064617860.9% vs 50.7%vs Methotrexatewk 24 · n 284NCT02376790
15 other results
  • 65% vs 50.7% wk 24 · n 283 · Phase 3 · primary NCT02376790
  • 83.1% vs 70.7% wk 48 · n 284 · Phase 3 · secondary NCT02376790
  • 80.4% vs 70.7% wk 48 · n 283 · Phase 3 · secondary NCT02376790
  • 77% vs 66.3% wk 36 · n 284 · Phase 3 · secondary NCT02376790
  • 74.2% vs 66.3% wk 36 · n 283 · Phase 3 · secondary NCT02376790
  • 67.6% vs 56.9% wk 24 · n 284 · Phase 3 · secondary NCT02376790
  • 71.9% vs 56.9% wk 24 · n 283 · Phase 3 · secondary NCT02376790
  • 69.5% vs 58.5% wk 16 · n 284 · Phase 3 · secondary NCT02376790
  • 71.8% vs 58.5% wk 16 · n 283 · Phase 3 · secondary NCT02376790
  • 65.5% vs 46.8% wk 12 · n 284 · Phase 3 · secondary NCT02376790
  • 70.3% vs 46.8% wk 12 · n 283 · Phase 3 · secondary NCT02376790
  • 60.2% vs 46.5% wk 8 · n 284 · Phase 3 · secondary NCT02376790
  • 60.8% vs 46.5% wk 8 · n 283 · Phase 3 · secondary NCT02376790
  • 44.3% vs 25% wk 4 · n 284 · Phase 3 · secondary NCT02376790
  • 46.4% vs 25% wk 4 · n 283 · Phase 3 · secondary NCT02376790
ACR50—Not posted · NCT0064617863% vs 49.3%vs Methotrexatewk 48 · n 284NCT02376790
13 other results
  • 60.2% vs 49.3% wk 48 · n 283 · Phase 3 · secondary NCT02376790
  • 57.3% vs 41.8% wk 36 · n 284 · Phase 3 · secondary NCT02376790
  • 56% vs 41.8% wk 36 · n 283 · Phase 3 · secondary NCT02376790
  • 44.4% vs 30.6% wk 24 · n 284 · Phase 3 · secondary NCT02376790
  • 45.7% vs 30.6% wk 24 · n 283 · Phase 3 · secondary NCT02376790
  • 43.8% vs 29.2% wk 16 · n 284 · Phase 3 · secondary NCT02376790
  • 43.4% vs 29.2% wk 16 · n 283 · Phase 3 · secondary NCT02376790
  • 40.4% vs 16.9% wk 12 · n 284 · Phase 3 · secondary NCT02376790
  • 39.2% vs 16.9% wk 12 · n 283 · Phase 3 · secondary NCT02376790
  • 31.3% vs 15.1% wk 8 · n 284 · Phase 3 · secondary NCT02376790
  • 30.1% vs 15.1% wk 8 · n 283 · Phase 3 · secondary NCT02376790
  • 16.5% vs 6% wk 4 · n 284 · Phase 3 · secondary NCT02376790
  • 18.8% vs 6% wk 4 · n 283 · Phase 3 · secondary NCT02376790
PASI 75—Not posted · NCT00646178—Not posted · NCT00317499
Minimal disease activity41.5% vs 13.1%vs MTXwk 16 · n 123NCT02814175
7 other results
  • 53.8% vs 52.4% wk 48 · n 65 · Phase 4 · secondary NCT03739853
  • 46.2% vs 36.5% wk 36 · n 65 · Phase 4 · secondary NCT03739853
  • 54.9% vs 66.7% wk 32 · n 91 · Phase 4 · secondary NCT02814175
  • 80.4% vs 66.7% wk 32 · n 51 · Phase 4 · secondary NCT02814175
  • 29.8% vs 66.7% wk 32 · n 57 · Phase 4 · secondary NCT02814175
  • 55.4% vs 57.1% wk 24 · n 65 · Phase 4 · secondary NCT03739853
  • 64.6% vs 63.5% wk 12 · n 65 · Phase 4 · secondary NCT03739853
51.3% vs 35.8%vs Methotrexatewk 48 · n 284NCT02376790
13 other results
  • 53.2% vs 35.8% wk 48 · n 283 · Phase 3 · secondary NCT02376790
  • 43.5% vs 30.3% wk 36 · n 284 · Phase 3 · secondary NCT02376790
  • 46.7% vs 30.3% wk 36 · n 283 · Phase 3 · secondary NCT02376790
  • 35.9% vs 22.9% wk 24 · n 284 · Phase 3 · secondary NCT02376790
  • 35.7% vs 22.9% wk 24 · n 283 · Phase 3 · secondary NCT02376790
  • 39.5% vs 25.7% wk 24 · n 284 · Phase 3 · secondary NCT02376790
  • 39.1% vs 25.7% wk 24 · n 283 · Phase 3 · secondary NCT02376790
  • 29.9% vs 11.6% wk 12 · n 284 · Phase 3 · secondary NCT02376790
  • 29.1% vs 11.6% wk 12 · n 283 · Phase 3 · secondary NCT02376790
  • 9.4% vs 3% wk 8 · n 284 · Phase 3 · secondary NCT02376790
  • 7.4% vs 3% wk 8 · n 283 · Phase 3 · secondary NCT02376790
  • 11.1% vs 5.7% wk 4 · n 284 · Phase 3 · secondary NCT02376790
  • 12.6% vs 5.7% wk 4 · n 283 · Phase 3 · secondary NCT02376790
HAQ-DI, change-0.5 vs -0.3vs MTXwk 16 · n 116NCT02814175-0.5 vs -0.4vs Methotrexatewk 16 · n 284NCT02376790
15 other results
  • -0.5 vs -0.4 wk 16 · n 283 · Phase 3 · secondary NCT02376790
  • -0.4 vs -0.3 wk 12 · n 284 · Phase 3 · secondary NCT02376790
  • -0.5 vs -0.3 wk 12 · n 283 · Phase 3 · secondary NCT02376790
  • -0.4 vs -0.3 wk 8 · n 284 · Phase 3 · secondary NCT02376790
  • -0.4 vs -0.3 wk 8 · n 283 · Phase 3 · secondary NCT02376790
  • -0.4 vs -0.4 wk 24 · n 284 · Phase 3 · secondary NCT02376790
  • -0.5 vs -0.4 wk 24 · n 283 · Phase 3 · secondary NCT02376790
  • -0.4 vs -0.4 wk 24 · n 258 · Phase 3 · secondary NCT02376790
  • -0.5 vs -0.4 wk 24 · n 257 · Phase 3 · secondary NCT02376790
  • -0.3 vs -0.2 wk 4 · n 284 · Phase 3 · secondary NCT02376790
  • -0.3 vs -0.2 wk 4 · n 283 · Phase 3 · secondary NCT02376790
  • -0.5 vs -0.5 wk 36 · n 284 · Phase 3 · secondary NCT02376790
  • -0.5 vs -0.5 wk 36 · n 283 · Phase 3 · secondary NCT02376790
  • -0.6 vs -0.5 wk 48 · n 284 · Phase 3 · secondary NCT02376790
  • -0.6 vs -0.5 wk 48 · n 283 · Phase 3 · secondary NCT02376790

ACR20

adalimumab
—Not posted · NCT00646178
etanercept
60.9% vs 50.7%vs Methotrexatewk 24 · n 284NCT02376790
15 other results
  • 65% vs 50.7% wk 24 · n 283 · Phase 3 · primary NCT02376790
  • 83.1% vs 70.7% wk 48 · n 284 · Phase 3 · secondary NCT02376790
  • 80.4% vs 70.7% wk 48 · n 283 · Phase 3 · secondary NCT02376790
  • 77% vs 66.3% wk 36 · n 284 · Phase 3 · secondary NCT02376790
  • 74.2% vs 66.3% wk 36 · n 283 · Phase 3 · secondary NCT02376790
  • 67.6% vs 56.9% wk 24 · n 284 · Phase 3 · secondary NCT02376790
  • 71.9% vs 56.9% wk 24 · n 283 · Phase 3 · secondary NCT02376790
  • 69.5% vs 58.5% wk 16 · n 284 · Phase 3 · secondary NCT02376790
  • 71.8% vs 58.5% wk 16 · n 283 · Phase 3 · secondary NCT02376790
  • 65.5% vs 46.8% wk 12 · n 284 · Phase 3 · secondary NCT02376790
  • 70.3% vs 46.8% wk 12 · n 283 · Phase 3 · secondary NCT02376790
  • 60.2% vs 46.5% wk 8 · n 284 · Phase 3 · secondary NCT02376790
  • 60.8% vs 46.5% wk 8 · n 283 · Phase 3 · secondary NCT02376790
  • 44.3% vs 25% wk 4 · n 284 · Phase 3 · secondary NCT02376790
  • 46.4% vs 25% wk 4 · n 283 · Phase 3 · secondary NCT02376790

ACR50

adalimumab
—Not posted · NCT00646178
etanercept
63% vs 49.3%vs Methotrexatewk 48 · n 284NCT02376790
13 other results
  • 60.2% vs 49.3% wk 48 · n 283 · Phase 3 · secondary NCT02376790
  • 57.3% vs 41.8% wk 36 · n 284 · Phase 3 · secondary NCT02376790
  • 56% vs 41.8% wk 36 · n 283 · Phase 3 · secondary NCT02376790
  • 44.4% vs 30.6% wk 24 · n 284 · Phase 3 · secondary NCT02376790
  • 45.7% vs 30.6% wk 24 · n 283 · Phase 3 · secondary NCT02376790
  • 43.8% vs 29.2% wk 16 · n 284 · Phase 3 · secondary NCT02376790
  • 43.4% vs 29.2% wk 16 · n 283 · Phase 3 · secondary NCT02376790
  • 40.4% vs 16.9% wk 12 · n 284 · Phase 3 · secondary NCT02376790
  • 39.2% vs 16.9% wk 12 · n 283 · Phase 3 · secondary NCT02376790
  • 31.3% vs 15.1% wk 8 · n 284 · Phase 3 · secondary NCT02376790
  • 30.1% vs 15.1% wk 8 · n 283 · Phase 3 · secondary NCT02376790
  • 16.5% vs 6% wk 4 · n 284 · Phase 3 · secondary NCT02376790
  • 18.8% vs 6% wk 4 · n 283 · Phase 3 · secondary NCT02376790

PASI 75

adalimumab
—Not posted · NCT00646178
etanercept
—Not posted · NCT00317499

Minimal disease activity

adalimumab
41.5% vs 13.1%vs MTXwk 16 · n 123NCT02814175
7 other results
  • 53.8% vs 52.4% wk 48 · n 65 · Phase 4 · secondary NCT03739853
  • 46.2% vs 36.5% wk 36 · n 65 · Phase 4 · secondary NCT03739853
  • 54.9% vs 66.7% wk 32 · n 91 · Phase 4 · secondary NCT02814175
  • 80.4% vs 66.7% wk 32 · n 51 · Phase 4 · secondary NCT02814175
  • 29.8% vs 66.7% wk 32 · n 57 · Phase 4 · secondary NCT02814175
  • 55.4% vs 57.1% wk 24 · n 65 · Phase 4 · secondary NCT03739853
  • 64.6% vs 63.5% wk 12 · n 65 · Phase 4 · secondary NCT03739853
etanercept
51.3% vs 35.8%vs Methotrexatewk 48 · n 284NCT02376790
13 other results
  • 53.2% vs 35.8% wk 48 · n 283 · Phase 3 · secondary NCT02376790
  • 43.5% vs 30.3% wk 36 · n 284 · Phase 3 · secondary NCT02376790
  • 46.7% vs 30.3% wk 36 · n 283 · Phase 3 · secondary NCT02376790
  • 35.9% vs 22.9% wk 24 · n 284 · Phase 3 · secondary NCT02376790
  • 35.7% vs 22.9% wk 24 · n 283 · Phase 3 · secondary NCT02376790
  • 39.5% vs 25.7% wk 24 · n 284 · Phase 3 · secondary NCT02376790
  • 39.1% vs 25.7% wk 24 · n 283 · Phase 3 · secondary NCT02376790
  • 29.9% vs 11.6% wk 12 · n 284 · Phase 3 · secondary NCT02376790
  • 29.1% vs 11.6% wk 12 · n 283 · Phase 3 · secondary NCT02376790
  • 9.4% vs 3% wk 8 · n 284 · Phase 3 · secondary NCT02376790
  • 7.4% vs 3% wk 8 · n 283 · Phase 3 · secondary NCT02376790
  • 11.1% vs 5.7% wk 4 · n 284 · Phase 3 · secondary NCT02376790
  • 12.6% vs 5.7% wk 4 · n 283 · Phase 3 · secondary NCT02376790

HAQ-DI, change

adalimumab
-0.5 vs -0.3vs MTXwk 16 · n 116NCT02814175
etanercept
-0.5 vs -0.4vs Methotrexatewk 16 · n 284NCT02376790
15 other results
  • -0.5 vs -0.4 wk 16 · n 283 · Phase 3 · secondary NCT02376790
  • -0.4 vs -0.3 wk 12 · n 284 · Phase 3 · secondary NCT02376790
  • -0.5 vs -0.3 wk 12 · n 283 · Phase 3 · secondary NCT02376790
  • -0.4 vs -0.3 wk 8 · n 284 · Phase 3 · secondary NCT02376790
  • -0.4 vs -0.3 wk 8 · n 283 · Phase 3 · secondary NCT02376790
  • -0.4 vs -0.4 wk 24 · n 284 · Phase 3 · secondary NCT02376790
  • -0.5 vs -0.4 wk 24 · n 283 · Phase 3 · secondary NCT02376790
  • -0.4 vs -0.4 wk 24 · n 258 · Phase 3 · secondary NCT02376790
  • -0.5 vs -0.4 wk 24 · n 257 · Phase 3 · secondary NCT02376790
  • -0.3 vs -0.2 wk 4 · n 284 · Phase 3 · secondary NCT02376790
  • -0.3 vs -0.2 wk 4 · n 283 · Phase 3 · secondary NCT02376790
  • -0.5 vs -0.5 wk 36 · n 284 · Phase 3 · secondary NCT02376790
  • -0.5 vs -0.5 wk 36 · n 283 · Phase 3 · secondary NCT02376790
  • -0.6 vs -0.5 wk 48 · n 284 · Phase 3 · secondary NCT02376790
  • -0.6 vs -0.5 wk 48 · n 283 · Phase 3 · secondary NCT02376790
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. adalimumab: 5 of 5 rows · etanercept: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab
Rows use multiple source trials
etanercept
DAS28-CRP
absolute change · score
-2 vs -0.9 MTX score @ 16wka,b
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
-1.92 vs -1.47 Methotrexate score @ 16wkc,a,b
NCT02376790 · Phase 3 · combination
show 1 more dose
-1.9 vs -1.47 Methotrexate score @ 16wk
NCT02376790 · Phase 3 · monotherapy
Dropout rate
4.6%d
NCT03739853 · Phase 4 · registry result, not featured evidence
show 4 more results
4.9%Part 1: ADA + MTX
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
—Part 2: ADA
NCT02814175 · Phase 4 · registry result, not featured evidence
—Part 2: ADA + MTX Escalated Dose
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
—Part 2: ADA ew + MTX
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
18.7%Etanercept + Methotrexated
NCT02376790 · Phase 3 · combination
show 5 more results
16.5%Etanercept Monotherapy
NCT02376790 · Phase 3 · monotherapy
35.5%
NCT00127842 · Phase 4 · registry result, not featured evidence
4%BIW/QW
NCT00245960 · Phase 4 · registry result, not featured evidence
2.9%QW/QW
NCT00245960 · Phase 4 · registry result, not featured evidence
—
NCT02986139 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—d
NCT03739853 · Phase 4 · registry result, not featured evidence
show 4 more results
2.4%Part 1: ADA + MTX
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
—Part 2: ADA
NCT02814175 · Phase 4 · registry result, not featured evidence
—Part 2: ADA + MTX Escalated Dose
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
—Part 2: ADA ew + MTX
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
—Etanercept + Methotrexated
NCT02376790 · Phase 3 · combination
show 5 more results
—Etanercept Monotherapy
NCT02376790 · Phase 3 · monotherapy
13.6%
NCT00127842 · Phase 4 · registry result, not featured evidence
1.6%BIW/QW
NCT00245960 · Phase 4 · registry result, not featured evidence
1.9%QW/QW
NCT00245960 · Phase 4 · registry result, not featured evidence
—
NCT02986139 · Phase 3 · registry result, not featured evidence
Serious AEs
3.1%d
NCT03739853 · Phase 4 · registry result, not featured evidence
show 4 more results
1.6%Part 1: ADA + MTX
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
1.9%Part 2: ADA
NCT02814175 · Phase 4 · registry result, not featured evidence
3.2%Part 2: ADA + MTX Escalated Dose
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
4.8%Part 2: ADA ew + MTX
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
6%Etanercept + Methotrexated
NCT02376790 · Phase 3 · combination
show 5 more results
6.7%Etanercept Monotherapy
NCT02376790 · Phase 3 · monotherapy
12.7%
NCT00127842 · Phase 4 · registry result, not featured evidence
—BIW/QW
NCT00245960 · Phase 4 · registry result, not featured evidence
—QW/QW
NCT00245960 · Phase 4 · registry result, not featured evidence
0.9%
NCT02986139 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
d
liver function test abnormalities 27.7%
nausea 23.1%
diarrhoea 9.2%
NCT03739853 · Phase 4 · registry result, not featured evidence
show 4 more results
headache 8.1%
upper respiratory tract infection 8.1%
cough 5.7%
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
upper respiratory tract infection 3.7%
alanine aminotransferase increased 1.9%
back pain 1.9%
NCT02814175 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 13.7%
nasopharyngitis 6.3%
nausea 4.2%
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
upper respiratory tract infection 14.3%
back pain 6.3%
psoriatic arthropathy 6.3%
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
d
nausea 14.4%
nasopharyngitis 9.5%
upper respiratory tract infection 8.1%
NCT02376790 · Phase 3 · combination
show 5 more results
nasopharyngitis 7.4%
nausea 6.4%
upper respiratory tract infection 6.4%
NCT02376790 · Phase 3 · monotherapy
nasopharyngitis 18.2%
upper respiratory tract infection 13.6%
injection site reaction 11.8%
NCT00127842 · Phase 4 · registry result, not featured evidence
BIW/QW
upper respiratory infection 13.2%
skin and appendages general disorders 11.9%
digestive general disorders 10%
NCT00245960 · Phase 4 · registry result, not featured evidence
QW/QW
skin and appendages general disorders 11%
digestive general disorders 9.9%
upper respiratory infection 9.7%
NCT00245960 · Phase 4 · registry result, not featured evidence
hypoaesthesia 1.9%
pain in extremity 1.9%
cellulitis 0.9%
NCT02986139 · Phase 3 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 4 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  4. dPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab

PASDAS 3.6 vs 4 Combination csDMARD score @ 24wk
absolute value · score
NCT03739853 · Phase 4 · registry result, not featured evidence
show 1 more result
3.5 vs 3.8 Combination csDMARD score @ 48wk
NCT03739853 · Phase 4 · registry result, not featured evidence
PsAID-12 3.5 vs 4.4 Combination csDMARD score @ 12wk
absolute value · score
NCT03739853 · Phase 4 · registry result, not featured evidence
show 3 more results
3.1 vs 3.5 Combination csDMARD score @ 24wk
NCT03739853 · Phase 4 · registry result, not featured evidence
3.3 vs 2.9 Combination csDMARD score @ 36wk
NCT03739853 · Phase 4 · registry result, not featured evidence
3 vs 3.3 Combination csDMARD score @ 48wk
NCT03739853 · Phase 4 · registry result, not featured evidence
DLQI -5.9 vs -3.1 MTX score @ 16wk
absolute change · score
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
Dactylitis -2.8 vs -0.9 MTX count @ 16wk
absolute change · count
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
PsAID -3.3 vs -1.7 MTX score @ 16wk
absolute change · score
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
ACR20 67.5% (n=123) vs 32.8% (n=122) MTX @ 16wk
responder rate · % of participants
ACR 20
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
ACR50 45.5% (n=123) vs 16.4% (n=122) MTX @ 16wk
responder rate · % of participants
ACR 50
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
ACR70 30.9% (n=123) vs 8.2% (n=122) MTX @ 16wk
responder rate · % of participants
ACR 70
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
Leeds Enthesitis Index -1.9 vs -1.1 MTX score @ 16wk
absolute change · score
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
PASDAS -2.8 vs -1.2 MTX score @ 16wk
absolute change · score
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
SF-36 PCS 8.9 vs 4.4 MTX score @ 16wk
absolute change · score
SF-36 PCS
NCT02814175 · Phase 4 · registry result, not featured evidence · combination
SF-36 MCS 4.4 vs 1.3 MTX score @ 16wk
absolute change · score
SF-36 MCS
NCT02814175 · Phase 4 · registry result, not featured evidence · combination

+ 4 further endpoints in the CSV export.

etanercept

ACR20 60.9% (n=284) vs 50.7% (n=284) Methotrexate @ 24wk
responder rate · % of participants
NCT02376790 · Phase 3 · monotherapy
show 15 more results
65% (n=283) vs 50.7% (n=284) Methotrexate @ 24wk
NCT02376790 · Phase 3 · combination
44.3% (n=284) vs 25% (n=284) Methotrexate @ 4wk
NCT02376790 · Phase 3 · monotherapy
46.4% (n=283) vs 25% (n=284) Methotrexate @ 4wk
NCT02376790 · Phase 3 · combination
60.2% (n=284) vs 46.5% (n=284) Methotrexate @ 8wk
NCT02376790 · Phase 3 · monotherapy
60.8% (n=283) vs 46.5% (n=284) Methotrexate @ 8wk
NCT02376790 · Phase 3 · combination
65.5% (n=284) vs 46.8% (n=284) Methotrexate @ 12wk
NCT02376790 · Phase 3 · monotherapy
70.3% (n=283) vs 46.8% (n=284) Methotrexate @ 12wk
NCT02376790 · Phase 3 · combination
69.5% (n=284) vs 58.5% (n=284) Methotrexate @ 16wk
NCT02376790 · Phase 3 · monotherapy
71.8% (n=283) vs 58.5% (n=284) Methotrexate @ 16wk
NCT02376790 · Phase 3 · combination
67.6% (n=284) vs 56.9% (n=284) Methotrexate @ 24wk
NCT02376790 · Phase 3 · monotherapy
71.9% (n=283) vs 56.9% (n=284) Methotrexate @ 24wk
NCT02376790 · Phase 3 · combination
77% (n=284) vs 66.3% (n=284) Methotrexate @ 36wk
NCT02376790 · Phase 3 · monotherapy
74.2% (n=283) vs 66.3% (n=284) Methotrexate @ 36wk
NCT02376790 · Phase 3 · combination
83.1% (n=284) vs 70.7% (n=284) Methotrexate @ 48wk
NCT02376790 · Phase 3 · monotherapy
80.4% (n=283) vs 70.7% (n=284) Methotrexate @ 48wk
NCT02376790 · Phase 3 · combination
ACR50 16.5% (n=284) vs 6% (n=284) Methotrexate @ 4wk
responder rate · % of participants
NCT02376790 · Phase 3 · monotherapy
show 13 more results
18.8% (n=283) vs 6% (n=284) Methotrexate @ 4wk
NCT02376790 · Phase 3 · combination
31.3% (n=284) vs 15.1% (n=284) Methotrexate @ 8wk
NCT02376790 · Phase 3 · monotherapy
30.1% (n=283) vs 15.1% (n=284) Methotrexate @ 8wk
NCT02376790 · Phase 3 · combination
40.4% (n=284) vs 16.9% (n=284) Methotrexate @ 12wk
NCT02376790 · Phase 3 · monotherapy
39.2% (n=283) vs 16.9% (n=284) Methotrexate @ 12wk
NCT02376790 · Phase 3 · combination
43.8% (n=284) vs 29.2% (n=284) Methotrexate @ 16wk
NCT02376790 · Phase 3 · monotherapy
43.4% (n=283) vs 29.2% (n=284) Methotrexate @ 16wk
NCT02376790 · Phase 3 · combination
44.4% (n=284) vs 30.6% (n=284) Methotrexate @ 24wk
NCT02376790 · Phase 3 · monotherapy
45.7% (n=283) vs 30.6% (n=284) Methotrexate @ 24wk
NCT02376790 · Phase 3 · combination
57.3% (n=284) vs 41.8% (n=284) Methotrexate @ 36wk
NCT02376790 · Phase 3 · monotherapy
56% (n=283) vs 41.8% (n=284) Methotrexate @ 36wk
NCT02376790 · Phase 3 · combination
63% (n=284) vs 49.3% (n=284) Methotrexate @ 48wk
NCT02376790 · Phase 3 · monotherapy
60.2% (n=283) vs 49.3% (n=284) Methotrexate @ 48wk
NCT02376790 · Phase 3 · combination
ACR70 3.6% (n=284) vs 2.8% (n=284) Methotrexate @ 4wk
responder rate · % of participants
NCT02376790 · Phase 3 · monotherapy
show 13 more results
5.1% (n=283) vs 2.8% (n=284) Methotrexate @ 4wk
NCT02376790 · Phase 3 · combination
15.2% (n=284) vs 4.4% (n=284) Methotrexate @ 8wk
NCT02376790 · Phase 3 · monotherapy
14.5% (n=283) vs 4.4% (n=284) Methotrexate @ 8wk
NCT02376790 · Phase 3 · combination
24.3% (n=284) vs 5.2% (n=284) Methotrexate @ 12wk
NCT02376790 · Phase 3 · monotherapy
22.3% (n=283) vs 5.2% (n=284) Methotrexate @ 12wk
NCT02376790 · Phase 3 · combination
24.2% (n=284) vs 10.7% (n=284) Methotrexate @ 16wk
NCT02376790 · Phase 3 · monotherapy
25.5% (n=283) vs 10.7% (n=284) Methotrexate @ 16wk
NCT02376790 · Phase 3 · combination
29.2% (n=284) vs 13.8% (n=284) Methotrexate @ 24wk
NCT02376790 · Phase 3 · monotherapy
27.7% (n=283) vs 13.8% (n=284) Methotrexate @ 24wk
NCT02376790 · Phase 3 · combination
38.5% (n=284) vs 19.6% (n=284) Methotrexate @ 36wk
NCT02376790 · Phase 3 · monotherapy
33.5% (n=283) vs 19.6% (n=284) Methotrexate @ 36wk
NCT02376790 · Phase 3 · combination
39.7% (n=284) vs 25.2% (n=284) Methotrexate @ 48wk
NCT02376790 · Phase 3 · monotherapy
39.7% (n=283) vs 25.2% (n=284) Methotrexate @ 48wk
NCT02376790 · Phase 3 · combination
Tender Joint Count -6.4 vs -5.7 Methotrexate tender joints @ 4wk
absolute change · tender joints
NCT02376790 · Phase 3 · monotherapy
show 13 more results
-7.4 vs -5.7 Methotrexate tender joints @ 4wk
NCT02376790 · Phase 3 · combination
-8.9 vs -7.8 Methotrexate tender joints @ 8wk
NCT02376790 · Phase 3 · monotherapy
-9.4 vs -7.8 Methotrexate tender joints @ 8wk
NCT02376790 · Phase 3 · combination
-9.8 vs -9.7 Methotrexate tender joints @ 12wk
NCT02376790 · Phase 3 · monotherapy
-10.8 vs -9.7 Methotrexate tender joints @ 12wk
NCT02376790 · Phase 3 · combination
-10.9 vs -10 Methotrexate tender joints @ 16wk
NCT02376790 · Phase 3 · monotherapy
-11.9 vs -10 Methotrexate tender joints @ 16wk
NCT02376790 · Phase 3 · combination
-10.9 vs -10.8 Methotrexate tender joints @ 24wk
NCT02376790 · Phase 3 · monotherapy
-11 vs -10.8 Methotrexate tender joints @ 24wk
NCT02376790 · Phase 3 · combination
-12.7 vs -13.5 Methotrexate tender joints @ 36wk
NCT02376790 · Phase 3 · monotherapy
-12.9 vs -13.5 Methotrexate tender joints @ 36wk
NCT02376790 · Phase 3 · combination
-13.9 vs -14.5 Methotrexate tender joints @ 48wk
NCT02376790 · Phase 3 · monotherapy
-12.9 vs -14.5 Methotrexate tender joints @ 48wk
NCT02376790 · Phase 3 · combination
Swollen Joint Count -4.8 vs -4.1 Methotrexate swollen joints @ 4wk
absolute change · swollen joints
NCT02376790 · Phase 3 · monotherapy
show 13 more results
-4.7 vs -4.1 Methotrexate swollen joints @ 4wk
NCT02376790 · Phase 3 · combination
-6.2 vs -5.4 Methotrexate swollen joints @ 8wk
NCT02376790 · Phase 3 · monotherapy
-6.5 vs -5.4 Methotrexate swollen joints @ 8wk
NCT02376790 · Phase 3 · combination
-6.8 vs -6.6 Methotrexate swollen joints @ 12wk
NCT02376790 · Phase 3 · monotherapy
-7.2 vs -6.6 Methotrexate swollen joints @ 12wk
NCT02376790 · Phase 3 · combination
-7.3 vs -7 Methotrexate swollen joints @ 16wk
NCT02376790 · Phase 3 · monotherapy
-7.8 vs -7 Methotrexate swollen joints @ 16wk
NCT02376790 · Phase 3 · combination
-7.6 vs -7 Methotrexate swollen joints @ 24wk
NCT02376790 · Phase 3 · monotherapy
-7.7 vs -7 Methotrexate swollen joints @ 24wk
NCT02376790 · Phase 3 · combination
-9 vs -9.2 Methotrexate swollen joints @ 36wk
NCT02376790 · Phase 3 · monotherapy
-8.4 vs -9.2 Methotrexate swollen joints @ 36wk
NCT02376790 · Phase 3 · combination
-9.2 vs -9.6 Methotrexate swollen joints @ 48wk
NCT02376790 · Phase 3 · monotherapy
-8.7 vs -9.6 Methotrexate swollen joints @ 48wk
NCT02376790 · Phase 3 · combination
Physician Global Assessment -23.1 vs -16.8 Methotrexate mm @ 4wk
absolute change · mm
NCT02376790 · Phase 3 · monotherapy
show 13 more results
-22.8 vs -16.8 Methotrexate mm @ 4wk
NCT02376790 · Phase 3 · combination
-29.7 vs -25 Methotrexate mm @ 8wk
NCT02376790 · Phase 3 · monotherapy
-30.4 vs -25 Methotrexate mm @ 8wk
NCT02376790 · Phase 3 · combination
-32.7 vs -26.8 Methotrexate mm @ 12wk
NCT02376790 · Phase 3 · monotherapy
-33.9 vs -26.8 Methotrexate mm @ 12wk
NCT02376790 · Phase 3 · combination
-34.9 vs -30.3 Methotrexate mm @ 16wk
NCT02376790 · Phase 3 · monotherapy
-36.2 vs -30.3 Methotrexate mm @ 16wk
NCT02376790 · Phase 3 · combination
-35.7 vs -29.6 Methotrexate mm @ 24wk
NCT02376790 · Phase 3 · monotherapy
-35.8 vs -29.6 Methotrexate mm @ 24wk
NCT02376790 · Phase 3 · combination
-42.8 vs -37.1 Methotrexate mm @ 36wk
NCT02376790 · Phase 3 · monotherapy
-39.9 vs -37.1 Methotrexate mm @ 36wk
NCT02376790 · Phase 3 · combination
-43.8 vs -41.4 Methotrexate mm @ 48wk
NCT02376790 · Phase 3 · monotherapy
-41.5 vs -41.4 Methotrexate mm @ 48wk
NCT02376790 · Phase 3 · combination
Patient Global Assessment -21.9 vs -11 Methotrexate mm @ 4wk
absolute change · mm
NCT02376790 · Phase 3 · monotherapy
show 13 more results
-21 vs -11 Methotrexate mm @ 4wk
NCT02376790 · Phase 3 · combination
-27.3 vs -15.6 Methotrexate mm @ 8wk
NCT02376790 · Phase 3 · monotherapy
-26.4 vs -15.6 Methotrexate mm @ 8wk
NCT02376790 · Phase 3 · combination
-29.9 vs -18.6 Methotrexate mm @ 12wk
NCT02376790 · Phase 3 · monotherapy
-28 vs -18.6 Methotrexate mm @ 12wk
NCT02376790 · Phase 3 · combination
-30.9 vs -22.7 Methotrexate mm @ 16wk
NCT02376790 · Phase 3 · monotherapy
-29.3 vs -22.7 Methotrexate mm @ 16wk
NCT02376790 · Phase 3 · combination
-32.3 vs -23 Methotrexate mm @ 24wk
NCT02376790 · Phase 3 · monotherapy
-29.6 vs -23 Methotrexate mm @ 24wk
NCT02376790 · Phase 3 · combination
-36.4 vs -26 Methotrexate mm @ 36wk
NCT02376790 · Phase 3 · monotherapy
-32.4 vs -26 Methotrexate mm @ 36wk
NCT02376790 · Phase 3 · combination
-38.8 vs -28.9 Methotrexate mm @ 48wk
NCT02376790 · Phase 3 · monotherapy
-33.3 vs -28.9 Methotrexate mm @ 48wk
NCT02376790 · Phase 3 · combination
Patient Assessment of Arthritis Pain -18.4 vs -8.9 Methotrexate mm @ 4wk
absolute change · mm
NCT02376790 · Phase 3 · monotherapy
show 13 more results
-18.5 vs -8.9 Methotrexate mm @ 4wk
NCT02376790 · Phase 3 · combination
-23.5 vs -14.5 Methotrexate mm @ 8wk
NCT02376790 · Phase 3 · monotherapy
-24 vs -14.5 Methotrexate mm @ 8wk
NCT02376790 · Phase 3 · combination
-24.1 vs -16 Methotrexate mm @ 12wk
NCT02376790 · Phase 3 · monotherapy
-24.9 vs -16 Methotrexate mm @ 12wk
NCT02376790 · Phase 3 · combination
-25.9 vs -20.9 Methotrexate mm @ 16wk
NCT02376790 · Phase 3 · monotherapy
-25.6 vs -20.9 Methotrexate mm @ 16wk
NCT02376790 · Phase 3 · combination
-26.4 vs -20.6 Methotrexate mm @ 24wk
NCT02376790 · Phase 3 · monotherapy
-26.9 vs -20.6 Methotrexate mm @ 24wk
NCT02376790 · Phase 3 · combination
-31.5 vs -23.9 Methotrexate mm @ 36wk
NCT02376790 · Phase 3 · monotherapy
-28.8 vs -23.9 Methotrexate mm @ 36wk
NCT02376790 · Phase 3 · combination
-32.5 vs -27.2 Methotrexate mm @ 48wk
NCT02376790 · Phase 3 · monotherapy
-31.1 vs -27.2 Methotrexate mm @ 48wk
NCT02376790 · Phase 3 · combination
CRP Change -5.91 vs -0.93 Methotrexate mg @ 4wk
absolute change · mg
NCT02376790 · Phase 3 · monotherapy
show 13 more results
-5.49 vs -0.93 Methotrexate mg @ 4wk
NCT02376790 · Phase 3 · combination
-7.51 vs -2.31 Methotrexate mg @ 8wk
NCT02376790 · Phase 3 · monotherapy
-5.19 vs -2.31 Methotrexate mg @ 8wk
NCT02376790 · Phase 3 · combination
-7.38 vs -3.36 Methotrexate mg @ 12wk
NCT02376790 · Phase 3 · monotherapy
-5.71 vs -3.36 Methotrexate mg @ 12wk
NCT02376790 · Phase 3 · combination
-7.4 vs -2.81 Methotrexate mg @ 16wk
NCT02376790 · Phase 3 · monotherapy
-5.59 vs -2.81 Methotrexate mg @ 16wk
NCT02376790 · Phase 3 · combination
-6.91 vs -2.6 Methotrexate mg @ 24wk
NCT02376790 · Phase 3 · monotherapy
-5.82 vs -2.6 Methotrexate mg @ 24wk
NCT02376790 · Phase 3 · combination
-7.36 vs -4.16 Methotrexate mg @ 36wk
NCT02376790 · Phase 3 · monotherapy
-5.82 vs -4.16 Methotrexate mg @ 36wk
NCT02376790 · Phase 3 · combination
-7.45 vs -4.88 Methotrexate mg @ 48wk
NCT02376790 · Phase 3 · monotherapy
-5.81 vs -4.88 Methotrexate mg @ 48wk
NCT02376790 · Phase 3 · combination
PSAAD -2.32 vs -1.63 Methotrexate score @ 12wk
absolute change · score
NCT02376790 · Phase 3 · monotherapy
show 7 more results
-2.37 vs -1.63 Methotrexate score @ 12wk
NCT02376790 · Phase 3 · combination
-2.64 vs -1.98 Methotrexate score @ 24wk
NCT02376790 · Phase 3 · monotherapy
-2.63 vs -1.98 Methotrexate score @ 24wk
NCT02376790 · Phase 3 · combination
-3.1 vs -2.46 Methotrexate score @ 36wk
NCT02376790 · Phase 3 · monotherapy
-2.95 vs -2.46 Methotrexate score @ 36wk
NCT02376790 · Phase 3 · combination
-3.23 vs -2.7 Methotrexate score @ 48wk
NCT02376790 · Phase 3 · monotherapy
-3.1 vs -2.7 Methotrexate score @ 48wk
NCT02376790 · Phase 3 · combination
CDAI -10.59 vs -8.38 Methotrexate score @ 4wk
absolute change · score
NCT02376790 · Phase 3 · monotherapy
show 13 more results
-10.68 vs -8.38 Methotrexate score @ 4wk
NCT02376790 · Phase 3 · combination
-14.13 vs -11.56 Methotrexate score @ 8wk
NCT02376790 · Phase 3 · monotherapy
-14.56 vs -11.56 Methotrexate score @ 8wk
NCT02376790 · Phase 3 · combination
-15.61 vs -13.93 Methotrexate score @ 12wk
NCT02376790 · Phase 3 · monotherapy
-16.12 vs -13.93 Methotrexate score @ 12wk
NCT02376790 · Phase 3 · combination
-16.49 vs -15.2 Methotrexate score @ 16wk
NCT02376790 · Phase 3 · monotherapy
-17.37 vs -15.2 Methotrexate score @ 16wk
NCT02376790 · Phase 3 · combination
-17.12 vs -15.74 Methotrexate score @ 24wk
NCT02376790 · Phase 3 · monotherapy
-16.43 vs -15.74 Methotrexate score @ 24wk
NCT02376790 · Phase 3 · combination
-19.79 vs -18.9 Methotrexate score @ 36wk
NCT02376790 · Phase 3 · monotherapy
-18.86 vs -18.9 Methotrexate score @ 36wk
NCT02376790 · Phase 3 · combination
-20.78 vs -20.16 Methotrexate score @ 48wk
NCT02376790 · Phase 3 · monotherapy
-19.35 vs -20.16 Methotrexate score @ 48wk
NCT02376790 · Phase 3 · combination
SDAI -11.12 vs -8.38 Methotrexate score @ 4wk
absolute change · score
NCT02376790 · Phase 3 · monotherapy
show 13 more results
-11.18 vs -8.38 Methotrexate score @ 4wk
NCT02376790 · Phase 3 · combination
-14.92 vs -11.77 Methotrexate score @ 8wk
NCT02376790 · Phase 3 · monotherapy
-15.14 vs -11.77 Methotrexate score @ 8wk
NCT02376790 · Phase 3 · combination
-16.44 vs -14.32 Methotrexate score @ 12wk
NCT02376790 · Phase 3 · monotherapy
-16.67 vs -14.32 Methotrexate score @ 12wk
NCT02376790 · Phase 3 · combination
-17.25 vs -15.55 Methotrexate score @ 16wk
NCT02376790 · Phase 3 · monotherapy
-17.79 vs -15.55 Methotrexate score @ 16wk
NCT02376790 · Phase 3 · combination
-17.75 vs -15.96 Methotrexate score @ 24wk
NCT02376790 · Phase 3 · monotherapy
-17.01 vs -15.96 Methotrexate score @ 24wk
NCT02376790 · Phase 3 · combination
-20.5 vs -19.27 Methotrexate score @ 36wk
NCT02376790 · Phase 3 · monotherapy
-19.46 vs -19.27 Methotrexate score @ 36wk
NCT02376790 · Phase 3 · combination
-21.61 vs -20.65 Methotrexate score @ 48wk
NCT02376790 · Phase 3 · monotherapy
-19.94 vs -20.65 Methotrexate score @ 48wk
NCT02376790 · Phase 3 · combination

+ 20 further endpoints in the CSV export.

Psoriasis

Shared mechanism: TNF-alpha · full Psoriasis pipeline

adalimumab · Humira

Marketed by AbbVie and partners

Approved in Psoriasismonoclonal antibody (fully human IgG1)
Partial signal

NCT00195676 · Phase 3 · completed

Eligibility for this study required prior participation in an earlier adalimumab psoriasis trial, making this an open-label continuation rather than a fresh, independently controlled study. Within the retreatment group, 76.5% of patients regained clear or minimal skin at 16 weeks, but with no placebo or comparison arm in this phase, that rate cannot be attributed to the drug with the same confidence as a controlled trial.

Next expected readout: April 2028 · NCT07529925 (registry estimate)

Reported efficacy

Percentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R: PGA 0/1 at 16 weeks after adalimumab retreatment: 89% in patients without relapse vs 69% in patients who relapsed; median time to relapse 141 days (178/285 stable-control patients relapsed) (not_applicable)

Result source: NCT00195676

etanercept · Enbrel

Marketed by Amgen and partners

Approved in Psoriasisfusion protein
Weak signal

NCT00111436 · Phase 3 · completed

Participants in this study had already been randomized in an earlier controlled trial and continued on etanercept here as an open-label extension to gather longer-term safety data, rather than as a fresh randomized comparison. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Subject incidence of adverse events, including infectious episodes" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: June 2030 · NCT07352566 (registry estimate)

Reported efficacy

Subject incidence of adverse events, including infectious episodes (72 weeks); Changes from baseline in laboratory values (72 weeks): Primary endpoint (incidence of adverse events/lab changes) in this 912-patient open-label long-term safety extension (Leonardi et al. 2010, cited by this PMC review), exactly matching this NCT's registered enrollment (912) and design (open-label extension, safety of 50mg QW/BIW etanercept, 48-72 weeks): well tolerated, no significant AE/infection-rate difference between dose groups, no TB/opportunistic infection/demyelination/lymphoma cases. (not_applicable)

Result source: NCT00111436

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumabetanercept
PASI 7577.8% vs 11.5%+66.3 vs placeboEow · wk 12 · n 338NCT01646073
7 other results
  • 80.1% vs 79% wk 16 · n 267 · Phase 3 · primary NCT02581345
  • 57.9% vs 32.4% 0.8 mg/kg · wk 16 · n 38 · Phase 3 · primary NCT01251614
  • 43.6% vs 32.4% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · primary NCT01251614
  • 45.3% vs 2.3% Eow · wk 7 · n 338 · Phase 3 · secondary NCT01646073
  • 9.8% vs 0% Eow · wk 3 · n 338 · Phase 3 · secondary NCT01646073
  • 30.6% vs 8.7% wk 16 · n 49 · Phase 4 · secondary NCT00735787
  • 67% vs 27% wk 16 · n 15 · Phase 4 · secondary NCT00932113
57% vs 11%+46 vs placebowk 12 · n 106NCT00078819
2 other results
  • 48.2% vs 11.9% 50 mg SC QW · wk 16 · n 83 · Phase 3 · secondary NCT01690299
  • 63.3% vs 26.3% wk 12 · n 30 · Phase 3 · secondary NCT03073200
PASI 9061.8% vs 54.2%vs EU RPPwk 16 · n 267NCT02581345
3 other results
  • 28.9% vs 21.6% 0.8 mg/kg · wk 16 · n 38 · Phase 3 · secondary NCT01251614
  • 30.8% vs 21.6% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · secondary NCT01251614
  • 20.4% vs 0% wk 16 · n 49 · Phase 4 · secondary NCT00735787
27% vs 7%+20 vs placebowk 12 · n 106NCT00078819
PASI 10018.4% vs 2.7%vs Methotrexate0.8 mg/kg · wk 16 · n 38NCT01251614
2 other results
  • 10.3% vs 2.7% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · secondary NCT01251614
  • 14.3% vs 0% wk 16 · n 49 · Phase 4 · secondary NCT00735787
—Not posted · NCT00111449
sPGA 0/160.5% vs 40.5%vs Methotrexate0.8 mg/kg · wk 16 · n 38NCT01251614
11 other results
  • 41% vs 40.5% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · primary NCT01251614
  • 80.5% vs 14.9% Eow · wk 12 · n 338 · Phase 3 · secondary NCT01646073
  • 57.4% vs 4.6% Eow · wk 7 · n 338 · Phase 3 · secondary NCT01646073
  • 20.1% vs 0% Eow · wk 3 · n 338 · Phase 3 · secondary NCT01646073
  • 68.9% vs 66.1% wk 16 · n 267 · Phase 3 · secondary NCT02581345
  • 30.6% vs 4.3% wk 16 · n 49 · Phase 4 · primary NCT00735787
  • 28.6% vs 13% wk 12 · n 49 · Phase 4 · secondary NCT00735787
  • 24.5% vs 8.7% wk 8 · n 49 · Phase 4 · secondary NCT00735787
  • 20.4% vs 4.3% wk 4 · n 49 · Phase 4 · secondary NCT00735787
  • 8.2% vs 4.3% wk 2 · n 49 · Phase 4 · secondary NCT00735787
  • 73% vs 27% wk 16 · n 15 · Phase 4 · secondary NCT00932113
28.9% vs 3.6%+25.3 vs placebo50 mg SC QW · wk 16 · n 83NCT01690299
2 other results
  • 53% vs 13% wk 12 · n 106 · Phase 3 · secondary NCT00078819
  • 53.3% vs 5.3% wk 12 · n 30 · Phase 3 · secondary NCT03073200
DLQI, change-4.8 vs -4.2−0.6 vs placebowk 16 · n 49NCT00735787
3 other results
  • -7.9 vs -3.7 wk 12 · n 33 · Phase 4 · secondary NCT01553058
  • -4.1 vs -3.1 wk 8 · n 49 · Phase 4 · secondary NCT00735787
  • -4.3 vs -3.4 wk 2 · n 49 · Phase 4 · secondary NCT00735787
-7.8 vs -3.9−3.9 vs placebo50 mg SC QW · wk 16 · n 80NCT01690299

PASI 75

adalimumab
77.8% vs 11.5%+66.3 vs placeboEow · wk 12 · n 338NCT01646073
7 other results
  • 80.1% vs 79% wk 16 · n 267 · Phase 3 · primary NCT02581345
  • 57.9% vs 32.4% 0.8 mg/kg · wk 16 · n 38 · Phase 3 · primary NCT01251614
  • 43.6% vs 32.4% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · primary NCT01251614
  • 45.3% vs 2.3% Eow · wk 7 · n 338 · Phase 3 · secondary NCT01646073
  • 9.8% vs 0% Eow · wk 3 · n 338 · Phase 3 · secondary NCT01646073
  • 30.6% vs 8.7% wk 16 · n 49 · Phase 4 · secondary NCT00735787
  • 67% vs 27% wk 16 · n 15 · Phase 4 · secondary NCT00932113
etanercept
57% vs 11%+46 vs placebowk 12 · n 106NCT00078819
2 other results
  • 48.2% vs 11.9% 50 mg SC QW · wk 16 · n 83 · Phase 3 · secondary NCT01690299
  • 63.3% vs 26.3% wk 12 · n 30 · Phase 3 · secondary NCT03073200

PASI 90

adalimumab
61.8% vs 54.2%vs EU RPPwk 16 · n 267NCT02581345
3 other results
  • 28.9% vs 21.6% 0.8 mg/kg · wk 16 · n 38 · Phase 3 · secondary NCT01251614
  • 30.8% vs 21.6% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · secondary NCT01251614
  • 20.4% vs 0% wk 16 · n 49 · Phase 4 · secondary NCT00735787
etanercept
27% vs 7%+20 vs placebowk 12 · n 106NCT00078819

PASI 100

adalimumab
18.4% vs 2.7%vs Methotrexate0.8 mg/kg · wk 16 · n 38NCT01251614
2 other results
  • 10.3% vs 2.7% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · secondary NCT01251614
  • 14.3% vs 0% wk 16 · n 49 · Phase 4 · secondary NCT00735787
etanercept
—Not posted · NCT00111449

sPGA 0/1

adalimumab
60.5% vs 40.5%vs Methotrexate0.8 mg/kg · wk 16 · n 38NCT01251614
11 other results
  • 41% vs 40.5% 0.4 mg/kg · wk 16 · n 39 · Phase 3 · primary NCT01251614
  • 80.5% vs 14.9% Eow · wk 12 · n 338 · Phase 3 · secondary NCT01646073
  • 57.4% vs 4.6% Eow · wk 7 · n 338 · Phase 3 · secondary NCT01646073
  • 20.1% vs 0% Eow · wk 3 · n 338 · Phase 3 · secondary NCT01646073
  • 68.9% vs 66.1% wk 16 · n 267 · Phase 3 · secondary NCT02581345
  • 30.6% vs 4.3% wk 16 · n 49 · Phase 4 · primary NCT00735787
  • 28.6% vs 13% wk 12 · n 49 · Phase 4 · secondary NCT00735787
  • 24.5% vs 8.7% wk 8 · n 49 · Phase 4 · secondary NCT00735787
  • 20.4% vs 4.3% wk 4 · n 49 · Phase 4 · secondary NCT00735787
  • 8.2% vs 4.3% wk 2 · n 49 · Phase 4 · secondary NCT00735787
  • 73% vs 27% wk 16 · n 15 · Phase 4 · secondary NCT00932113
etanercept
28.9% vs 3.6%+25.3 vs placebo50 mg SC QW · wk 16 · n 83NCT01690299
2 other results
  • 53% vs 13% wk 12 · n 106 · Phase 3 · secondary NCT00078819
  • 53.3% vs 5.3% wk 12 · n 30 · Phase 3 · secondary NCT03073200

DLQI, change

adalimumab
-4.8 vs -4.2−0.6 vs placebowk 16 · n 49NCT00735787
3 other results
  • -7.9 vs -3.7 wk 12 · n 33 · Phase 4 · secondary NCT01553058
  • -4.1 vs -3.1 wk 8 · n 49 · Phase 4 · secondary NCT00735787
  • -4.3 vs -3.4 wk 2 · n 49 · Phase 4 · secondary NCT00735787
etanercept
-7.8 vs -3.9−3.9 vs placebo50 mg SC QW · wk 16 · n 80NCT01690299
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
14 other shared endpoints and safety

Coverage. adalimumab: 18 of 18 rows · etanercept: 18 of 18 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab
Rows use multiple source trials
etanercept
Rows use multiple source trials
DLQI
absolute change · score
Maintenance
-5.18 vs -4.74 placebo score @ 28wka,b,c
NCT00735787 · Phase 4 · registry result, not featured evidence
-0.4 vs 2 placebo score @ 24wka,b,c
NCT00581555 · Phase 4 · registry result, not featured evidence
DLQI
percent change · % of baseline
No placebo or comparator arm
-79.16% (n=49) @ 24wka,b
NCT01644396 · Phase 4 · registry result, not featured evidence
36.95% (n=75) @ 24wka,b
NCT02749370 · Phase 4 · registry result, not featured evidence
DLQI
absolute change · score
No placebo or comparator arm
-4.8 score @ 24wkd,a,b
NCT02533375 · Phase 3 · registry result, not featured evidence
-10.5 score @ 24wk50 mg BW/QWe,d,a,b
NCT00663052 · Phase 4 · registry result, not featured evidence
show 1 more dose
-9.2 score @ 24wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
PASI
percent change · % of baseline
Maintenance
-86.43% (n=246) vs -85.53% (n=120) EU RPP @ 52wkd,a,b,f
NCT02581345 · Phase 3 · registry result, not featured evidence
-13.3% (n=38) vs 121.9% (n=19) placebo @ 24wkd,a,b,f
NCT00581555 · Phase 4 · registry result, not featured evidence
PASI
absolute change · score
Maintenance
-9 vs -0.9 placebo score @ 26wkEOWd,a,b,g
NCT02016482 · Phase 3 · registry result, not featured evidence
-1.8 vs 2.9 placebo score @ 24wkd,a,b,g
NCT00581555 · Phase 4 · registry result, not featured evidence
PASI
percent change · % of baseline
No placebo or comparator arm
-91.18% (n=50) @ 24wka,b
NCT01644396 · Phase 4 · registry result, not featured evidence
2 other source trials
-43.6% (n=10) @ 24wk
NCT02533375 · Phase 3 · registry result, not featured evidence
-91.07% (n=333) @ 24wkEow
NCT01646073 · Phase 3 · registry result, not featured evidence
57.67% (n=77) @ 24wka,b
NCT02749370 · Phase 4 · registry result, not featured evidence
2 other source trials
0.86% (n=140) @ 24wk50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
72.56% (n=143) @ 24wk50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
PASI
absolute change · score
No placebo or comparator arm
-16.8 score @ 24wkd,a,b
NCT02533375 · Phase 3 · registry result, not featured evidence
-17.4 score @ 24wk50 mg BW/QWe,d,a,b
NCT00663052 · Phase 4 · registry result, not featured evidence
show 1 more dose
-15.4 score @ 24wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
PASI 100
responder rate · % of participants
No placebo or comparator arm
64% (n=50) @ 24wka
NCT01644396 · Phase 4 · registry result, not featured evidence
5.3% (n=38) @ 24wk*e,a
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 2 Participants as posted
show 3 more doses
6.9% (n=29) @ 24wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 2 Participants as posted
5.4% (n=37) @ 24wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted
14.3% (n=7) @ 24wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
PASI 50
responder rate · % of participants
Induction
42.9% (n=49) vs 21.7% (n=23) placebo @ 16wk*h,i,b
NCT00735787 · Phase 4 · registry result, not featured evidence · converted to % from 21 subjects as posted
1 other source trial
91% (n=267) vs 93.4% (n=271) EU RPP @ 16wk*
NCT02581345 · Phase 3 · registry result, not featured evidence · converted to % from 243 Participants as posted
83.1% (n=83) vs 33.3% (n=84) placebo @ 16wk50 mg SC QWh,i,b
NCT01690299 · Phase 3 · registry result, not featured evidence
PASI 50
responder rate · % of participants
No placebo or comparator arm
96% (n=50) @ 24wka,b
NCT01644396 · Phase 4 · registry result, not featured evidence
3 other source trials
40% (n=10) @ 24wk*
NCT02533375 · Phase 3 · registry result, not featured evidence · converted to % from 4 Participants as posted
89.9% (n=89) @ 24wk*40 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 80 Participants as posted
94.8% (n=58) @ 24wk*80 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 55 Participants as posted
62.3% (n=77) @ 24wka,b
NCT02749370 · Phase 4 · registry result, not featured evidence
5 other source trials
92.5% (n=133) @ 24wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
81% (n=137) @ 24wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
84.38% (n=33) @ 24wkOnce Weekly
NCT00581100 · Phase 4 · registry result, not featured evidence
85.71% (n=36) @ 24wkTwice, Then Once Weekly
NCT00581100 · Phase 4 · registry result, not featured evidence
88.7% (n=143) @ 24wk50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
PASI 75
responder rate · % of participants
No placebo or comparator arm
82% (n=50) @ 24wka,b
NCT01644396 · Phase 4 · registry result, not featured evidence
4 other source trials
40% (n=10) @ 24wk*
NCT02533375 · Phase 3 · registry result, not featured evidence · converted to % from 4 Participants as posted
87.7% (n=333) @ 24wkEow
NCT01646073 · Phase 3 · registry result, not featured evidence
77.5% (n=89) @ 24wk*40 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 69 Participants as posted
86.2% (n=58) @ 24wk*80 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 50 Participants as posted
45.5% (n=77) @ 24wka,b
NCT02749370 · Phase 4 · registry result, not featured evidence
13 other source trials
44.7% (n=38) @ 24wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 17 Participants as posted
55.2% (n=29) @ 24wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 16 Participants as posted
51.4% (n=37) @ 24wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 19 Participants as posted
100% (n=7) @ 24wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted
78.2% (n=133) @ 24wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
78.2% (n=133) @ 24wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
59.9% (n=137) @ 24wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
59.9% (n=137) @ 24wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
62.5% (n=33) @ 24wkOnce Weekly
NCT00581100 · Phase 4 · registry result, not featured evidence
77.14% (n=36) @ 24wkTwice, Then Once Weekly
NCT00581100 · Phase 4 · registry result, not featured evidence
60.3% (n=143) @ 24wk50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
69.3% (n=295) @ 24wk
NCT01235442 · Phase 3 · registry result, not featured evidence · combination
63.6% (n=297) @ 24wk
NCT01235442 · Phase 3 · registry result, not featured evidence · monotherapy
PASI 90
responder rate · % of participants
No placebo or comparator arm
76% (n=50) @ 24wka,b
NCT01644396 · Phase 4 · registry result, not featured evidence
3 other source trials
10% (n=10) @ 24wk*
NCT02533375 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted
56.2% (n=89) @ 24wk*40 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 50 Participants as posted
67.2% (n=58) @ 24wk*80 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 39 Participants as posted
22.1% (n=77) @ 24wka,b
NCT02749370 · Phase 4 · registry result, not featured evidence
7 other source trials
15.8% (n=38) @ 24wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 6 Participants as posted
20.7% (n=29) @ 24wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 6 Participants as posted
16.2% (n=37) @ 24wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 6 Participants as posted
42.9% (n=7) @ 24wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
49.6% (n=133) @ 24wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
32.8% (n=137) @ 24wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
27% (n=143) @ 24wk50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
PGA =0
responder rate · % of participants
No placebo or comparator arm
70% (n=50) @ 24wka,b
NCT01644396 · Phase 4 · registry result, not featured evidence
1 other source trial
45.6% (n=333) @ 24wkEow
NCT01646073 · Phase 3 · registry result, not featured evidence
21.1% (n=133) @ 24wk50 mg BW/QWe,a,b
NCT00663052 · Phase 4 · registry result, not featured evidence
show 1 more dose
12.4% (n=137) @ 24wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
sPGA 0/1
responder rate · % of participants
No placebo or comparator arm
80% (n=50) @ 24wka,b
NCT01644396 · Phase 4 · registry result, not featured evidence
3 other source trials
83.8% (n=333) @ 24wkEow
NCT01646073 · Phase 3 · registry result, not featured evidence
32.3% (n=31) @ 24wk*40 mg every week
NCT00927069 · Phase 3 · registry result, not featured evidence · converted to % from 10 Participants as posted
30.4% (n=23) @ 24wk*40 mg every week
NCT00927069 · Phase 3 · registry result, not featured evidence · converted to % from 7 Participants as posted
33.8% (n=77) @ 24wka,b
NCT02749370 · Phase 4 · registry result, not featured evidence
11 other source trials
34.2% (n=38) @ 24wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 13 Participants as posted
37.9% (n=29) @ 24wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 11 Participants as posted
32.4% (n=37) @ 24wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 12 Participants as posted
100% (n=7) @ 24wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted
69.9% (n=133) @ 24wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
50.4% (n=137) @ 24wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
75% (n=32) @ 24wkOnce Weekly
NCT00581100 · Phase 4 · registry result, not featured evidence
68.57% (n=35) @ 24wkTwice, Then Once Weekly
NCT00581100 · Phase 4 · registry result, not featured evidence
45.4% (n=143) @ 24wk50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
61.7% (n=295) @ 24wk
NCT01235442 · Phase 3 · registry result, not featured evidence · combination
54.8% (n=297) @ 24wk
NCT01235442 · Phase 3 · registry result, not featured evidence · monotherapy
Dropout rate
41.3%j
NCT00195676 · Phase 3
show 35 more results
6.7%
NCT00932113 · Phase 4 · registry result, not featured evidence
3%
NCT01553058 · Phase 4 · registry result, not featured evidence
0%
NCT01644396 · Phase 4 · registry result, not featured evidence
4.7%
NCT01265823 · Phase 4 · registry result, not featured evidence
16.3%
NCT00735787 · Phase 4 · registry result, not featured evidence
9.4%
NCT05637515 · Phase 3 · registry result, not featured evidence
50%
NCT02533375 · Phase 3 · registry result, not featured evidence
5.2%Part 1 and Part 2: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
—Part 1: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
—Part 2: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
13.8%EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
—EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
—EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
21.1%0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
33.3%0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
1.5%Eow
NCT01646073 · Phase 3 · registry result, not featured evidence
—Eow
NCT01646073 · Phase 3 · registry result, not featured evidence
11%Sub-optimal Response to Etanercept
NCT00566722 · Phase 3 · registry result, not featured evidence
4.9%Sub-optimal Response to MTX
NCT00566722 · Phase 3 · registry result, not featured evidence
17.2%Sub-optimal Response to Narrow-ban
NCT00566722 · Phase 3 · registry result, not featured evidence
—40 mg every week
NCT00927069 · Phase 3 · registry result, not featured evidence
—40 mg every week
NCT00927069 · Phase 3 · registry result, not featured evidence
2%Group A
NCT00927069 · Phase 3 · registry result, not featured evidence
2.9%Group B
NCT00927069 · Phase 3 · registry result, not featured evidence
7.7%Adalimumab + Calcipotriol/Betameth
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
7.1%Adalimumab + Placebo
NCT00574249 · Phase 3 · registry result, not featured evidence
11.8%40 mg Eow
NCT00513370 · Phase 3 · registry result, not featured evidence
22.4%80 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence
24.7%40 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence
0%
NCT01872546 · Phase 2 · registry result, not featured evidence
11.1%
NCT01320293 · Phase na · registry result, not featured evidence
—0.8 mg/kg QWj
NCT00078819 · Phase 3
show 35 more results
—0.8 mg/kg QW
NCT00078819 · Phase 3
—0.8 mg/kg QW
NCT00078819 · Phase 3
—0.8 mg/kg QW
NCT00078819 · Phase 3
—0.8 mg/kg QW
NCT00078819 · Phase 3
—0.8 mg/kg QW
NCT00078819 · Phase 3
0.9%Etanercept
NCT00078819 · Phase 3
17.5%
NCT02749370 · Phase 4 · registry result, not featured evidence
16%
NCT01971346 · Phase 4 · registry result, not featured evidence
18.9%
NCT02274792 · Phase 4 · registry result, not featured evidence
16.3%
NCT00992394 · Phase 4 · registry result, not featured evidence
0%
NCT01053819 · Phase 4 · registry result, not featured evidence
5.1%Part 1 - Etanercept
NCT00640393 · Phase 4 · registry result, not featured evidence
—Part 2 - Etanercept
NCT00640393 · Phase 4 · registry result, not featured evidence
—Part 2 - Etanercept and nbUVB
NCT00640393 · Phase 4 · registry result, not featured evidence · combination
6.5%50 mg BIW/QW
NCT00791765 · Phase 4 · registry result, not featured evidence
27.6%
NCT00332332 · Phase 4 · registry result, not featured evidence
8.8%50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
7.3%50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
34.5%
NCT00581555 · Phase 4 · registry result, not featured evidence
14.7%Once Weekly
NCT00581100 · Phase 4 · registry result, not featured evidence
18.4%Twice, Then Once Weekly
NCT00581100 · Phase 4 · registry result, not featured evidence
27.7%Continuous
NCT00195507 · Phase 4 · registry result, not featured evidence
32.5%Intermittent
NCT00195507 · Phase 4 · registry result, not featured evidence
0%
NCT03073200 · Phase 3 · registry result, not featured evidence
77.5%
NCT00141921 · Phase 3 · registry result, not featured evidence
2.4%50 mg SC QW
NCT01690299 · Phase 3 · registry result, not featured evidence
—50 mg SC QW
NCT01690299 · Phase 3 · registry result, not featured evidence
5.6%50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
—Etanercept Monotherapy
NCT01313221 · Phase 3 · registry result, not featured evidence · monotherapy
14.9%Etanercept + Clobetasol Propionate
NCT01235442 · Phase 3 · registry result, not featured evidence · combination
14.8%Etanercept Monotherapy
NCT01235442 · Phase 3 · registry result, not featured evidence · monotherapy
7.2%50 mg
NCT00482170 · Phase 3 · registry result, not featured evidence
9.3%50 mg
NCT00482170 · Phase 3 · registry result, not featured evidence
0%50 mg twice weekly
NCT00585650 · Phase 1/2 · registry result, not featured evidence
33.3%
NCT01170715 · Phase na · registry result, not featured evidence
Discontinued due to AEs
5.6%j
NCT00195676 · Phase 3
show 35 more results
—
NCT00932113 · Phase 4 · registry result, not featured evidence
—
NCT01553058 · Phase 4 · registry result, not featured evidence
—
NCT01644396 · Phase 4 · registry result, not featured evidence
—
NCT01265823 · Phase 4 · registry result, not featured evidence
—
NCT00735787 · Phase 4 · registry result, not featured evidence
—
NCT05637515 · Phase 3 · registry result, not featured evidence
20%
NCT02533375 · Phase 3 · registry result, not featured evidence
1%Part 1 and Part 2: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
—Part 1: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
—Part 2: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
4.6%EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
—EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
—EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
2.6%0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
0%0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
0.6%Eow
NCT01646073 · Phase 3 · registry result, not featured evidence
—Eow
NCT01646073 · Phase 3 · registry result, not featured evidence
0%Sub-optimal Response to Etanercept
NCT00566722 · Phase 3 · registry result, not featured evidence
0%Sub-optimal Response to MTX
NCT00566722 · Phase 3 · registry result, not featured evidence
6.9%Sub-optimal Response to Narrow-ban
NCT00566722 · Phase 3 · registry result, not featured evidence
—40 mg every week
NCT00927069 · Phase 3 · registry result, not featured evidence
—40 mg every week
NCT00927069 · Phase 3 · registry result, not featured evidence
—Group A
NCT00927069 · Phase 3 · registry result, not featured evidence
—Group B
NCT00927069 · Phase 3 · registry result, not featured evidence
4.9%Adalimumab + Calcipotriol/Betameth
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
1.6%Adalimumab + Placebo
NCT00574249 · Phase 3 · registry result, not featured evidence
—40 mg Eow
NCT00513370 · Phase 3 · registry result, not featured evidence
—80 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence
—40 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence
—
NCT01872546 · Phase 2 · registry result, not featured evidence
5.6%
NCT01320293 · Phase na · registry result, not featured evidence
—0.8 mg/kg QWj
NCT00078819 · Phase 3
show 35 more results
—0.8 mg/kg QW
NCT00078819 · Phase 3
—0.8 mg/kg QW
NCT00078819 · Phase 3
—0.8 mg/kg QW
NCT00078819 · Phase 3
—0.8 mg/kg QW
NCT00078819 · Phase 3
—0.8 mg/kg QW
NCT00078819 · Phase 3
0.9%Etanercept
NCT00078819 · Phase 3
—
NCT02749370 · Phase 4 · registry result, not featured evidence
—
NCT01971346 · Phase 4 · registry result, not featured evidence
—
NCT02274792 · Phase 4 · registry result, not featured evidence
5.8%
NCT00992394 · Phase 4 · registry result, not featured evidence
—
NCT01053819 · Phase 4 · registry result, not featured evidence
—Part 1 - Etanercept
NCT00640393 · Phase 4 · registry result, not featured evidence
—Part 2 - Etanercept
NCT00640393 · Phase 4 · registry result, not featured evidence
—Part 2 - Etanercept and nbUVB
NCT00640393 · Phase 4 · registry result, not featured evidence · combination
1.6%50 mg BIW/QW
NCT00791765 · Phase 4 · registry result, not featured evidence
5.3%
NCT00332332 · Phase 4 · registry result, not featured evidence
4.4%50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
2.2%50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
5.2%
NCT00581555 · Phase 4 · registry result, not featured evidence
2.9%Once Weekly
NCT00581100 · Phase 4 · registry result, not featured evidence
5.3%Twice, Then Once Weekly
NCT00581100 · Phase 4 · registry result, not featured evidence
6.7%Continuous
NCT00195507 · Phase 4 · registry result, not featured evidence
3.6%Intermittent
NCT00195507 · Phase 4 · registry result, not featured evidence
—
NCT03073200 · Phase 3 · registry result, not featured evidence
2.7%
NCT00141921 · Phase 3 · registry result, not featured evidence
1.2%50 mg SC QW
NCT01690299 · Phase 3 · registry result, not featured evidence
—50 mg SC QW
NCT01690299 · Phase 3 · registry result, not featured evidence
0%50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
—Etanercept Monotherapy
NCT01313221 · Phase 3 · registry result, not featured evidence · monotherapy
2%Etanercept + Clobetasol Propionate
NCT01235442 · Phase 3 · registry result, not featured evidence · combination
1.3%Etanercept Monotherapy
NCT01235442 · Phase 3 · registry result, not featured evidence · monotherapy
2.4%50 mg
NCT00482170 · Phase 3 · registry result, not featured evidence
6.5%50 mg
NCT00482170 · Phase 3 · registry result, not featured evidence
—50 mg twice weekly
NCT00585650 · Phase 1/2 · registry result, not featured evidence
—
NCT01170715 · Phase na · registry result, not featured evidence
Serious AEs
12.9%j
NCT00195676 · Phase 3
show 35 more results
0%
NCT00932113 · Phase 4 · registry result, not featured evidence
6.1%
NCT01553058 · Phase 4 · registry result, not featured evidence
0%
NCT01644396 · Phase 4 · registry result, not featured evidence
0.7%
NCT01265823 · Phase 4 · registry result, not featured evidence
4.1%
NCT00735787 · Phase 4 · registry result, not featured evidence
1.7%
NCT05637515 · Phase 3 · registry result, not featured evidence
30%
NCT02533375 · Phase 3 · registry result, not featured evidence
—Part 1 and Part 2: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
1.4%Part 1: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
3.7%Part 2: M923
NCT02581345 · Phase 3 · registry result, not featured evidence
—EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
7.3%EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
3.2%EOW
NCT02016482 · Phase 3 · registry result, not featured evidence
0%0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
0%0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
5.7%0.8 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
7.7%0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
0%0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
0%0.4 mg/kg
NCT01251614 · Phase 3 · registry result, not featured evidence
—Eow
NCT01646073 · Phase 3 · registry result, not featured evidence
1.2%Eow
NCT01646073 · Phase 3 · registry result, not featured evidence
4.9%Sub-optimal Response to Etanercept
NCT00566722 · Phase 3 · registry result, not featured evidence
0%Sub-optimal Response to MTX
NCT00566722 · Phase 3 · registry result, not featured evidence
3.4%Sub-optimal Response to Narrow-ban
NCT00566722 · Phase 3 · registry result, not featured evidence
—40 mg every week
NCT00927069 · Phase 3 · registry result, not featured evidence
—40 mg every week
NCT00927069 · Phase 3 · registry result, not featured evidence
0%Group A
NCT00927069 · Phase 3 · registry result, not featured evidence
0%Group B
NCT00927069 · Phase 3 · registry result, not featured evidence
4.4%Adalimumab + Calcipotriol/Betameth
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
4.1%Adalimumab + Placebo
NCT00574249 · Phase 3 · registry result, not featured evidence
—40 mg Eow
NCT00513370 · Phase 3 · registry result, not featured evidence
19%80 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence
21.3%40 mg every other week
NCT00647400 · Phase 2/3 · registry result, not featured evidence
0%
NCT01872546 · Phase 2 · registry result, not featured evidence
5.6%
NCT01320293 · Phase na · registry result, not featured evidence
0%0.8 mg/kg QWj
NCT00078819 · Phase 3
show 35 more results
0%0.8 mg/kg QW
NCT00078819 · Phase 3
0%0.8 mg/kg QW
NCT00078819 · Phase 3
0%0.8 mg/kg QW
NCT00078819 · Phase 3
0%0.8 mg/kg QW
NCT00078819 · Phase 3
0%0.8 mg/kg QW
NCT00078819 · Phase 3
—Etanercept
NCT00078819 · Phase 3
2.5%
NCT02749370 · Phase 4 · registry result, not featured evidence
2.2%
NCT01971346 · Phase 4 · registry result, not featured evidence
3.8%
NCT02274792 · Phase 4 · registry result, not featured evidence
4.8%
NCT00992394 · Phase 4 · registry result, not featured evidence
0%
NCT01053819 · Phase 4 · registry result, not featured evidence
1%Part 1 - Etanercept
NCT00640393 · Phase 4 · registry result, not featured evidence
5.3%Part 2 - Etanercept
NCT00640393 · Phase 4 · registry result, not featured evidence
0%Part 2 - Etanercept and nbUVB
NCT00640393 · Phase 4 · registry result, not featured evidence · combination
3.4%50 mg BIW/QW
NCT00791765 · Phase 4 · registry result, not featured evidence
5.2%
NCT00332332 · Phase 4 · registry result, not featured evidence
2.2%50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
2.9%50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
3.4%
NCT00581555 · Phase 4 · registry result, not featured evidence
0%Once Weekly
NCT00581100 · Phase 4 · registry result, not featured evidence
5.3%Twice, Then Once Weekly
NCT00581100 · Phase 4 · registry result, not featured evidence
—Continuous
NCT00195507 · Phase 4 · registry result, not featured evidence
—Intermittent
NCT00195507 · Phase 4 · registry result, not featured evidence
3.3%
NCT03073200 · Phase 3 · registry result, not featured evidence
3.9%
NCT00141921 · Phase 3 · registry result, not featured evidence
—50 mg SC QW
NCT01690299 · Phase 3 · registry result, not featured evidence
2.4%50 mg SC QW
NCT01690299 · Phase 3 · registry result, not featured evidence
—50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
2.3%Etanercept Monotherapy
NCT01313221 · Phase 3 · registry result, not featured evidence · monotherapy
2.4%Etanercept + Clobetasol Propionate
NCT01235442 · Phase 3 · registry result, not featured evidence · combination
2%Etanercept Monotherapy
NCT01235442 · Phase 3 · registry result, not featured evidence · monotherapy
2.9%50 mg
NCT00482170 · Phase 3 · registry result, not featured evidence
2.4%50 mg
NCT00482170 · Phase 3 · registry result, not featured evidence
0%50 mg twice weekly
NCT00585650 · Phase 1/2 · registry result, not featured evidence
9.5%
NCT01170715 · Phase na · registry result, not featured evidence
Most frequent reported AEs
j
nasopharyngitis 26.6%
upper respiratory tract infection 20.3%
headache 11.2%
NCT00195676 · Phase 3
show 29 more results
upper respiratory tract infection 40%
dizziness 13.3%
flu-like symptoms 13.3%
NCT00932113 · Phase 4 · registry result, not featured evidence
upper respiratory infection 9.1% (placebo 12.9%)
joint range of motion decrease 6.1% (placebo 0%)
headache 3% (placebo 6.5%)
NCT01553058 · Phase 4 · registry result, not featured evidence
latent tuberculosis 8%
rhinitis 6%
alanine aminotransferase increased 2%
NCT01644396 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 11.3%
hyperglycemia 10.7%
arthralgia 6.7%
NCT01265823 · Phase 4 · registry result, not featured evidence
nasopharyngitis 26.5% (placebo 13%)
headache 14.3% (placebo 4.3%)
cough 8.2% (placebo 4.3%)
NCT00735787 · Phase 4 · registry result, not featured evidence
headache 2.2%
nasopharyngitis 2.2%
upper respiratory tract infection 2.2%
NCT05637515 · Phase 3 · registry result, not featured evidence
nasopharyngitis 30%
pruritus 30%
hypoalbuminaemia 20%
NCT02533375 · Phase 3 · registry result, not featured evidence
injection site reaction 23.9%
nasopharyngitis 6.7%
headache 3.2%
NCT02581345 · Phase 3 · registry result, not featured evidence
nasopharyngitis 14.8%
psoriasis 10.3%
injection site reaction 10%
NCT02581345 · Phase 3 · registry result, not featured evidence
EOW
upper respiratory tract infection 8.3% (placebo 8.3%)
headache 5.5% (placebo 0%)
nasopharyngitis 5.5% (placebo 9.3%)
NCT02016482 · Phase 3 · registry result, not featured evidence
EOW
nasopharyngitis 12.8% (placebo 9.3%)
upper respiratory tract infection 4.3% (placebo 8.3%)
depression 3.2% (placebo 0.9%)
NCT02016482 · Phase 3 · registry result, not featured evidence
0.8 mg/kg
nasopharyngitis 21.1%
headache 15.8%
dry skin 7.9%
NCT01251614 · Phase 3 · registry result, not featured evidence
0.8 mg/kg
nasopharyngitis 18.5%
back pain 11.1%
headache 11.1%
NCT01251614 · Phase 3 · registry result, not featured evidence
0.8 mg/kg
nasopharyngitis 28.7%
headache 25.3%
upper respiratory tract infection 14.9%
NCT01251614 · Phase 3 · registry result, not featured evidence
0.4 mg/kg
nasopharyngitis 25.6%
headache 17.9%
cough 10.3%
NCT01251614 · Phase 3 · registry result, not featured evidence
0.4 mg/kg
cough 18.2%
decreased appetite 9.1%
gastroenteritis 9.1%
NCT01251614 · Phase 3 · registry result, not featured evidence
0.4 mg/kg
nasopharyngitis 23.1%
agitation 7.7%
cough 7.7%
NCT01251614 · Phase 3 · registry result, not featured evidence
Eow
upper respiratory tract infection 10.1% (placebo 6.9%)
oropharyngeal pain 4.1% (placebo 1.1%)
nasopharyngitis 3.8% (placebo 5.7%)
NCT01646073 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 6.1%
cough 3.7%
headache 3.7%
NCT00566722 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 12.2%
injection site erythema 7.3%
nasopharyngitis 7.3%
NCT00566722 · Phase 3 · registry result, not featured evidence
fatigue 6.9%
pharyngitis 6.9%
abdominal pain 3.4%
NCT00566722 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 18%
back pain 8%
common cold 8%
NCT00927069 · Phase 3 · registry result, not featured evidence
headache 11.4%
common cold 5.7%
upper respiratory tract infection 5.7%
NCT00927069 · Phase 3 · registry result, not featured evidence
nasopharyngitis 8.7%
headache 5.2%
psoriasis 5.2%
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 6.3%
headache 6%
pruritus 5.8%
NCT00574249 · Phase 3 · registry result, not featured evidence
40 mg Eow
nasopharyngitis 10.8%
upper respiratory tract infection 10.8%
headache 4.9%
NCT00513370 · Phase 3 · registry result, not featured evidence
80 mg every other week
nasopharyngitis 77.6%
blood triglycerides increased 29.3%
blood creatine phosphokinase increased 25.9%
NCT00647400 · Phase 2/3 · registry result, not featured evidence
40 mg every other week
nasopharyngitis 75.3%
blood triglycerides increased 24.7%
alanine aminotransferase increased 23.6%
NCT00647400 · Phase 2/3 · registry result, not featured evidence
upper respiratory tract infection 22.2%
elbow strain 5.6%
heartburn 5.6%
NCT01320293 · Phase na · registry result, not featured evidence
0.8 mg/kg QWj
upper respiratory tract infection 12.5% (placebo 11.4%)
skin papilloma 6.3% (placebo 0%)
acne 3.1% (placebo 0%)
NCT00078819 · Phase 3
show 31 more results
0.8 mg/kg QW
upper respiratory tract infection 17% (placebo 11.4%)
headache 13.2% (placebo 12.4%)
influenza 7.5% (placebo 1.9%)
NCT00078819 · Phase 3
0.8 mg/kg QW
upper respiratory tract infection 42.4% (placebo 11.4%)
headache 20.3% (placebo 12.4%)
nasopharyngitis 20.3% (placebo 8.6%)
NCT00078819 · Phase 3
0.8 mg/kg QW
upper respiratory tract infection 30.8% (placebo 11.4%)
headache 20.2% (placebo 12.4%)
nasopharyngitis 18.8% (placebo 8.6%)
NCT00078819 · Phase 3
0.8 mg/kg QW
upper respiratory tract infection 25% (placebo 11.4%)
abdominal pain 8.3% (placebo 0%)
body tinea 8.3% (placebo 0%)
NCT00078819 · Phase 3
0.8 mg/kg QW
nasopharyngitis 10.3% (placebo 8.6%)
headache 8.8% (placebo 12.4%)
acne 2.9% (placebo 0%)
NCT00078819 · Phase 3
back pain 2.5%
exostosis 2.5%
injection related reaction 2.5%
NCT02749370 · Phase 4 · registry result, not featured evidence
nasal congestion 8.7%
gi distress 6.5%
injection site reaction 6.5%
NCT01971346 · Phase 4 · registry result, not featured evidence
injection site reaction 7.6%
psoriasis 6.1%
headache 5.3%
NCT02274792 · Phase 4 · registry result, not featured evidence
nasopharyngitis 26.2%
bronchitis 10.7%
arthralgia 7.1%
NCT00992394 · Phase 4 · registry result, not featured evidence
common cold 9.1%
injection site reaction 4%
upper respiratory tract infection 4%
NCT00640393 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 15.8%
common cold 13.2%
injection site reaction 0%
NCT00640393 · Phase 4 · registry result, not featured evidence
common cold 5.4%
upper respiratory tract infection 2.7%
injection site reaction 0%
NCT00640393 · Phase 4 · registry result, not featured evidence · combination
50 mg BIW/QW
nasopharyngitis 8.5% (placebo 8.1%)
upper respiratory tract infection 8.5% (placebo 14.5%)
arthralgia 6.8% (placebo 3.2%)
NCT00791765 · Phase 4 · registry result, not featured evidence
nasopharyngitis 7.8%
headache 7%
upper respiratory tract infection 7%
NCT00332332 · Phase 4 · registry result, not featured evidence
50 mg BW/QW
headache 11%
nasopharyngitis 10.3%
upper respiratory tract infection 6.6%
NCT00663052 · Phase 4 · registry result, not featured evidence
50 mg QW/QW
nasopharyngitis 16.1%
headache 10.9%
diarrhoea 7.3%
NCT00663052 · Phase 4 · registry result, not featured evidence
headache 29.3% (placebo 33.9%)
nasopharyngitis 19% (placebo 21%)
hypertension 15.5% (placebo 14.5%)
NCT00581555 · Phase 4 · registry result, not featured evidence
Once Weekly
nasopharyngitis 11.8%
headache nos 8.8%
alopecia areata 2.9%
NCT00581100 · Phase 4 · registry result, not featured evidence
Twice, Then Once Weekly
headache nos 10.5%
nasopharyngitis 10.5%
dermatitis allergic 5.3%
NCT00581100 · Phase 4 · registry result, not featured evidence
upper respiratory infection 17.9%
headache 17.6%
nervous 13.4%
NCT00195507 · Phase 4 · registry result, not featured evidence
upper respiratory infection 17.4%
headache 12.9%
arthralgia 11%
NCT00195507 · Phase 4 · registry result, not featured evidence
influenza 6.7% (placebo 0%)
pharyngitis 6.7% (placebo 0%)
bronchitis 3.3% (placebo 0%)
NCT03073200 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 37.6%
nasopharyngitis 26%
headache 21.5%
NCT00141921 · Phase 3 · registry result, not featured evidence
50 mg SC QW
nasopharyngitis 9.6% (placebo 9.5%)
headache 6% (placebo 3.6%)
cough 4.8% (placebo 3.6%)
NCT01690299 · Phase 3 · registry result, not featured evidence
nasopharyngitis 13.6%
headache 10.7%
injection site reaction 9%
NCT01313221 · Phase 3 · registry result, not featured evidence · monotherapy
nasopharyngitis 8.3%
upper respiratory tract infection 6.9%
sinusitis 6.3%
NCT01235442 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 11.6%
nasopharyngitis 8.6%
headache 7.3%
NCT01235442 · Phase 3 · registry result, not featured evidence · monotherapy
50 mg
nasopharyngitis 11.6%
injection site reaction 8.7%
headache 6.3%
NCT00482170 · Phase 3 · registry result, not featured evidence
50 mg
nasopharyngitis 12.8%
injection site erythema 8.1%
injection site reaction 8.1%
NCT00482170 · Phase 3 · registry result, not featured evidence
50 mg twice weekly
upper respiratory infection 37.5% (placebo 33.3%)
NCT00585650 · Phase 1/2 · registry result, not featured evidence
upper respiratory infection 28.6%
fatigue 9.5%
rash 9.5%
NCT01170715 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cAssessment timepoints differ: 28 weeks versus 24 weeks.
  4. dTrial phases differ: Phase 3 versus Phase 4.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fAssessment timepoints differ: 52 weeks versus 24 weeks.
  7. gAssessment timepoints differ: 26 weeks versus 24 weeks.
  8. hTrial phases differ: Phase 4 versus Phase 3.
  9. iPopulation context differs: registered conditions differ.
  10. jPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab

BSA Involvement 5.9% (n=15) vs 10.7% (n=15) Methotrexate (MTX) @ 16wk
absolute value · percentage points
NCT00932113 · Phase 4 · registry result, not featured evidence
Target Lesion TOTAL 1.2 vs 3.4 Methotrexate (MTX) score @ 16wk
absolute change · score
NCT00932113 · Phase 4 · registry result, not featured evidence
Aortic Vascular Inflammation TBR -0.067 vs -0.052 placebo ratio @ 12wk
absolute change · ratio
NCT01553058 · Phase 4 · registry result, not featured evidence
Total Cholesterol Change mg/dL 1.48 vs 5 placebo mg/dL @ 12wk
absolute change · mg/dL
NCT01553058 · Phase 4 · registry result, not featured evidence
PASI 75 46.9% (n=32) vs 6.7% (n=30) placebo @ 12wk
responder rate · % of participants
PASI75
NCT01553058 · Phase 4 · registry result, not featured evidence · converted to % from 15 Participants as posted
PGA 0-1 43.8% (n=32) vs 6.7% (n=30) placebo @ 12wk
responder rate · % of participants
PGA Clear/Almost Clear
NCT01553058 · Phase 4 · registry result, not featured evidence · converted to % from 14 Participants as posted
EQ-5D 0.07 vs 0 placebo score @ 12wk
absolute change · score
NCT01553058 · Phase 4 · registry result, not featured evidence
PGA Improvement 40% (n=50) @ 2wk
responder rate · % of participants
No placebo or comparator arm
NCT01644396 · Phase 4 · registry result, not featured evidence
show 5 more results
74% (n=50) @ 4wk
NCT01644396 · Phase 4 · registry result, not featured evidence
98% (n=50) @ 8wk
NCT01644396 · Phase 4 · registry result, not featured evidence
98% (n=50) @ 12wk
NCT01644396 · Phase 4 · registry result, not featured evidence
100% (n=50) @ 16wk
NCT01644396 · Phase 4 · registry result, not featured evidence
96% (n=50) @ 24wk
NCT01644396 · Phase 4 · registry result, not featured evidence
NAPSI -68.06% (n=22) @ 24wk
percent change · % of baseline
No placebo or comparator arm
NCT01644396 · Phase 4 · registry result, not featured evidence
show 2 more results
-40% (n=213) @ 16wk
NCT00574249 · Phase 3 · registry result, not featured evidence
-37.5% (n=212) @ 16wk
NCT00574249 · Phase 3 · registry result, not featured evidence · combination
DLQI Less Than or Equal 5 65% (n=150) @ 4wk
responder rate · % of participants
No placebo or comparator arm
NCT01265823 · Phase 4 · registry result, not featured evidence
show 1 more result
86% (n=150) @ 16wk
NCT01265823 · Phase 4 · registry result, not featured evidence
DLQI 5.2 score @ 4wk
absolute value · score
No placebo or comparator arm
Score at Week 4
NCT01265823 · Phase 4 · registry result, not featured evidence
DLQI 1.8 score @ 16wk
absolute value · score
No placebo or comparator arm
Score at Week 16
NCT01265823 · Phase 4 · registry result, not featured evidence

+ 163 further endpoints in the CSV export.

etanercept

CDLQI 52.3% (n=100) vs 17.5% (n=102) placebo @ 12wk
absolute change · percentage points
NCT00078819 · Phase 3
sPGA Leq2 21.1% (n=77) @ 4wk
responder rate · % of participants
No placebo or comparator arm
NCT02749370 · Phase 4 · registry result, not featured evidence
show 5 more results
55.8% (n=77) @ 8wk
NCT02749370 · Phase 4 · registry result, not featured evidence
62.3% (n=77) @ 12wk
NCT02749370 · Phase 4 · registry result, not featured evidence
59.7% (n=77) @ 16wk
NCT02749370 · Phase 4 · registry result, not featured evidence
55.8% (n=77) @ 20wk
NCT02749370 · Phase 4 · registry result, not featured evidence
57.1% (n=77) @ 24wk
NCT02749370 · Phase 4 · registry result, not featured evidence
sPGA 2.9 score @ 4wk
absolute value · score
No placebo or comparator arm
NCT02749370 · Phase 4 · registry result, not featured evidence
show 5 more results
2.4 score @ 8wk
NCT02749370 · Phase 4 · registry result, not featured evidence
2.2 score @ 12wk
NCT02749370 · Phase 4 · registry result, not featured evidence
2.2 score @ 16wk
NCT02749370 · Phase 4 · registry result, not featured evidence
2.2 score @ 20wk
NCT02749370 · Phase 4 · registry result, not featured evidence
2.2 score @ 24wk
NCT02749370 · Phase 4 · registry result, not featured evidence
sPGA Improvement 1 Grade 40.8% (n=77) @ 4wk
responder rate · % of participants
No placebo or comparator arm
NCT02749370 · Phase 4 · registry result, not featured evidence
show 5 more results
70.1% (n=77) @ 8wk
NCT02749370 · Phase 4 · registry result, not featured evidence
75.3% (n=77) @ 12wk
NCT02749370 · Phase 4 · registry result, not featured evidence
72.7% (n=77) @ 16wk
NCT02749370 · Phase 4 · registry result, not featured evidence
74% (n=77) @ 20wk
NCT02749370 · Phase 4 · registry result, not featured evidence
74% (n=77) @ 24wk
NCT02749370 · Phase 4 · registry result, not featured evidence
sPGA Improvement 2 Grade 7.9% (n=77) @ 4wk
responder rate · % of participants
No placebo or comparator arm
NCT02749370 · Phase 4 · registry result, not featured evidence
show 5 more results
31.2% (n=77) @ 8wk
NCT02749370 · Phase 4 · registry result, not featured evidence
32.5% (n=77) @ 12wk
NCT02749370 · Phase 4 · registry result, not featured evidence
37.7% (n=77) @ 16wk
NCT02749370 · Phase 4 · registry result, not featured evidence
36.4% (n=77) @ 20wk
NCT02749370 · Phase 4 · registry result, not featured evidence
39% (n=77) @ 24wk
NCT02749370 · Phase 4 · registry result, not featured evidence
BSA -1.8% (n=133) @ 2wk50 mg BW/QW
absolute change · percentage points
No placebo or comparator arm
NCT00663052 · Phase 4 · registry result, not featured evidence
show 24 more results
-0.3% (n=137) @ 2wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
-5.3% (n=133) @ 4wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
-3.1% (n=137) @ 4wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
-13.4% (n=133) @ 8wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
-8.4% (n=137) @ 8wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
-20% (n=133) @ 12wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
-12.7% (n=137) @ 12wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
-23.8% (n=133) @ 16wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
-15.9% (n=137) @ 16wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
-25.4% (n=133) @ 20wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
-18.2% (n=137) @ 20wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
-25.9% (n=133) @ 24wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
-19% (n=137) @ 24wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
62.47% (n=143) @ 12wk50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
72.88% (n=143) @ 16wk50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
75.86% (n=143) @ 20wk50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
75.39% (n=143) @ 24wk50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
13.47% (n=77) @ 4wk
NCT02749370 · Phase 4 · registry result, not featured evidence
31.03% (n=77) @ 8wk
NCT02749370 · Phase 4 · registry result, not featured evidence
44.49% (n=77) @ 12wk
NCT02749370 · Phase 4 · registry result, not featured evidence
48.26% (n=77) @ 16wk
NCT02749370 · Phase 4 · registry result, not featured evidence
49.97% (n=77) @ 20wk
NCT02749370 · Phase 4 · registry result, not featured evidence
46.89% (n=77) @ 24wk
NCT02749370 · Phase 4 · registry result, not featured evidence
-69.9% (n=226) @ 52wk
NCT00332332 · Phase 4 · registry result, not featured evidence
PSI Total 14.7 score @ 1wk
absolute value · score
No placebo or comparator arm
NCT02749370 · Phase 4 · registry result, not featured evidence
show 8 more results
13.7 score @ 2wk
NCT02749370 · Phase 4 · registry result, not featured evidence
12.1 score @ 3wk
NCT02749370 · Phase 4 · registry result, not featured evidence
11.7 score @ 4wk
NCT02749370 · Phase 4 · registry result, not featured evidence
10 score @ 8wk
NCT02749370 · Phase 4 · registry result, not featured evidence
8.8 score @ 12wk
NCT02749370 · Phase 4 · registry result, not featured evidence
10.1 score @ 16wk
NCT02749370 · Phase 4 · registry result, not featured evidence
9.9 score @ 20wk
NCT02749370 · Phase 4 · registry result, not featured evidence
9.6 score @ 24wk
NCT02749370 · Phase 4 · registry result, not featured evidence
PGA AUC 1.33 score @ 52wk
absolute value · score
No placebo or comparator arm
NCT00992394 · Phase 4 · registry result, not featured evidence
DLQI AUC 2.96 score @ 52wk
absolute value · score
No placebo or comparator arm
NCT00992394 · Phase 4 · registry result, not featured evidence
PGA 1.4 score @ 52wk
absolute value · score
No placebo or comparator arm
NCT00992394 · Phase 4 · registry result, not featured evidence
BSA Involvement 19.06% (n=37) @ 0wk
absolute value · percentage points
No placebo or comparator arm
NCT00640393 · Phase 4 · registry result, not featured evidence · combination
show 19 more results
23.65% (n=38) @ 0wk
NCT00640393 · Phase 4 · registry result, not featured evidence
6.69% (n=37) @ 12wk
NCT00640393 · Phase 4 · registry result, not featured evidence · combination
8.28% (n=38) @ 12wk
NCT00640393 · Phase 4 · registry result, not featured evidence
4.92% (n=37) @ 16wk
NCT00640393 · Phase 4 · registry result, not featured evidence · combination
7.27% (n=38) @ 16wk
NCT00640393 · Phase 4 · registry result, not featured evidence
4.43% (n=37) @ 20wk
NCT00640393 · Phase 4 · registry result, not featured evidence · combination
6.53% (n=38) @ 20wk
NCT00640393 · Phase 4 · registry result, not featured evidence
3.28% (n=37) @ 24wk
NCT00640393 · Phase 4 · registry result, not featured evidence · combination
7.19% (n=38) @ 24wk
NCT00640393 · Phase 4 · registry result, not featured evidence
17.82% (n=7) @ 0wk
NCT00640393 · Phase 4 · registry result, not featured evidence · combination
24.24% (n=28) @ 0wk
NCT00640393 · Phase 4 · registry result, not featured evidence
6.04% (n=7) @ 12wk
NCT00640393 · Phase 4 · registry result, not featured evidence · combination
8.63% (n=28) @ 12wk
NCT00640393 · Phase 4 · registry result, not featured evidence
2.93% (n=7) @ 16wk
NCT00640393 · Phase 4 · registry result, not featured evidence · combination
7.57% (n=28) @ 16wk
NCT00640393 · Phase 4 · registry result, not featured evidence
2.07% (n=7) @ 20wk
NCT00640393 · Phase 4 · registry result, not featured evidence · combination
6.68% (n=28) @ 20wk
NCT00640393 · Phase 4 · registry result, not featured evidence
1.57% (n=7) @ 24wk
NCT00640393 · Phase 4 · registry result, not featured evidence · combination
7.21% (n=28) @ 24wk
NCT00640393 · Phase 4 · registry result, not featured evidence
DLQI 11.92 score @ 0wk
absolute value · score
No placebo or comparator arm
NCT00640393 · Phase 4 · registry result, not featured evidence · combination
show 19 more results
12.47 score @ 0wk
NCT00640393 · Phase 4 · registry result, not featured evidence
3.69 score @ 12wk
NCT00640393 · Phase 4 · registry result, not featured evidence · combination
5.97 score @ 12wk
NCT00640393 · Phase 4 · registry result, not featured evidence
3.06 score @ 16wk
NCT00640393 · Phase 4 · registry result, not featured evidence · combination
6.03 score @ 16wk
NCT00640393 · Phase 4 · registry result, not featured evidence
2.69 score @ 20wk
NCT00640393 · Phase 4 · registry result, not featured evidence · combination
6.05 score @ 20wk
NCT00640393 · Phase 4 · registry result, not featured evidence
2.83 score @ 24wk
NCT00640393 · Phase 4 · registry result, not featured evidence · combination
6 score @ 24wk
NCT00640393 · Phase 4 · registry result, not featured evidence
9.43 score @ 0wk
NCT00640393 · Phase 4 · registry result, not featured evidence · combination
12.3 score @ 0wk
NCT00640393 · Phase 4 · registry result, not featured evidence
3 score @ 12wk
NCT00640393 · Phase 4 · registry result, not featured evidence · combination
6.07 score @ 12wk
NCT00640393 · Phase 4 · registry result, not featured evidence
1.71 score @ 16wk
NCT00640393 · Phase 4 · registry result, not featured evidence · combination
5.89 score @ 16wk
NCT00640393 · Phase 4 · registry result, not featured evidence
0.71 score @ 20wk
NCT00640393 · Phase 4 · registry result, not featured evidence · combination
6 score @ 20wk
NCT00640393 · Phase 4 · registry result, not featured evidence
0.57 score @ 24wk
NCT00640393 · Phase 4 · registry result, not featured evidence · combination
5.89 score @ 24wk
NCT00640393 · Phase 4 · registry result, not featured evidence

+ 33 further endpoints in the CSV export.

Rheumatoid Arthritis

Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline

adalimumab · Humira

Marketed by AbbVie and partners

Approved in Rheumatoid Arthritismonoclonal antibody (fully human IgG1)
Reliable signal

NCT00195702 · Phase 3 · completed

This was a large, randomized, double-blind, placebo-controlled trial. More patients on adalimumab responded on the ACR20 joint-response measure than on placebo (about 61-63% vs about 30%, p<0.001 for both doses), and adalimumab also significantly slowed radiographic joint damage and improved physical function compared with placebo (p<0.001 for both).

Next expected readout: December 2027 · NCT06440629 (registry estimate)

Reported efficacy

Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 24; Change From Baseline in Modified Total Sharp X-ray Score at Week 52 (Baseline and Week 52); Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 52 (Baseline and Week 52): Primary 1, ACR20 at week 24: 63% (40 mg every other week) and 61% (20 mg weekly) vs 30% placebo, all with methotrexate (P<=0.001 for each), met. Primary 2, change in modified total Sharp score at week 52: 0.1 and 0.8 vs 2.7 (P<=0.001 for each), met. Primary 3, change in HAQ disability index at week 52: -0.59 and -0.61 vs -0.25 (P<=0.001 for each), met. (met)

Result source: NCT00195702

etanercept · Enbrel

Marketed by Amgen and partners

Approved in Rheumatoid Arthritisfusion protein
Partial signal

NCT03780959 · Phase 2/3 · completed

After 90 days of open-label etanercept, 51 responding children were randomized to continue etanercept or receive placebo in a double-blind comparison. The clinical primary endpoint, disease flare, was met in favor of etanercept (28% vs 81% with placebo; p=0.0030), but the randomized sample was small, limiting the strength of the evidence.

Next expected readout: March 2028 · NCT03414502 (registry estimate)

Reported efficacy

Percentage of Participants With Disease Flare in Part 2 (End of part 1 (day 90) and months 4 to 7): Percentage of Participants With Disease Flare in Part 2 (End of part 1 (day 90) and months 4 to 7): Part 2: Etanercept 0.4 mg/kg 28% vs Part 2: Placebo 81% (met)

Result source: NCT03780959

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumabetanercept
ACR2063.3% vs 29.5%+33.8 vs placebo40 mg every other week · wk 24 · n 207NCT00195702
28 other results
  • 50.3% vs 33.9% 40 mg every other week · wk 12 · n 159 · Phase 3 · primary NCT00647270
  • 57% vs 35% 40 mg · wk 12 · n 121 · Phase 2/3 · primary NCT00538902
  • 47.3% vs 33.9% 80 mg monthly · wk 12 · n 205 · Phase 3 · primary NCT00647270
  • 51.2% vs 35% 80 mg · wk 12 · n 121 · Phase 2/3 · primary NCT00538902
  • 60.8% vs 29.5% 20 mg weekly · wk 24 · n 212 · Phase 3 · primary NCT00195702
  • 58.9% vs 24% 40 mg every other week · wk 52 · n 207 · Phase 3 · secondary NCT00195702
  • 54.7% vs 24% 20 mg weekly · wk 52 · n 212 · Phase 3 · secondary NCT00195702
  • 75.4% vs 56.4% wk 26 · n 171 · Phase 3 · secondary NCT00870467
  • 50% vs 59.9% wk 76 · n 274 · Phase 3 · secondary NCT00195663
  • 69% vs 59.9% wk 76 · n 268 · Phase 3 · secondary NCT00195663
  • 54.4% vs 62.6% wk 52 · n 274 · Phase 3 · secondary NCT00195663
  • 72.8% vs 62.6% wk 52 · n 268 · Phase 3 · secondary NCT00195663
  • 49.3% vs 56% wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 69.4% vs 56% wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 53.3% vs 61.5% wk 26 · n 274 · Phase 3 · secondary NCT00195663
  • 68.7% vs 61.5% wk 26 · n 268 · Phase 3 · secondary NCT00195663
  • 69.2% vs 71.4% wk 12 · n 454 · Phase 4 · primary NCT01500278
  • 84.8% vs 80.4% wk 78 · n 105 · Phase 4 · secondary NCT00420927
  • 66.4% vs 80.4% wk 78 · n 259 · Phase 4 · secondary NCT00420927
  • 64.5% vs 60.8% wk 6 · n 454 · Phase 4 · secondary NCT01500278
  • 68% vs 68% 40 mg every other week · wk 24 · n 50 · Phase 2 · secondary NCT01712178
  • 62% vs 68% 40 mg every other week · wk 12 · n 50 · Phase 2 · secondary NCT01712178
  • 51.3% vs 65.7% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 56.4% vs 68.6% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 46.2% vs 65.7% wk 104 · n 39 · Phase 4 · secondary NCT01162421
  • 66.7% vs 60% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 64.1% vs 37.1% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 69.2% vs 57.1% wk 13 · n 39 · Phase 4 · secondary NCT01162421
78.6% vs 62.5%vs Methotrexate25 mg · wk 52 · n 182NCT00445770
63 other results
  • 79.7% vs 59.1% 25 mg · wk 48 · n 182 · Phase 3 · secondary NCT00445770
  • 75.3% vs 59.7% 25 mg · wk 40 · n 182 · Phase 3 · secondary NCT00445770
  • 80.8% vs 58% 25 mg · wk 32 · n 182 · Phase 3 · secondary NCT00445770
  • 77.5% vs 56.3% 25 mg · wk 24 · n 182 · Phase 3 · secondary NCT00445770
  • 78.6% vs 58.5% 25 mg · wk 20 · n 182 · Phase 3 · secondary NCT00445770
  • 75.3% vs 51.7% 25 mg · wk 16 · n 182 · Phase 3 · secondary NCT00445770
  • 77.5% vs 48.3% 25 mg · wk 12 · n 182 · Phase 3 · secondary NCT00445770
  • 68.7% vs 43.2% 25 mg · wk 8 · n 182 · Phase 3 · secondary NCT00445770
  • 56.9% vs 27.3% 25 mg · wk 4 · n 182 · Phase 3 · secondary NCT00445770
  • 49.4% vs 16.1% 25 mg · wk 2 · n 182 · Phase 3 · secondary NCT00445770
  • 75.9% vs 62.5% 10 mg · wk 52 · n 192 · Phase 3 · secondary NCT00445770
  • 76.4% vs 59.1% 10 mg · wk 48 · n 192 · Phase 3 · secondary NCT00445770
  • 78.5% vs 59.7% 10 mg · wk 40 · n 192 · Phase 3 · secondary NCT00445770
  • 79.1% vs 58% 10 mg · wk 32 · n 192 · Phase 3 · secondary NCT00445770
  • 77% vs 56.3% 10 mg · wk 24 · n 192 · Phase 3 · secondary NCT00445770
  • 75.4% vs 58.5% 10 mg · wk 20 · n 192 · Phase 3 · secondary NCT00445770
  • 73.8% vs 51.7% 10 mg · wk 16 · n 192 · Phase 3 · secondary NCT00445770
  • 70.2% vs 48.3% 10 mg · wk 12 · n 192 · Phase 3 · secondary NCT00445770
  • 68.1% vs 43.2% 10 mg · wk 8 · n 192 · Phase 3 · secondary NCT00445770
  • 55.5% vs 27.3% 10 mg · wk 4 · n 192 · Phase 3 · secondary NCT00445770
  • 54% vs 16.1% 10 mg · wk 2 · n 192 · Phase 3 · secondary NCT00445770
  • 78% vs 47.2% 50 mg · wk 72 · n 200 · Phase 4 · secondary NCT00565409
  • 79.5% vs 46.7% 50 mg · wk 80 · n 200 · Phase 4 · secondary NCT00565409
  • 76.5% vs 48.7% 50 mg · wk 64 · n 200 · Phase 4 · secondary NCT00565409
  • 75.5% vs 48.7% 50 mg · wk 88 · n 200 · Phase 4 · secondary NCT00565409
  • 75% vs 50.3% 50 mg · wk 56 · n 200 · Phase 4 · secondary NCT00565409
  • 77% vs 50.3% 50 mg · wk 48 · n 200 · Phase 4 · secondary NCT00565409
  • 76.9% vs 61.2% 50 mg · wk 40 · n 200 · Phase 4 · secondary NCT00565409
  • 86.5% vs 88.3% 50 mg · wk 36 · n 200 · Phase 4 · secondary NCT00565409
  • 74.6% vs 47.2% 25 mg · wk 72 · n 201 · Phase 4 · secondary NCT00565409
  • 77.6% vs 46.7% 25 mg · wk 80 · n 201 · Phase 4 · secondary NCT00565409
  • 74.1% vs 48.7% 25 mg · wk 64 · n 201 · Phase 4 · secondary NCT00565409
  • 74.6% vs 48.7% 25 mg · wk 88 · n 201 · Phase 4 · secondary NCT00565409
  • 74.6% vs 50.3% 25 mg · wk 56 · n 201 · Phase 4 · secondary NCT00565409
  • 76.1% vs 50.3% 25 mg · wk 48 · n 201 · Phase 4 · secondary NCT00565409
  • 77.7% vs 61.2% 25 mg · wk 40 · n 201 · Phase 4 · secondary NCT00565409
  • 85.1% vs 88.3% 25 mg · wk 36 · n 201 · Phase 4 · secondary NCT00565409
  • 90.5% vs 61.5% wk 76 · n 63 · Phase 4 · secondary NCT00913458
  • 96.8% vs 67.7% wk 64 · n 63 · Phase 4 · secondary NCT00913458
  • 87.3% vs 47.7% wk 91 · n 63 · Phase 4 · secondary NCT00913458
  • 93.7% vs 86.2% wk 56 · n 63 · Phase 4 · secondary NCT00913458
  • 96.8% vs 98.5% wk 52 · n 63 · Phase 4 · secondary NCT00913458
  • 51.9% vs 54.8% wk 20 · n 106 · Phase 4 · secondary NCT01313208
  • 49.1% vs 47.1% wk 16 · n 106 · Phase 4 · secondary NCT01313208
  • 40.6% vs 28.8% wk 12 · n 106 · Phase 4 · secondary NCT01313208
  • 50% vs 23.1% wk 8 · n 106 · Phase 4 · secondary NCT01313208
  • 36.8% vs 19.2% wk 4 · n 106 · Phase 4 · secondary NCT01313208
  • 28.6% vs 14.9% wk 2 · n 106 · Phase 4 · secondary NCT01313208
  • 89.2% vs 87.3% wk 76 · n 260 · Phase 4 · secondary NCT00848354
  • 88.8% vs 91.3% wk 63 · n 260 · Phase 4 · secondary NCT00848354
  • 90.9% vs 89.2% wk 89 · n 260 · Phase 4 · secondary NCT00848354
  • 90% vs 86.5% wk 50 · n 260 · Phase 4 · secondary NCT00848354
  • 91.7% vs 90.8% wk 102 · n 260 · Phase 4 · secondary NCT00848354
  • 86.9% vs 81.0% wk 37 · n 260 · Phase 4 · secondary NCT00848354
  • 90.0% vs 83.3% wk 115 · n 260 · Phase 4 · secondary NCT00848354
  • 83.2% vs 50% wk 24 · n 279 · Phase 4 · secondary NCT00848354
  • 89.2% vs 89.2% wk 128 · n 260 · Phase 4 · secondary NCT00848354
  • 84.6% vs 58.5% wk 20 · n 279 · Phase 4 · secondary NCT00848354
  • 84.2% vs 57.8% wk 16 · n 279 · Phase 4 · secondary NCT00848354
  • 79.6% vs 54.9% wk 12 · n 279 · Phase 4 · secondary NCT00848354
  • 73.8% vs 49.3% wk 8 · n 279 · Phase 4 · secondary NCT00848354
  • 63.8% vs 34.5% wk 4 · n 279 · Phase 4 · secondary NCT00848354
  • 47.8% vs 19.3% wk 2 · n 279 · Phase 4 · secondary NCT00848354
ACR5041.2% vs 45.9%vs Methotrexatewk 52 · n 274NCT00195663
19 other results
  • 61.6% vs 45.9% wk 52 · n 268 · Phase 3 · primary NCT00195663
  • 64.3% vs 38.7% wk 26 · n 171 · Phase 3 · secondary NCT00870467
  • 41.6% vs 44.4% wk 76 · n 274 · Phase 3 · secondary NCT00195663
  • 60.1% vs 44.4% wk 76 · n 268 · Phase 3 · secondary NCT00195663
  • 36.9% vs 42.8% wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 59% vs 42.8% wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 35% vs 40.5% wk 26 · n 274 · Phase 3 · secondary NCT00195663
  • 58.6% vs 40.5% wk 26 · n 268 · Phase 3 · secondary NCT00195663
  • 78.1% vs 69.6% wk 78 · n 105 · Phase 4 · secondary NCT00420927
  • 46.3% vs 69.6% wk 78 · n 259 · Phase 4 · secondary NCT00420927
  • 48% vs 50% 40 mg every other week · wk 24 · n 50 · Phase 2 · secondary NCT01712178
  • 36% vs 40% 40 mg every other week · wk 12 · n 50 · Phase 2 · secondary NCT01712178
  • 38.5% vs 45.7% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 43.6% vs 34.3% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 33.3% vs 42.9% wk 104 · n 39 · Phase 4 · secondary NCT01162421
  • 48.7% vs 40% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 43.6% vs 22.9% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 38.5% vs 22.9% wk 13 · n 39 · Phase 4 · secondary NCT01162421
  • 64.7% vs 51.6% wk 12 · n 17 · Phase 2 · secondary NCT03823391
62.1% vs 36.9%vs Methotrexate25 mg · wk 52 · n 182NCT00445770
65 other results
  • 57.7% vs 39.2% 25 mg · wk 48 · n 182 · Phase 3 · secondary NCT00445770
  • 58.8% vs 36.9% 25 mg · wk 40 · n 182 · Phase 3 · secondary NCT00445770
  • 59.3% vs 34.7% 25 mg · wk 32 · n 182 · Phase 3 · secondary NCT00445770
  • 54.4% vs 32.4% 25 mg · wk 24 · n 182 · Phase 3 · secondary NCT00445770
  • 50.5% vs 30.7% 25 mg · wk 20 · n 182 · Phase 3 · secondary NCT00445770
  • 44% vs 26.1% 25 mg · wk 16 · n 182 · Phase 3 · secondary NCT00445770
  • 42.3% vs 23.9% 25 mg · wk 12 · n 182 · Phase 3 · secondary NCT00445770
  • 35.7% vs 15.3% 25 mg · wk 8 · n 182 · Phase 3 · secondary NCT00445770
  • 22.5% vs 4% 25 mg · wk 4 · n 182 · Phase 3 · secondary NCT00445770
  • 16% vs 2.3% 25 mg · wk 2 · n 182 · Phase 3 · secondary NCT00445770
  • 59.4% vs 36.9% 10 mg · wk 52 · n 192 · Phase 3 · secondary NCT00445770
  • 57.3% vs 39.2% 10 mg · wk 48 · n 192 · Phase 3 · secondary NCT00445770
  • 60.4% vs 36.9% 10 mg · wk 40 · n 192 · Phase 3 · secondary NCT00445770
  • 60.4% vs 34.7% 10 mg · wk 32 · n 192 · Phase 3 · secondary NCT00445770
  • 53.6% vs 32.4% 10 mg · wk 24 · n 192 · Phase 3 · secondary NCT00445770
  • 50% vs 30.7% 10 mg · wk 20 · n 192 · Phase 3 · secondary NCT00445770
  • 50% vs 26.1% 10 mg · wk 16 · n 192 · Phase 3 · secondary NCT00445770
  • 47.4% vs 23.9% 10 mg · wk 12 · n 192 · Phase 3 · secondary NCT00445770
  • 38.5% vs 15.3% 10 mg · wk 8 · n 192 · Phase 3 · secondary NCT00445770
  • 28.1% vs 4% 10 mg · wk 4 · n 192 · Phase 3 · secondary NCT00445770
  • 14.7% vs 2.3% 10 mg · wk 2 · n 192 · Phase 3 · secondary NCT00445770
  • 62.0% vs 23.2% wk 24 · n 279 · Phase 4 · primary NCT00848354
  • 63% vs 26.9% 50 mg · wk 72 · n 200 · Phase 4 · secondary NCT00565409
  • 62.5% vs 27.4% 50 mg · wk 80 · n 200 · Phase 4 · secondary NCT00565409
  • 59% vs 27.9% 50 mg · wk 64 · n 200 · Phase 4 · secondary NCT00565409
  • 62.5% vs 25.9% 50 mg · wk 88 · n 200 · Phase 4 · secondary NCT00565409
  • 62% vs 28.9% 50 mg · wk 56 · n 200 · Phase 4 · secondary NCT00565409
  • 58% vs 33.5% 50 mg · wk 48 · n 200 · Phase 4 · secondary NCT00565409
  • 60.5% vs 41% 50 mg · wk 40 · n 200 · Phase 4 · secondary NCT00565409
  • 76.5% vs 74.1% 50 mg · wk 36 · n 200 · Phase 4 · secondary NCT00565409
  • 53.7% vs 26.9% 25 mg · wk 72 · n 201 · Phase 4 · secondary NCT00565409
  • 58.7% vs 27.4% 25 mg · wk 80 · n 201 · Phase 4 · secondary NCT00565409
  • 55.7% vs 27.9% 25 mg · wk 64 · n 201 · Phase 4 · secondary NCT00565409
  • 57.2% vs 25.9% 25 mg · wk 88 · n 201 · Phase 4 · secondary NCT00565409
  • 56.2% vs 28.9% 25 mg · wk 56 · n 201 · Phase 4 · secondary NCT00565409
  • 59.2% vs 33.5% 25 mg · wk 48 · n 201 · Phase 4 · secondary NCT00565409
  • 57.9% vs 41% 25 mg · wk 40 · n 201 · Phase 4 · secondary NCT00565409
  • 70.6% vs 74.1% 25 mg · wk 36 · n 201 · Phase 4 · secondary NCT00565409
  • 85.7% vs 50.8% wk 76 · n 63 · Phase 4 · secondary NCT00913458
  • 93.7% vs 50.8% wk 64 · n 63 · Phase 4 · secondary NCT00913458
  • 76.2% vs 44.6% wk 91 · n 63 · Phase 4 · secondary NCT00913458
  • 87.3% vs 73.8% wk 56 · n 63 · Phase 4 · secondary NCT00913458
  • 92.1% vs 95.4% wk 52 · n 63 · Phase 4 · secondary NCT00913458
  • 33% vs 28.8% wk 24 · n 106 · Phase 4 · secondary NCT01313208
  • 29.2% vs 28.8% wk 20 · n 106 · Phase 4 · secondary NCT01313208
  • 30.2% vs 22.1% wk 16 · n 106 · Phase 4 · secondary NCT01313208
  • 20.8% vs 12.5% wk 12 · n 106 · Phase 4 · secondary NCT01313208
  • 19.8% vs 4.8% wk 8 · n 106 · Phase 4 · secondary NCT01313208
  • 13.2% vs 4.8% wk 4 · n 106 · Phase 4 · secondary NCT01313208
  • 5.7% vs 3% wk 2 · n 106 · Phase 4 · secondary NCT01313208
  • 67.3% vs 58.7% wk 76 · n 260 · Phase 4 · secondary NCT00848354
  • 68.5% vs 62.7% wk 63 · n 260 · Phase 4 · secondary NCT00848354
  • 73.4% vs 60.8% wk 89 · n 260 · Phase 4 · secondary NCT00848354
  • 65.8% vs 60.3% wk 50 · n 260 · Phase 4 · secondary NCT00848354
  • 73.4% vs 61.7% wk 102 · n 260 · Phase 4 · secondary NCT00848354
  • 67.3% vs 53.2% wk 37 · n 260 · Phase 4 · secondary NCT00848354
  • 72.6% vs 59.2% wk 115 · n 260 · Phase 4 · secondary NCT00848354
  • 62.0% vs 23.2% wk 24 · n 279 · Phase 4 · secondary NCT00848354
  • 70.5% vs 65% wk 128 · n 260 · Phase 4 · secondary NCT00848354
  • 59.1% vs 27.5% wk 20 · n 279 · Phase 4 · secondary NCT00848354
  • 56.3% vs 24.6% wk 16 · n 279 · Phase 4 · secondary NCT00848354
  • 52.3% vs 21.1% wk 12 · n 279 · Phase 4 · secondary NCT00848354
  • 42.3% vs 16.9% wk 8 · n 279 · Phase 4 · secondary NCT00848354
  • 31.5% vs 8.4% wk 4 · n 279 · Phase 4 · secondary NCT00848354
  • 15.8% vs 2.9% wk 2 · n 279 · Phase 4 · secondary NCT00848354
ACR7047.4% vs 22.7%+24.7 vs placebowk 26 · n 171NCT00870467
16 other results
  • 28.8% vs 29.2% wk 76 · n 274 · Phase 3 · secondary NCT00195663
  • 47.4% vs 29.2% wk 76 · n 268 · Phase 3 · secondary NCT00195663
  • 25.9% vs 27.2% wk 52 · n 274 · Phase 3 · secondary NCT00195663
  • 45.5% vs 27.2% wk 52 · n 268 · Phase 3 · secondary NCT00195663
  • 28.1% vs 28.4% wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 46.6% vs 28.4% wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 19.7% vs 22.2% wk 26 · n 274 · Phase 3 · secondary NCT00195663
  • 42.5% vs 22.2% wk 26 · n 268 · Phase 3 · secondary NCT00195663
  • 69.5% vs 57.1% wk 78 · n 105 · Phase 4 · secondary NCT00420927
  • 30.1% vs 57.1% wk 78 · n 259 · Phase 4 · secondary NCT00420927
  • 30.8% vs 20% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 30.8% vs 14.3% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 23.1% vs 40% wk 104 · n 39 · Phase 4 · secondary NCT01162421
  • 25.6% vs 22.9% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 28.2% vs 8.6% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 15.4% vs 2.9% wk 13 · n 39 · Phase 4 · secondary NCT01162421
36.3% vs 15.9%vs Methotrexate25 mg · wk 52 · n 182NCT00445770
64 other results
  • 36.3% vs 18.2% 25 mg · wk 48 · n 182 · Phase 3 · secondary NCT00445770
  • 35.7% vs 14.8% 25 mg · wk 40 · n 182 · Phase 3 · secondary NCT00445770
  • 31.3% vs 11.9% 25 mg · wk 32 · n 182 · Phase 3 · secondary NCT00445770
  • 25.8% vs 11.9% 25 mg · wk 24 · n 182 · Phase 3 · secondary NCT00445770
  • 25.3% vs 13.1% 25 mg · wk 20 · n 182 · Phase 3 · secondary NCT00445770
  • 18.7% vs 9.7% 25 mg · wk 16 · n 182 · Phase 3 · secondary NCT00445770
  • 15.4% vs 9.7% 25 mg · wk 12 · n 182 · Phase 3 · secondary NCT00445770
  • 11% vs 2.8% 25 mg · wk 8 · n 182 · Phase 3 · secondary NCT00445770
  • 8.2% vs 0.6% 25 mg · wk 4 · n 182 · Phase 3 · secondary NCT00445770
  • 3.8% vs 0% 25 mg · wk 2 · n 182 · Phase 3 · secondary NCT00445770
  • 33.9% vs 15.9% 10 mg · wk 52 · n 192 · Phase 3 · secondary NCT00445770
  • 34.4% vs 18.2% 10 mg · wk 48 · n 192 · Phase 3 · secondary NCT00445770
  • 31.3% vs 14.8% 10 mg · wk 40 · n 192 · Phase 3 · secondary NCT00445770
  • 28.1% vs 11.9% 10 mg · wk 32 · n 192 · Phase 3 · secondary NCT00445770
  • 25.5% vs 11.9% 10 mg · wk 24 · n 192 · Phase 3 · secondary NCT00445770
  • 25% vs 13.1% 10 mg · wk 20 · n 192 · Phase 3 · secondary NCT00445770
  • 17.7% vs 9.7% 10 mg · wk 16 · n 192 · Phase 3 · secondary NCT00445770
  • 21.9% vs 9.7% 10 mg · wk 12 · n 192 · Phase 3 · secondary NCT00445770
  • 15.1% vs 2.8% 10 mg · wk 8 · n 192 · Phase 3 · secondary NCT00445770
  • 7.8% vs 0.6% 10 mg · wk 4 · n 192 · Phase 3 · secondary NCT00445770
  • 4.2% vs 0% 10 mg · wk 2 · n 192 · Phase 3 · secondary NCT00445770
  • 32% vs 10.7% 50 mg · wk 72 · n 200 · Phase 4 · secondary NCT00565409
  • 34% vs 10.7% 50 mg · wk 80 · n 200 · Phase 4 · secondary NCT00565409
  • 33% vs 10.2% 50 mg · wk 64 · n 200 · Phase 4 · secondary NCT00565409
  • 35.5% vs 11.2% 50 mg · wk 88 · n 200 · Phase 4 · secondary NCT00565409
  • 31% vs 10.2% 50 mg · wk 56 · n 200 · Phase 4 · secondary NCT00565409
  • 28% vs 9.6% 50 mg · wk 48 · n 200 · Phase 4 · secondary NCT00565409
  • 28.7% vs 17.6% 50 mg · wk 40 · n 200 · Phase 4 · secondary NCT00565409
  • 42% vs 33% 50 mg · wk 36 · n 200 · Phase 4 · secondary NCT00565409
  • 31.3% vs 10.7% 25 mg · wk 72 · n 201 · Phase 4 · secondary NCT00565409
  • 30.3% vs 10.7% 25 mg · wk 80 · n 201 · Phase 4 · secondary NCT00565409
  • 28.9% vs 10.2% 25 mg · wk 64 · n 201 · Phase 4 · secondary NCT00565409
  • 31.3% vs 11.2% 25 mg · wk 88 · n 201 · Phase 4 · secondary NCT00565409
  • 31.3% vs 10.2% 25 mg · wk 56 · n 201 · Phase 4 · secondary NCT00565409
  • 30.8% vs 9.6% 25 mg · wk 48 · n 201 · Phase 4 · secondary NCT00565409
  • 27.9% vs 17.6% 25 mg · wk 40 · n 201 · Phase 4 · secondary NCT00565409
  • 33.3% vs 33% 25 mg · wk 36 · n 201 · Phase 4 · secondary NCT00565409
  • 74.6% vs 38.5% wk 76 · n 63 · Phase 4 · secondary NCT00913458
  • 77.8% vs 36.9% wk 64 · n 63 · Phase 4 · secondary NCT00913458
  • 69.8% vs 38.5% wk 91 · n 63 · Phase 4 · secondary NCT00913458
  • 73% vs 56.9% wk 56 · n 63 · Phase 4 · secondary NCT00913458
  • 82.5% vs 80% wk 52 · n 63 · Phase 4 · secondary NCT00913458
  • 16% vs 12.5% wk 24 · n 106 · Phase 4 · secondary NCT01313208
  • 17% vs 10.6% wk 20 · n 106 · Phase 4 · secondary NCT01313208
  • 8.5% vs 9.6% wk 16 · n 106 · Phase 4 · secondary NCT01313208
  • 5.7% vs 1% wk 12 · n 106 · Phase 4 · secondary NCT01313208
  • 5.7% vs 0% wk 8 · n 106 · Phase 4 · secondary NCT01313208
  • 1.9% vs 0% wk 4 · n 106 · Phase 4 · secondary NCT01313208
  • 1.9% vs 0% wk 2 · n 106 · Phase 4 · secondary NCT01313208
  • 41.9% vs 34.1% wk 76 · n 260 · Phase 4 · secondary NCT00848354
  • 39.6% vs 34.1% wk 63 · n 260 · Phase 4 · secondary NCT00848354
  • 53.1% vs 38.3% wk 89 · n 260 · Phase 4 · secondary NCT00848354
  • 45% vs 32.5% wk 50 · n 260 · Phase 4 · secondary NCT00848354
  • 49.0% vs 36.7% wk 102 · n 260 · Phase 4 · secondary NCT00848354
  • 40.4% vs 30.2% wk 37 · n 260 · Phase 4 · secondary NCT00848354
  • 48.5% vs 35% wk 115 · n 260 · Phase 4 · secondary NCT00848354
  • 34.8% vs 11.3% wk 24 · n 279 · Phase 4 · secondary NCT00848354
  • 49.0% vs 40% wk 128 · n 260 · Phase 4 · secondary NCT00848354
  • 30.1% vs 10.6% wk 20 · n 279 · Phase 4 · secondary NCT00848354
  • 27.6% vs 9.2% wk 16 · n 279 · Phase 4 · secondary NCT00848354
  • 20.1% vs 4.2% wk 12 · n 279 · Phase 4 · secondary NCT00848354
  • 16.1% vs 3.5% wk 8 · n 279 · Phase 4 · secondary NCT00848354
  • 7.2% vs 2.1% wk 4 · n 279 · Phase 4 · secondary NCT00848354
  • 3.6% vs 0.7% wk 2 · n 279 · Phase 4 · secondary NCT00848354
DAS28-CRP remission38.5% vs 42.9%vs Standard of Carewk 104 · n 39NCT01162421
5 other results
  • 30.8% vs 34.3% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 35.9% vs 22.9% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 28.2% vs 31.4% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 35.9% vs 11.4% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 17.9% vs 8.6% wk 13 · n 39 · Phase 4 · secondary NCT01162421
54.5% vs 69.1%vs Standard COBRA-Slim Inductionwk 104 · n 55NCT03649061
1 other result
  • 58.2% vs 43.6% wk 28 · n 55 · Phase 4 · secondary NCT03649061
HAQ-DI, change-0.6 vs -0.3−0.3 vs placebo40 mg every other week · wk 52 · n 204NCT00195702
22 other results
  • -0.6 vs -0.3 20 mg weekly · wk 52 · n 212 · Phase 3 · primary NCT00195702
  • -0.6 vs -0.2 40 mg every other week · wk 24 · n 204 · Phase 3 · secondary NCT00195702
  • -0.4 vs -0.1 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.4 vs -0.1 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.3 vs 0 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.2 vs 0 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.5 vs -0.3 40 mg · wk 12 · n 120 · Phase 2/3 · secondary NCT00538902
  • -0.4 vs -0.1 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.4 vs -0.1 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.2 vs 0 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.2 vs 0 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.4 vs -0.3 80 mg · wk 12 · n 120 · Phase 2/3 · secondary NCT00538902
  • -0.6 vs -0.2 20 mg weekly · wk 24 · n 212 · Phase 3 · secondary NCT00195702
  • -0.8 vs -0.8 wk 52 · n 191 · Phase 3 · secondary NCT00195663
  • -1.1 vs -0.8 wk 52 · n 213 · Phase 3 · secondary NCT00195663
  • -0.6 vs -0.7 wk 104 · n 454 · Phase 4 · secondary NCT01500278
  • -0.5 vs -0.6 wk 104 · n 38 · Phase 4 · secondary NCT01162421
  • -0.6 vs -0.6 wk 78 · n 38 · Phase 4 · secondary NCT01162421
  • -0.5 vs -0.6 wk 52 · n 38 · Phase 4 · secondary NCT01162421
  • -0.5 vs -0.5 wk 39 · n 38 · Phase 4 · secondary NCT01162421
  • -0.5 vs -0.3 wk 26 · n 38 · Phase 4 · secondary NCT01162421
  • -0.4 vs -0.4 wk 13 · n 38 · Phase 4 · secondary NCT01162421
-0.6 vs -0.3vs Methotrexate25 mg · wk 52 · n 182NCT00445770
31 other results
  • -0.6 vs -0.3 25 mg · wk 48 · n 182 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 25 mg · wk 40 · n 182 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 25 mg · wk 32 · n 182 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 25 mg · wk 24 · n 182 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 25 mg · wk 20 · n 182 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.3 25 mg · wk 16 · n 182 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.3 25 mg · wk 12 · n 182 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.2 25 mg · wk 8 · n 182 · Phase 3 · secondary NCT00445770
  • -0.4 vs -0.1 25 mg · wk 4 · n 182 · Phase 3 · secondary NCT00445770
  • -0.3 vs -0.1 25 mg · wk 2 · n 182 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 10 mg · wk 52 · n 192 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 10 mg · wk 48 · n 192 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 10 mg · wk 40 · n 192 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 10 mg · wk 32 · n 192 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.3 10 mg · wk 24 · n 192 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.3 10 mg · wk 20 · n 192 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.3 10 mg · wk 16 · n 192 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.3 10 mg · wk 12 · n 192 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.2 10 mg · wk 8 · n 192 · Phase 3 · secondary NCT00445770
  • -0.3 vs -0.1 10 mg · wk 4 · n 192 · Phase 3 · secondary NCT00445770
  • -0.3 vs -0.1 10 mg · wk 2 · n 192 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.4 wk 24 · n 106 · Phase 4 · secondary NCT01313208
  • -0.4 vs -0.4 wk 20 · n 106 · Phase 4 · secondary NCT01313208
  • -0.4 vs -0.3 wk 16 · n 106 · Phase 4 · secondary NCT01313208
  • -0.4 vs -0.2 wk 12 · n 106 · Phase 4 · secondary NCT01313208
  • -0.4 vs -0.2 wk 8 · n 106 · Phase 4 · secondary NCT01313208
  • -0.3 vs -0.2 wk 4 · n 106 · Phase 4 · secondary NCT01313208
  • -0.3 vs -0.1 wk 2 · n 106 · Phase 4 · secondary NCT01313208
  • -0.8 vs -0.5 wk 24 · n 279 · Phase 4 · secondary NCT00848354
  • 0.9 vs 0.7 wk 104 · n 55 · Phase 4 · secondary NCT03649061
  • 0.8 vs 0.7 wk 28 · n 55 · Phase 4 · secondary NCT03649061
Modified Sharp score, change0.1 vs 2.7−2.6 vs placebo40 mg every other week · wk 52 · n 183NCT00195702
15 other results
  • 0.8 vs 2.7 20 mg weekly · wk 52 · n 196 · Phase 3 · primary NCT00195702
  • 1.5 vs 2.4 wk 26 · n 148 · Phase 3 · primary NCT00870467
  • 3 vs 5.7 wk 52 · n 274 · Phase 3 · primary NCT00195663
  • 1.3 vs 5.7 wk 52 · n 268 · Phase 3 · primary NCT00195663
  • 0.3 vs 1.3 40 mg every other week · wk 24 · n 183 · Phase 3 · secondary NCT00195702
  • 0.1 vs 4.8 40 mg every other week · wk 416 · n 81 · Phase 3 · secondary NCT00195702
  • 0.7 vs 6.2 40 mg every other week · wk 520 · n 79 · Phase 3 · secondary NCT00195702
  • 0.6 vs 1.3 20 mg weekly · wk 24 · n 196 · Phase 3 · secondary NCT00195702
  • 1.2 vs 4.8 20 mg weekly, then 40 mg every other week · wk 416 · n 70 · Phase 3 · secondary NCT00195702
  • 2.6 vs 6.2 20 mg weekly, then 40 mg every other week · wk 520 · n 70 · Phase 3 · secondary NCT00195702
  • 5.5 vs 10.4 wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 1.9 vs 10.4 wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 0.0 vs 2.2 wk 104 · n 39 · Phase 4 · secondary NCT01162421
  • 0.2 vs 1.6 wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 0.0 vs 0.9 wk 26 · n 39 · Phase 4 · secondary NCT01162421
3.3 vs 9.8vs Methotrexate25 mg · wk 52 · n 181NCT00445770
11 other results
  • 5.2 vs 9.8 10 mg · wk 52 · n 190 · Phase 3 · primary NCT00445770
  • 1.7 vs 5.1 25 mg · wk 24 · n 181 · Phase 3 · secondary NCT00445770
  • 2.4 vs 5.1 10 mg · wk 24 · n 190 · Phase 3 · secondary NCT00445770
  • 0 vs 0.5 wk 91 · n 63 · Phase 4 · secondary NCT00913458
  • 0 vs -1 50 mg · wk 48 · n 19 · Phase 4 · secondary NCT00858780
  • 0 vs -1 25 mg · wk 48 · n 22 · Phase 4 · secondary NCT00858780
  • 7 vs 7.3 wk 102 · n 159 · Phase 4 · secondary NCT00259610
  • 4.8 vs 7.3 wk 102 · n 166 · Phase 4 · secondary NCT00259610
  • 0.4 vs 1.4 wk 24 · n 247 · Phase 4 · secondary NCT00848354
  • 0.8 vs 0.7 wk 104 · n 55 · Phase 4 · secondary NCT03649061
  • 0.3 vs 0.5 wk 52 · n 55 · Phase 4 · secondary NCT03649061

ACR20

adalimumab
63.3% vs 29.5%+33.8 vs placebo40 mg every other week · wk 24 · n 207NCT00195702
28 other results
  • 50.3% vs 33.9% 40 mg every other week · wk 12 · n 159 · Phase 3 · primary NCT00647270
  • 57% vs 35% 40 mg · wk 12 · n 121 · Phase 2/3 · primary NCT00538902
  • 47.3% vs 33.9% 80 mg monthly · wk 12 · n 205 · Phase 3 · primary NCT00647270
  • 51.2% vs 35% 80 mg · wk 12 · n 121 · Phase 2/3 · primary NCT00538902
  • 60.8% vs 29.5% 20 mg weekly · wk 24 · n 212 · Phase 3 · primary NCT00195702
  • 58.9% vs 24% 40 mg every other week · wk 52 · n 207 · Phase 3 · secondary NCT00195702
  • 54.7% vs 24% 20 mg weekly · wk 52 · n 212 · Phase 3 · secondary NCT00195702
  • 75.4% vs 56.4% wk 26 · n 171 · Phase 3 · secondary NCT00870467
  • 50% vs 59.9% wk 76 · n 274 · Phase 3 · secondary NCT00195663
  • 69% vs 59.9% wk 76 · n 268 · Phase 3 · secondary NCT00195663
  • 54.4% vs 62.6% wk 52 · n 274 · Phase 3 · secondary NCT00195663
  • 72.8% vs 62.6% wk 52 · n 268 · Phase 3 · secondary NCT00195663
  • 49.3% vs 56% wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 69.4% vs 56% wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 53.3% vs 61.5% wk 26 · n 274 · Phase 3 · secondary NCT00195663
  • 68.7% vs 61.5% wk 26 · n 268 · Phase 3 · secondary NCT00195663
  • 69.2% vs 71.4% wk 12 · n 454 · Phase 4 · primary NCT01500278
  • 84.8% vs 80.4% wk 78 · n 105 · Phase 4 · secondary NCT00420927
  • 66.4% vs 80.4% wk 78 · n 259 · Phase 4 · secondary NCT00420927
  • 64.5% vs 60.8% wk 6 · n 454 · Phase 4 · secondary NCT01500278
  • 68% vs 68% 40 mg every other week · wk 24 · n 50 · Phase 2 · secondary NCT01712178
  • 62% vs 68% 40 mg every other week · wk 12 · n 50 · Phase 2 · secondary NCT01712178
  • 51.3% vs 65.7% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 56.4% vs 68.6% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 46.2% vs 65.7% wk 104 · n 39 · Phase 4 · secondary NCT01162421
  • 66.7% vs 60% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 64.1% vs 37.1% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 69.2% vs 57.1% wk 13 · n 39 · Phase 4 · secondary NCT01162421
etanercept
78.6% vs 62.5%vs Methotrexate25 mg · wk 52 · n 182NCT00445770
63 other results
  • 79.7% vs 59.1% 25 mg · wk 48 · n 182 · Phase 3 · secondary NCT00445770
  • 75.3% vs 59.7% 25 mg · wk 40 · n 182 · Phase 3 · secondary NCT00445770
  • 80.8% vs 58% 25 mg · wk 32 · n 182 · Phase 3 · secondary NCT00445770
  • 77.5% vs 56.3% 25 mg · wk 24 · n 182 · Phase 3 · secondary NCT00445770
  • 78.6% vs 58.5% 25 mg · wk 20 · n 182 · Phase 3 · secondary NCT00445770
  • 75.3% vs 51.7% 25 mg · wk 16 · n 182 · Phase 3 · secondary NCT00445770
  • 77.5% vs 48.3% 25 mg · wk 12 · n 182 · Phase 3 · secondary NCT00445770
  • 68.7% vs 43.2% 25 mg · wk 8 · n 182 · Phase 3 · secondary NCT00445770
  • 56.9% vs 27.3% 25 mg · wk 4 · n 182 · Phase 3 · secondary NCT00445770
  • 49.4% vs 16.1% 25 mg · wk 2 · n 182 · Phase 3 · secondary NCT00445770
  • 75.9% vs 62.5% 10 mg · wk 52 · n 192 · Phase 3 · secondary NCT00445770
  • 76.4% vs 59.1% 10 mg · wk 48 · n 192 · Phase 3 · secondary NCT00445770
  • 78.5% vs 59.7% 10 mg · wk 40 · n 192 · Phase 3 · secondary NCT00445770
  • 79.1% vs 58% 10 mg · wk 32 · n 192 · Phase 3 · secondary NCT00445770
  • 77% vs 56.3% 10 mg · wk 24 · n 192 · Phase 3 · secondary NCT00445770
  • 75.4% vs 58.5% 10 mg · wk 20 · n 192 · Phase 3 · secondary NCT00445770
  • 73.8% vs 51.7% 10 mg · wk 16 · n 192 · Phase 3 · secondary NCT00445770
  • 70.2% vs 48.3% 10 mg · wk 12 · n 192 · Phase 3 · secondary NCT00445770
  • 68.1% vs 43.2% 10 mg · wk 8 · n 192 · Phase 3 · secondary NCT00445770
  • 55.5% vs 27.3% 10 mg · wk 4 · n 192 · Phase 3 · secondary NCT00445770
  • 54% vs 16.1% 10 mg · wk 2 · n 192 · Phase 3 · secondary NCT00445770
  • 78% vs 47.2% 50 mg · wk 72 · n 200 · Phase 4 · secondary NCT00565409
  • 79.5% vs 46.7% 50 mg · wk 80 · n 200 · Phase 4 · secondary NCT00565409
  • 76.5% vs 48.7% 50 mg · wk 64 · n 200 · Phase 4 · secondary NCT00565409
  • 75.5% vs 48.7% 50 mg · wk 88 · n 200 · Phase 4 · secondary NCT00565409
  • 75% vs 50.3% 50 mg · wk 56 · n 200 · Phase 4 · secondary NCT00565409
  • 77% vs 50.3% 50 mg · wk 48 · n 200 · Phase 4 · secondary NCT00565409
  • 76.9% vs 61.2% 50 mg · wk 40 · n 200 · Phase 4 · secondary NCT00565409
  • 86.5% vs 88.3% 50 mg · wk 36 · n 200 · Phase 4 · secondary NCT00565409
  • 74.6% vs 47.2% 25 mg · wk 72 · n 201 · Phase 4 · secondary NCT00565409
  • 77.6% vs 46.7% 25 mg · wk 80 · n 201 · Phase 4 · secondary NCT00565409
  • 74.1% vs 48.7% 25 mg · wk 64 · n 201 · Phase 4 · secondary NCT00565409
  • 74.6% vs 48.7% 25 mg · wk 88 · n 201 · Phase 4 · secondary NCT00565409
  • 74.6% vs 50.3% 25 mg · wk 56 · n 201 · Phase 4 · secondary NCT00565409
  • 76.1% vs 50.3% 25 mg · wk 48 · n 201 · Phase 4 · secondary NCT00565409
  • 77.7% vs 61.2% 25 mg · wk 40 · n 201 · Phase 4 · secondary NCT00565409
  • 85.1% vs 88.3% 25 mg · wk 36 · n 201 · Phase 4 · secondary NCT00565409
  • 90.5% vs 61.5% wk 76 · n 63 · Phase 4 · secondary NCT00913458
  • 96.8% vs 67.7% wk 64 · n 63 · Phase 4 · secondary NCT00913458
  • 87.3% vs 47.7% wk 91 · n 63 · Phase 4 · secondary NCT00913458
  • 93.7% vs 86.2% wk 56 · n 63 · Phase 4 · secondary NCT00913458
  • 96.8% vs 98.5% wk 52 · n 63 · Phase 4 · secondary NCT00913458
  • 51.9% vs 54.8% wk 20 · n 106 · Phase 4 · secondary NCT01313208
  • 49.1% vs 47.1% wk 16 · n 106 · Phase 4 · secondary NCT01313208
  • 40.6% vs 28.8% wk 12 · n 106 · Phase 4 · secondary NCT01313208
  • 50% vs 23.1% wk 8 · n 106 · Phase 4 · secondary NCT01313208
  • 36.8% vs 19.2% wk 4 · n 106 · Phase 4 · secondary NCT01313208
  • 28.6% vs 14.9% wk 2 · n 106 · Phase 4 · secondary NCT01313208
  • 89.2% vs 87.3% wk 76 · n 260 · Phase 4 · secondary NCT00848354
  • 88.8% vs 91.3% wk 63 · n 260 · Phase 4 · secondary NCT00848354
  • 90.9% vs 89.2% wk 89 · n 260 · Phase 4 · secondary NCT00848354
  • 90% vs 86.5% wk 50 · n 260 · Phase 4 · secondary NCT00848354
  • 91.7% vs 90.8% wk 102 · n 260 · Phase 4 · secondary NCT00848354
  • 86.9% vs 81.0% wk 37 · n 260 · Phase 4 · secondary NCT00848354
  • 90.0% vs 83.3% wk 115 · n 260 · Phase 4 · secondary NCT00848354
  • 83.2% vs 50% wk 24 · n 279 · Phase 4 · secondary NCT00848354
  • 89.2% vs 89.2% wk 128 · n 260 · Phase 4 · secondary NCT00848354
  • 84.6% vs 58.5% wk 20 · n 279 · Phase 4 · secondary NCT00848354
  • 84.2% vs 57.8% wk 16 · n 279 · Phase 4 · secondary NCT00848354
  • 79.6% vs 54.9% wk 12 · n 279 · Phase 4 · secondary NCT00848354
  • 73.8% vs 49.3% wk 8 · n 279 · Phase 4 · secondary NCT00848354
  • 63.8% vs 34.5% wk 4 · n 279 · Phase 4 · secondary NCT00848354
  • 47.8% vs 19.3% wk 2 · n 279 · Phase 4 · secondary NCT00848354

ACR50

adalimumab
41.2% vs 45.9%vs Methotrexatewk 52 · n 274NCT00195663
19 other results
  • 61.6% vs 45.9% wk 52 · n 268 · Phase 3 · primary NCT00195663
  • 64.3% vs 38.7% wk 26 · n 171 · Phase 3 · secondary NCT00870467
  • 41.6% vs 44.4% wk 76 · n 274 · Phase 3 · secondary NCT00195663
  • 60.1% vs 44.4% wk 76 · n 268 · Phase 3 · secondary NCT00195663
  • 36.9% vs 42.8% wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 59% vs 42.8% wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 35% vs 40.5% wk 26 · n 274 · Phase 3 · secondary NCT00195663
  • 58.6% vs 40.5% wk 26 · n 268 · Phase 3 · secondary NCT00195663
  • 78.1% vs 69.6% wk 78 · n 105 · Phase 4 · secondary NCT00420927
  • 46.3% vs 69.6% wk 78 · n 259 · Phase 4 · secondary NCT00420927
  • 48% vs 50% 40 mg every other week · wk 24 · n 50 · Phase 2 · secondary NCT01712178
  • 36% vs 40% 40 mg every other week · wk 12 · n 50 · Phase 2 · secondary NCT01712178
  • 38.5% vs 45.7% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 43.6% vs 34.3% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 33.3% vs 42.9% wk 104 · n 39 · Phase 4 · secondary NCT01162421
  • 48.7% vs 40% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 43.6% vs 22.9% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 38.5% vs 22.9% wk 13 · n 39 · Phase 4 · secondary NCT01162421
  • 64.7% vs 51.6% wk 12 · n 17 · Phase 2 · secondary NCT03823391
etanercept
62.1% vs 36.9%vs Methotrexate25 mg · wk 52 · n 182NCT00445770
65 other results
  • 57.7% vs 39.2% 25 mg · wk 48 · n 182 · Phase 3 · secondary NCT00445770
  • 58.8% vs 36.9% 25 mg · wk 40 · n 182 · Phase 3 · secondary NCT00445770
  • 59.3% vs 34.7% 25 mg · wk 32 · n 182 · Phase 3 · secondary NCT00445770
  • 54.4% vs 32.4% 25 mg · wk 24 · n 182 · Phase 3 · secondary NCT00445770
  • 50.5% vs 30.7% 25 mg · wk 20 · n 182 · Phase 3 · secondary NCT00445770
  • 44% vs 26.1% 25 mg · wk 16 · n 182 · Phase 3 · secondary NCT00445770
  • 42.3% vs 23.9% 25 mg · wk 12 · n 182 · Phase 3 · secondary NCT00445770
  • 35.7% vs 15.3% 25 mg · wk 8 · n 182 · Phase 3 · secondary NCT00445770
  • 22.5% vs 4% 25 mg · wk 4 · n 182 · Phase 3 · secondary NCT00445770
  • 16% vs 2.3% 25 mg · wk 2 · n 182 · Phase 3 · secondary NCT00445770
  • 59.4% vs 36.9% 10 mg · wk 52 · n 192 · Phase 3 · secondary NCT00445770
  • 57.3% vs 39.2% 10 mg · wk 48 · n 192 · Phase 3 · secondary NCT00445770
  • 60.4% vs 36.9% 10 mg · wk 40 · n 192 · Phase 3 · secondary NCT00445770
  • 60.4% vs 34.7% 10 mg · wk 32 · n 192 · Phase 3 · secondary NCT00445770
  • 53.6% vs 32.4% 10 mg · wk 24 · n 192 · Phase 3 · secondary NCT00445770
  • 50% vs 30.7% 10 mg · wk 20 · n 192 · Phase 3 · secondary NCT00445770
  • 50% vs 26.1% 10 mg · wk 16 · n 192 · Phase 3 · secondary NCT00445770
  • 47.4% vs 23.9% 10 mg · wk 12 · n 192 · Phase 3 · secondary NCT00445770
  • 38.5% vs 15.3% 10 mg · wk 8 · n 192 · Phase 3 · secondary NCT00445770
  • 28.1% vs 4% 10 mg · wk 4 · n 192 · Phase 3 · secondary NCT00445770
  • 14.7% vs 2.3% 10 mg · wk 2 · n 192 · Phase 3 · secondary NCT00445770
  • 62.0% vs 23.2% wk 24 · n 279 · Phase 4 · primary NCT00848354
  • 63% vs 26.9% 50 mg · wk 72 · n 200 · Phase 4 · secondary NCT00565409
  • 62.5% vs 27.4% 50 mg · wk 80 · n 200 · Phase 4 · secondary NCT00565409
  • 59% vs 27.9% 50 mg · wk 64 · n 200 · Phase 4 · secondary NCT00565409
  • 62.5% vs 25.9% 50 mg · wk 88 · n 200 · Phase 4 · secondary NCT00565409
  • 62% vs 28.9% 50 mg · wk 56 · n 200 · Phase 4 · secondary NCT00565409
  • 58% vs 33.5% 50 mg · wk 48 · n 200 · Phase 4 · secondary NCT00565409
  • 60.5% vs 41% 50 mg · wk 40 · n 200 · Phase 4 · secondary NCT00565409
  • 76.5% vs 74.1% 50 mg · wk 36 · n 200 · Phase 4 · secondary NCT00565409
  • 53.7% vs 26.9% 25 mg · wk 72 · n 201 · Phase 4 · secondary NCT00565409
  • 58.7% vs 27.4% 25 mg · wk 80 · n 201 · Phase 4 · secondary NCT00565409
  • 55.7% vs 27.9% 25 mg · wk 64 · n 201 · Phase 4 · secondary NCT00565409
  • 57.2% vs 25.9% 25 mg · wk 88 · n 201 · Phase 4 · secondary NCT00565409
  • 56.2% vs 28.9% 25 mg · wk 56 · n 201 · Phase 4 · secondary NCT00565409
  • 59.2% vs 33.5% 25 mg · wk 48 · n 201 · Phase 4 · secondary NCT00565409
  • 57.9% vs 41% 25 mg · wk 40 · n 201 · Phase 4 · secondary NCT00565409
  • 70.6% vs 74.1% 25 mg · wk 36 · n 201 · Phase 4 · secondary NCT00565409
  • 85.7% vs 50.8% wk 76 · n 63 · Phase 4 · secondary NCT00913458
  • 93.7% vs 50.8% wk 64 · n 63 · Phase 4 · secondary NCT00913458
  • 76.2% vs 44.6% wk 91 · n 63 · Phase 4 · secondary NCT00913458
  • 87.3% vs 73.8% wk 56 · n 63 · Phase 4 · secondary NCT00913458
  • 92.1% vs 95.4% wk 52 · n 63 · Phase 4 · secondary NCT00913458
  • 33% vs 28.8% wk 24 · n 106 · Phase 4 · secondary NCT01313208
  • 29.2% vs 28.8% wk 20 · n 106 · Phase 4 · secondary NCT01313208
  • 30.2% vs 22.1% wk 16 · n 106 · Phase 4 · secondary NCT01313208
  • 20.8% vs 12.5% wk 12 · n 106 · Phase 4 · secondary NCT01313208
  • 19.8% vs 4.8% wk 8 · n 106 · Phase 4 · secondary NCT01313208
  • 13.2% vs 4.8% wk 4 · n 106 · Phase 4 · secondary NCT01313208
  • 5.7% vs 3% wk 2 · n 106 · Phase 4 · secondary NCT01313208
  • 67.3% vs 58.7% wk 76 · n 260 · Phase 4 · secondary NCT00848354
  • 68.5% vs 62.7% wk 63 · n 260 · Phase 4 · secondary NCT00848354
  • 73.4% vs 60.8% wk 89 · n 260 · Phase 4 · secondary NCT00848354
  • 65.8% vs 60.3% wk 50 · n 260 · Phase 4 · secondary NCT00848354
  • 73.4% vs 61.7% wk 102 · n 260 · Phase 4 · secondary NCT00848354
  • 67.3% vs 53.2% wk 37 · n 260 · Phase 4 · secondary NCT00848354
  • 72.6% vs 59.2% wk 115 · n 260 · Phase 4 · secondary NCT00848354
  • 62.0% vs 23.2% wk 24 · n 279 · Phase 4 · secondary NCT00848354
  • 70.5% vs 65% wk 128 · n 260 · Phase 4 · secondary NCT00848354
  • 59.1% vs 27.5% wk 20 · n 279 · Phase 4 · secondary NCT00848354
  • 56.3% vs 24.6% wk 16 · n 279 · Phase 4 · secondary NCT00848354
  • 52.3% vs 21.1% wk 12 · n 279 · Phase 4 · secondary NCT00848354
  • 42.3% vs 16.9% wk 8 · n 279 · Phase 4 · secondary NCT00848354
  • 31.5% vs 8.4% wk 4 · n 279 · Phase 4 · secondary NCT00848354
  • 15.8% vs 2.9% wk 2 · n 279 · Phase 4 · secondary NCT00848354

ACR70

adalimumab
47.4% vs 22.7%+24.7 vs placebowk 26 · n 171NCT00870467
16 other results
  • 28.8% vs 29.2% wk 76 · n 274 · Phase 3 · secondary NCT00195663
  • 47.4% vs 29.2% wk 76 · n 268 · Phase 3 · secondary NCT00195663
  • 25.9% vs 27.2% wk 52 · n 274 · Phase 3 · secondary NCT00195663
  • 45.5% vs 27.2% wk 52 · n 268 · Phase 3 · secondary NCT00195663
  • 28.1% vs 28.4% wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 46.6% vs 28.4% wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 19.7% vs 22.2% wk 26 · n 274 · Phase 3 · secondary NCT00195663
  • 42.5% vs 22.2% wk 26 · n 268 · Phase 3 · secondary NCT00195663
  • 69.5% vs 57.1% wk 78 · n 105 · Phase 4 · secondary NCT00420927
  • 30.1% vs 57.1% wk 78 · n 259 · Phase 4 · secondary NCT00420927
  • 30.8% vs 20% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 30.8% vs 14.3% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 23.1% vs 40% wk 104 · n 39 · Phase 4 · secondary NCT01162421
  • 25.6% vs 22.9% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 28.2% vs 8.6% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 15.4% vs 2.9% wk 13 · n 39 · Phase 4 · secondary NCT01162421
etanercept
36.3% vs 15.9%vs Methotrexate25 mg · wk 52 · n 182NCT00445770
64 other results
  • 36.3% vs 18.2% 25 mg · wk 48 · n 182 · Phase 3 · secondary NCT00445770
  • 35.7% vs 14.8% 25 mg · wk 40 · n 182 · Phase 3 · secondary NCT00445770
  • 31.3% vs 11.9% 25 mg · wk 32 · n 182 · Phase 3 · secondary NCT00445770
  • 25.8% vs 11.9% 25 mg · wk 24 · n 182 · Phase 3 · secondary NCT00445770
  • 25.3% vs 13.1% 25 mg · wk 20 · n 182 · Phase 3 · secondary NCT00445770
  • 18.7% vs 9.7% 25 mg · wk 16 · n 182 · Phase 3 · secondary NCT00445770
  • 15.4% vs 9.7% 25 mg · wk 12 · n 182 · Phase 3 · secondary NCT00445770
  • 11% vs 2.8% 25 mg · wk 8 · n 182 · Phase 3 · secondary NCT00445770
  • 8.2% vs 0.6% 25 mg · wk 4 · n 182 · Phase 3 · secondary NCT00445770
  • 3.8% vs 0% 25 mg · wk 2 · n 182 · Phase 3 · secondary NCT00445770
  • 33.9% vs 15.9% 10 mg · wk 52 · n 192 · Phase 3 · secondary NCT00445770
  • 34.4% vs 18.2% 10 mg · wk 48 · n 192 · Phase 3 · secondary NCT00445770
  • 31.3% vs 14.8% 10 mg · wk 40 · n 192 · Phase 3 · secondary NCT00445770
  • 28.1% vs 11.9% 10 mg · wk 32 · n 192 · Phase 3 · secondary NCT00445770
  • 25.5% vs 11.9% 10 mg · wk 24 · n 192 · Phase 3 · secondary NCT00445770
  • 25% vs 13.1% 10 mg · wk 20 · n 192 · Phase 3 · secondary NCT00445770
  • 17.7% vs 9.7% 10 mg · wk 16 · n 192 · Phase 3 · secondary NCT00445770
  • 21.9% vs 9.7% 10 mg · wk 12 · n 192 · Phase 3 · secondary NCT00445770
  • 15.1% vs 2.8% 10 mg · wk 8 · n 192 · Phase 3 · secondary NCT00445770
  • 7.8% vs 0.6% 10 mg · wk 4 · n 192 · Phase 3 · secondary NCT00445770
  • 4.2% vs 0% 10 mg · wk 2 · n 192 · Phase 3 · secondary NCT00445770
  • 32% vs 10.7% 50 mg · wk 72 · n 200 · Phase 4 · secondary NCT00565409
  • 34% vs 10.7% 50 mg · wk 80 · n 200 · Phase 4 · secondary NCT00565409
  • 33% vs 10.2% 50 mg · wk 64 · n 200 · Phase 4 · secondary NCT00565409
  • 35.5% vs 11.2% 50 mg · wk 88 · n 200 · Phase 4 · secondary NCT00565409
  • 31% vs 10.2% 50 mg · wk 56 · n 200 · Phase 4 · secondary NCT00565409
  • 28% vs 9.6% 50 mg · wk 48 · n 200 · Phase 4 · secondary NCT00565409
  • 28.7% vs 17.6% 50 mg · wk 40 · n 200 · Phase 4 · secondary NCT00565409
  • 42% vs 33% 50 mg · wk 36 · n 200 · Phase 4 · secondary NCT00565409
  • 31.3% vs 10.7% 25 mg · wk 72 · n 201 · Phase 4 · secondary NCT00565409
  • 30.3% vs 10.7% 25 mg · wk 80 · n 201 · Phase 4 · secondary NCT00565409
  • 28.9% vs 10.2% 25 mg · wk 64 · n 201 · Phase 4 · secondary NCT00565409
  • 31.3% vs 11.2% 25 mg · wk 88 · n 201 · Phase 4 · secondary NCT00565409
  • 31.3% vs 10.2% 25 mg · wk 56 · n 201 · Phase 4 · secondary NCT00565409
  • 30.8% vs 9.6% 25 mg · wk 48 · n 201 · Phase 4 · secondary NCT00565409
  • 27.9% vs 17.6% 25 mg · wk 40 · n 201 · Phase 4 · secondary NCT00565409
  • 33.3% vs 33% 25 mg · wk 36 · n 201 · Phase 4 · secondary NCT00565409
  • 74.6% vs 38.5% wk 76 · n 63 · Phase 4 · secondary NCT00913458
  • 77.8% vs 36.9% wk 64 · n 63 · Phase 4 · secondary NCT00913458
  • 69.8% vs 38.5% wk 91 · n 63 · Phase 4 · secondary NCT00913458
  • 73% vs 56.9% wk 56 · n 63 · Phase 4 · secondary NCT00913458
  • 82.5% vs 80% wk 52 · n 63 · Phase 4 · secondary NCT00913458
  • 16% vs 12.5% wk 24 · n 106 · Phase 4 · secondary NCT01313208
  • 17% vs 10.6% wk 20 · n 106 · Phase 4 · secondary NCT01313208
  • 8.5% vs 9.6% wk 16 · n 106 · Phase 4 · secondary NCT01313208
  • 5.7% vs 1% wk 12 · n 106 · Phase 4 · secondary NCT01313208
  • 5.7% vs 0% wk 8 · n 106 · Phase 4 · secondary NCT01313208
  • 1.9% vs 0% wk 4 · n 106 · Phase 4 · secondary NCT01313208
  • 1.9% vs 0% wk 2 · n 106 · Phase 4 · secondary NCT01313208
  • 41.9% vs 34.1% wk 76 · n 260 · Phase 4 · secondary NCT00848354
  • 39.6% vs 34.1% wk 63 · n 260 · Phase 4 · secondary NCT00848354
  • 53.1% vs 38.3% wk 89 · n 260 · Phase 4 · secondary NCT00848354
  • 45% vs 32.5% wk 50 · n 260 · Phase 4 · secondary NCT00848354
  • 49.0% vs 36.7% wk 102 · n 260 · Phase 4 · secondary NCT00848354
  • 40.4% vs 30.2% wk 37 · n 260 · Phase 4 · secondary NCT00848354
  • 48.5% vs 35% wk 115 · n 260 · Phase 4 · secondary NCT00848354
  • 34.8% vs 11.3% wk 24 · n 279 · Phase 4 · secondary NCT00848354
  • 49.0% vs 40% wk 128 · n 260 · Phase 4 · secondary NCT00848354
  • 30.1% vs 10.6% wk 20 · n 279 · Phase 4 · secondary NCT00848354
  • 27.6% vs 9.2% wk 16 · n 279 · Phase 4 · secondary NCT00848354
  • 20.1% vs 4.2% wk 12 · n 279 · Phase 4 · secondary NCT00848354
  • 16.1% vs 3.5% wk 8 · n 279 · Phase 4 · secondary NCT00848354
  • 7.2% vs 2.1% wk 4 · n 279 · Phase 4 · secondary NCT00848354
  • 3.6% vs 0.7% wk 2 · n 279 · Phase 4 · secondary NCT00848354

DAS28-CRP remission

adalimumab
38.5% vs 42.9%vs Standard of Carewk 104 · n 39NCT01162421
5 other results
  • 30.8% vs 34.3% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 35.9% vs 22.9% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 28.2% vs 31.4% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 35.9% vs 11.4% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 17.9% vs 8.6% wk 13 · n 39 · Phase 4 · secondary NCT01162421
etanercept
54.5% vs 69.1%vs Standard COBRA-Slim Inductionwk 104 · n 55NCT03649061
1 other result
  • 58.2% vs 43.6% wk 28 · n 55 · Phase 4 · secondary NCT03649061

HAQ-DI, change

adalimumab
-0.6 vs -0.3−0.3 vs placebo40 mg every other week · wk 52 · n 204NCT00195702
22 other results
  • -0.6 vs -0.3 20 mg weekly · wk 52 · n 212 · Phase 3 · primary NCT00195702
  • -0.6 vs -0.2 40 mg every other week · wk 24 · n 204 · Phase 3 · secondary NCT00195702
  • -0.4 vs -0.1 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.4 vs -0.1 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.3 vs 0 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.2 vs 0 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.5 vs -0.3 40 mg · wk 12 · n 120 · Phase 2/3 · secondary NCT00538902
  • -0.4 vs -0.1 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.4 vs -0.1 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.2 vs 0 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.2 vs 0 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.4 vs -0.3 80 mg · wk 12 · n 120 · Phase 2/3 · secondary NCT00538902
  • -0.6 vs -0.2 20 mg weekly · wk 24 · n 212 · Phase 3 · secondary NCT00195702
  • -0.8 vs -0.8 wk 52 · n 191 · Phase 3 · secondary NCT00195663
  • -1.1 vs -0.8 wk 52 · n 213 · Phase 3 · secondary NCT00195663
  • -0.6 vs -0.7 wk 104 · n 454 · Phase 4 · secondary NCT01500278
  • -0.5 vs -0.6 wk 104 · n 38 · Phase 4 · secondary NCT01162421
  • -0.6 vs -0.6 wk 78 · n 38 · Phase 4 · secondary NCT01162421
  • -0.5 vs -0.6 wk 52 · n 38 · Phase 4 · secondary NCT01162421
  • -0.5 vs -0.5 wk 39 · n 38 · Phase 4 · secondary NCT01162421
  • -0.5 vs -0.3 wk 26 · n 38 · Phase 4 · secondary NCT01162421
  • -0.4 vs -0.4 wk 13 · n 38 · Phase 4 · secondary NCT01162421
etanercept
-0.6 vs -0.3vs Methotrexate25 mg · wk 52 · n 182NCT00445770
31 other results
  • -0.6 vs -0.3 25 mg · wk 48 · n 182 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 25 mg · wk 40 · n 182 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 25 mg · wk 32 · n 182 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 25 mg · wk 24 · n 182 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 25 mg · wk 20 · n 182 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.3 25 mg · wk 16 · n 182 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.3 25 mg · wk 12 · n 182 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.2 25 mg · wk 8 · n 182 · Phase 3 · secondary NCT00445770
  • -0.4 vs -0.1 25 mg · wk 4 · n 182 · Phase 3 · secondary NCT00445770
  • -0.3 vs -0.1 25 mg · wk 2 · n 182 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 10 mg · wk 52 · n 192 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 10 mg · wk 48 · n 192 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 10 mg · wk 40 · n 192 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 10 mg · wk 32 · n 192 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.3 10 mg · wk 24 · n 192 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.3 10 mg · wk 20 · n 192 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.3 10 mg · wk 16 · n 192 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.3 10 mg · wk 12 · n 192 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.2 10 mg · wk 8 · n 192 · Phase 3 · secondary NCT00445770
  • -0.3 vs -0.1 10 mg · wk 4 · n 192 · Phase 3 · secondary NCT00445770
  • -0.3 vs -0.1 10 mg · wk 2 · n 192 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.4 wk 24 · n 106 · Phase 4 · secondary NCT01313208
  • -0.4 vs -0.4 wk 20 · n 106 · Phase 4 · secondary NCT01313208
  • -0.4 vs -0.3 wk 16 · n 106 · Phase 4 · secondary NCT01313208
  • -0.4 vs -0.2 wk 12 · n 106 · Phase 4 · secondary NCT01313208
  • -0.4 vs -0.2 wk 8 · n 106 · Phase 4 · secondary NCT01313208
  • -0.3 vs -0.2 wk 4 · n 106 · Phase 4 · secondary NCT01313208
  • -0.3 vs -0.1 wk 2 · n 106 · Phase 4 · secondary NCT01313208
  • -0.8 vs -0.5 wk 24 · n 279 · Phase 4 · secondary NCT00848354
  • 0.9 vs 0.7 wk 104 · n 55 · Phase 4 · secondary NCT03649061
  • 0.8 vs 0.7 wk 28 · n 55 · Phase 4 · secondary NCT03649061

Modified Sharp score, change

adalimumab
0.1 vs 2.7−2.6 vs placebo40 mg every other week · wk 52 · n 183NCT00195702
15 other results
  • 0.8 vs 2.7 20 mg weekly · wk 52 · n 196 · Phase 3 · primary NCT00195702
  • 1.5 vs 2.4 wk 26 · n 148 · Phase 3 · primary NCT00870467
  • 3 vs 5.7 wk 52 · n 274 · Phase 3 · primary NCT00195663
  • 1.3 vs 5.7 wk 52 · n 268 · Phase 3 · primary NCT00195663
  • 0.3 vs 1.3 40 mg every other week · wk 24 · n 183 · Phase 3 · secondary NCT00195702
  • 0.1 vs 4.8 40 mg every other week · wk 416 · n 81 · Phase 3 · secondary NCT00195702
  • 0.7 vs 6.2 40 mg every other week · wk 520 · n 79 · Phase 3 · secondary NCT00195702
  • 0.6 vs 1.3 20 mg weekly · wk 24 · n 196 · Phase 3 · secondary NCT00195702
  • 1.2 vs 4.8 20 mg weekly, then 40 mg every other week · wk 416 · n 70 · Phase 3 · secondary NCT00195702
  • 2.6 vs 6.2 20 mg weekly, then 40 mg every other week · wk 520 · n 70 · Phase 3 · secondary NCT00195702
  • 5.5 vs 10.4 wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 1.9 vs 10.4 wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 0.0 vs 2.2 wk 104 · n 39 · Phase 4 · secondary NCT01162421
  • 0.2 vs 1.6 wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 0.0 vs 0.9 wk 26 · n 39 · Phase 4 · secondary NCT01162421
etanercept
3.3 vs 9.8vs Methotrexate25 mg · wk 52 · n 181NCT00445770
11 other results
  • 5.2 vs 9.8 10 mg · wk 52 · n 190 · Phase 3 · primary NCT00445770
  • 1.7 vs 5.1 25 mg · wk 24 · n 181 · Phase 3 · secondary NCT00445770
  • 2.4 vs 5.1 10 mg · wk 24 · n 190 · Phase 3 · secondary NCT00445770
  • 0 vs 0.5 wk 91 · n 63 · Phase 4 · secondary NCT00913458
  • 0 vs -1 50 mg · wk 48 · n 19 · Phase 4 · secondary NCT00858780
  • 0 vs -1 25 mg · wk 48 · n 22 · Phase 4 · secondary NCT00858780
  • 7 vs 7.3 wk 102 · n 159 · Phase 4 · secondary NCT00259610
  • 4.8 vs 7.3 wk 102 · n 166 · Phase 4 · secondary NCT00259610
  • 0.4 vs 1.4 wk 24 · n 247 · Phase 4 · secondary NCT00848354
  • 0.8 vs 0.7 wk 104 · n 55 · Phase 4 · secondary NCT03649061
  • 0.3 vs 0.5 wk 52 · n 55 · Phase 4 · secondary NCT03649061
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
37 other shared endpoints and safety

Coverage. adalimumab: 41 of 41 rows · etanercept: 41 of 41 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab
Rows use multiple source trials
etanercept
Rows use multiple source trials
ACR20
responder rate · % of participants
No placebo or comparator arm
97% (n=133) @ 52wk*a,b,c,d
NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 129 participants as posted
show 1 more dose
80% (n=5) @ 52wk*
NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 4 participants as posted
69.3% (n=306) @ 52wk*50 mg QWb,c,d
NCT00913458 · Phase 4 · registry result, not featured evidence · combination · converted to % from 212 Participants as posted
ACR50
responder rate · % of participants
No placebo or comparator arm
88% (n=133) @ 52wk*a,b,c,d
NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 117 participants as posted
show 1 more dose
40% (n=5) @ 52wk*
NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 2 participants as posted
66% (n=306) @ 52wk*50 mg QWb,c,d
NCT00913458 · Phase 4 · registry result, not featured evidence · combination · converted to % from 202 Participants as posted
ACR70
responder rate · % of participants
No placebo or comparator arm
65.4% (n=133) @ 52wk*a,b,c,d
NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 87 participants as posted
show 1 more dose
0% (n=5) @ 52wk*
NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 0 participants as posted
57.5% (n=306) @ 52wk*50 mg QWb,c,d
NCT00913458 · Phase 4 · registry result, not featured evidence · combination · converted to % from 176 Participants as posted
ACR90
responder rate · % of participants
No placebo or comparator arm
16.3% (n=98) @ 26wk20 mg MTXa,b,c
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
show 3 more doses
17.2% (n=99) @ 26wk10 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
10% (n=100) @ 26wk5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
7.1% (n=98) @ 26wk2.5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
22.9% (n=306) @ 26wk*50 mg QWb,c
NCT00913458 · Phase 4 · registry result, not featured evidence · combination · converted to % from 70 Participants as posted
CDAI
absolute change · score
-26.3 vs -27.99 ABBV-3373 score @ 12wke,c
NCT03823391 · Phase 2 · registry result, not featured evidence
3.15 vs 5.39 Methotrexate score @ 12wka,e,c
NCT02373813 · Phase 3 · registry result, not featured evidence · monotherapy
show 1 more dose
3.24 vs 5.39 Methotrexate score @ 12wk
NCT02373813 · Phase 3 · registry result, not featured evidence · combination
CDAI Clinical Remission
responder rate · % of participants
55.2% (n=105) vs 48.2% (n=112) placebo @ 78wk*a,c,d,f
NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 58 Participants as posted
show 1 more dose
15.1% (n=259) vs 48.2% (n=112) placebo @ 78wk*
NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 39 Participants as posted
8.5% (n=106) vs 3.8% (n=104) placebo @ 24wkc,d,f
NCT01313208 · Phase 4 · registry result, not featured evidence
Clinical Remission
responder rate · % of participants
43.3% (n=30) vs 50% (n=8) placebo @ 16wk*c,d,g
NCT02198651 · Phase 4 · registry result, not featured evidence · converted to % from 13 Participants as posted
21.4% (n=42) vs 7% (n=43) Methotrexate*c,d,g
NCT00443430 · Phase 4 · registry result, not featured evidence · combination · converted to % from 9 participants as posted
CRP Change
absolute change · mg
-11.2 vs -13.5 Standard of Care mg @ 104wkc,d,h
NCT01162421 · Phase 4 · registry result, not featured evidence
0 vs -1.42 placebo mg @ 48wk50 mga,c,d,h
NCT00858780 · Phase 4 · registry result, not featured evidence
show 1 more dose
0 vs -1.42 placebo mg @ 48wk25 mg
NCT00858780 · Phase 4 · registry result, not featured evidence
DAS Remission
responder rate · % of participants
No placebo or comparator arm
57.2% (n=236) @ 520wk*b,c,d,i
NCT00195650 · Phase 3 · registry result, not featured evidence · converted to % from 135 participants as posted
63.1% (n=306) @ 52wk*50 mg QWb,c,d,i
NCT00913458 · Phase 4 · registry result, not featured evidence · combination · converted to % from 193 Participants as posted
DAS28
absolute change · score
-3.71 vs -3.04 placebo score @ 78wka,c,j
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
-2.7 vs -3.04 placebo score @ 78wk
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
-3.41 vs -3.51 DMARD + Methotrexate score @ 128wkc,j
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
DAS28
absolute value · score
3.54 vs 3.46 Adalimumab score @ 24wk40 mg every other weekk,c,d,l
NCT01712178 · Phase 2 · registry result, not featured evidence
1.99 vs 2.07 placebo score @ 36wk50 mga,k,c,d,l
NCT00565409 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
2.06 vs 2.07 placebo score @ 36wk25 mg
NCT00565409 · Phase 4 · registry result, not featured evidence · combination
DAS28
absolute change · score
No placebo or comparator arm
-2.2 score @ 36wka,k,c,d
NCT01752855 · Phase 2 · registry result, not featured evidence
show 1 more dose
-2.4 score @ 36wk
NCT01752855 · Phase 2 · registry result, not featured evidence
-1.89 score @ 36wk50 mgk,c,d
NCT00565409 · Phase 4 · registry result, not featured evidence · combination
DAS28 Low Disease Activity
responder rate · % of participants
58.8% (n=17) vs 54.8% (n=31) ABBV-3373 @ 12wkk,c,d
NCT03823391 · Phase 2 · registry result, not featured evidence
33% (n=106) vs 21.2% (n=104) placebo @ 12wkk,c,d
NCT01313208 · Phase 4 · registry result, not featured evidence
DAS28 Remission
responder rate · % of participants
23.4% (n=274) vs 20.6% (n=257) Methotrexate @ 52wk*a,b,c
NCT00195663 · Phase 3 · registry result, not featured evidence · converted to % from 64 participants as posted
show 1 more dose
42.9% (n=268) vs 20.6% (n=257) Methotrexate @ 52wk*
NCT00195663 · Phase 3 · registry result, not featured evidence · combination · converted to % from 115 participants as posted
49.8% (n=265) vs 27.8% (n=263) M @ 52wk*b,c
NCT00195494 · Phase 4 · registry result, not featured evidence · combination · converted to % from 132 participants as posted
DAS28-CRP
absolute change · score
-2.51 vs -2.65 ABBV-3373 score @ 12wke,c
NCT03823391 · Phase 2 · registry result, not featured evidence
0.42 vs 0.84 Methotrexate score @ 12wka,e,c
NCT02373813 · Phase 3 · registry result, not featured evidence · monotherapy
show 1 more dose
0.41 vs 0.84 Methotrexate score @ 12wk
NCT02373813 · Phase 3 · registry result, not featured evidence · combination
DAS28-ESR
absolute change · score
-2.55 vs -2.76 ABBV-3373 score @ 12wkk,c,d,g
NCT03823391 · Phase 2 · registry result, not featured evidence
3 vs 2.9 MTX + SSZ + HCQ scorea,k,c,d,g
NCT00259610 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
3.1 vs 2.9 MTX + SSZ + HCQ score
NCT00259610 · Phase 4 · registry result, not featured evidence · combination
DAS28-ESR
absolute change · score
No placebo or comparator arm
-3.7 score @ 52wka,c,d,m
NCT00870467 · Phase 3 · registry result, not featured evidence
show 1 more dose
-1.9 score @ 52wk
NCT00870467 · Phase 3 · registry result, not featured evidence
-2.8 score @ 24wkc,d,m
NCT02378506 · Phase 3 · registry result, not featured evidence
DAS28-ESR LDAS
responder rate · % of participants
35.5% (n=454) vs 33.5% (n=454) ADA+MTX @ 104wka,c,d,n
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
show 2 more doses
45.6% (n=353) vs 42.4% (n=361) ADA+MTX @ 104wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
47.7% (n=310) vs 46.6% (n=298) ADA+MTX @ 104wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
43.6% (n=163) vs 17.3% (n=168) placebo @ 52wkc,d,n
NCT01578850 · Phase 4 · registry result, not featured evidence
DAS28-ESR Remission
responder rate · % of participants
30.4% (n=171) vs 14.7% (n=163) placebo @ 26wk*b,c,d,o
NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 52 participants as posted
53.2% (n=163) vs 29.5% (n=168) placebo @ 52wkb,c,d,o
NCT01578850 · Phase 4 · registry result, not featured evidence
Disease Flare
responder rate · % of participants
36.3% (n=102) vs 45% (n=20) placebop,c,d,g
NCT02198651 · Phase 4 · registry result, not featured evidence
1 other source trial
15.4% (n=39) vs 8.6% (n=35) Standard of Care @ 104wk
NCT01162421 · Phase 4 · registry result, not featured evidence
28% (n=25) vs 81% (n=26) placebo0.4 mg/kgp,c,d,g
NCT03780959 · Phase 2/3 · monotherapy · Rheumatoid Arthritis · phase 2/3
1 other source trial
52.1% (n=163) vs 79.8% (n=168) placebo @ 52wk
NCT01578850 · Phase 4 · registry result, not featured evidence
Erosion
absolute change · score
1.7 vs 3.7 Methotrexate score @ 52wka,c
NCT00195663 · Phase 3 · registry result, not featured evidence
show 1 more dose
0.8 vs 3.7 Methotrexate score @ 52wk
NCT00195663 · Phase 3 · registry result, not featured evidence · combination
2.03 vs 5.43 Methotrexate score @ 52wk25 mga,c
NCT00445770 · Phase 3 · registry result, not featured evidence
show 1 more dose
2.75 vs 5.43 Methotrexate score @ 52wk10 mg
NCT00445770 · Phase 3 · registry result, not featured evidence
EULAR Good
responder rate · % of participants
43.6% (n=39) vs 54.3% (n=35) Standard of Care @ 104wkc,d,q
NCT01162421 · Phase 4 · registry result, not featured evidence
75.73% (n=260) vs 70% (n=126) DMARD + Methotrexate @ 128wka,c,d,q
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
57.68% (n=260) vs 55% (n=126) DMARD + Methotrexate @ 128wk
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
EULAR Good, Moderate
responder rate · % of participants
63% (n=64) vs 63% (n=64) AbbVie Adalimumab @ 24wkb,c,d
NCT03172325 · Phase 3 · registry result, not featured evidence
92.45% (n=279) vs 65.49% (n=142) DMARD + Methotrexate @ 24wka,b,c,d
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
91.76% (n=279) vs 64.79% (n=142) DMARD + Methotrexate @ 24wk
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
HAQ-DI
absolute change · score
No placebo or comparator arm
-0.6 score @ 24wk40 mg or 80 mg every other weekc,d
NCT00603993 · Phase 3 · registry result, not featured evidence
2 other source trials
-0.4 score @ 24wk40 mg every other week
NCT00235872 · Phase 3 · registry result, not featured evidence
-0.49 score @ 24wk40 mg Eow
NCT00235833 · Phase 2 · registry result, not featured evidence
-0.5 score @ 24wkc,d
NCT02378506 · Phase 3 · registry result, not featured evidence
Modified Sharp
absolute change · score
No placebo or comparator arm
1.6 score @ 52wka,b,c
NCT00870467 · Phase 3 · registry result, not featured evidence
show 1 more dose
9.6 score @ 52wk
NCT00870467 · Phase 3 · registry result, not featured evidence
0.1 score @ 52wka,b,c
NCT00654368 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
0.3 score @ 52wk
NCT00654368 · Phase 4 · registry result, not featured evidence · monotherapy
Morning Stiffness Duration
absolute change · minutes
No placebo or comparator arm
-104.8 minutes @ 36wk40 mg or 80 mg every other weekb,c,d
NCT00603993 · Phase 3 · registry result, not featured evidence
1 other source trial
-79.9 minutes @ 36wk40 mg every other week
NCT00235872 · Phase 3 · registry result, not featured evidence
-112.36 minutes @ 36wk50 mgb,c,d
NCT00565409 · Phase 4 · registry result, not featured evidence · combination
mTSS no Progression
event count · % of participants
82.4% (n=102) vs 68.8% (n=112) placebo @ 78wk*a,c,r
NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 84 Participants as posted
show 1 more dose
70.3% (n=259) vs 68.8% (n=112) placebo @ 78wk*
NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 182 Participants as posted
79.7% (n=246) vs 58.7% (n=230) M @ 52wk*c,r
NCT00195494 · Phase 4 · registry result, not featured evidence · combination · converted to % from 196 participants as posted
Patient Global Assessment
absolute change · score
-22.3 vs -22.4 Standard of Care score @ 52wkc,d
NCT01162421 · Phase 4 · registry result, not featured evidence
-3.91 vs -3.02 placebo score @ 52wkc,d
NCT01578850 · Phase 4 · registry result, not featured evidence
2 other source trials
-3.04 vs -1.97 Methotrexate score @ 52wk10 mg
NCT00445770 · Phase 3 · registry result, not featured evidence
-2.91 vs -1.97 Methotrexate score @ 52wk25 mg
NCT00445770 · Phase 3 · registry result, not featured evidence
Patient Global Assessment
absolute change · score
No placebo or comparator arm
-31.6 score @ 36wk40 mg or 80 mg every other weekb,c,d
NCT00603993 · Phase 3 · registry result, not featured evidence
2 other source trials
-26.9 score @ 36wk40 mg every other week
NCT00235872 · Phase 3 · registry result, not featured evidence
-33 score @ 36wk40 mg Eow
NCT00235833 · Phase 2 · registry result, not featured evidence
-2.46 score @ 36wk50 mgb,c,d
NCT00565409 · Phase 4 · registry result, not featured evidence · combination
Physician Global Assessment
absolute change · score
-47.3 vs -43.8 Standard of Care score @ 52wkc,d
NCT01162421 · Phase 4 · registry result, not featured evidence
-4.77 vs -3.74 placebo score @ 52wkc,d
NCT01578850 · Phase 4 · registry result, not featured evidence
2 other source trials
-3.68 vs -2.72 Methotrexate score @ 52wk10 mg
NCT00445770 · Phase 3 · registry result, not featured evidence
-4.07 vs -2.72 Methotrexate score @ 52wk25 mg
NCT00445770 · Phase 3 · registry result, not featured evidence
Physician Global Assessment
absolute change · score
No placebo or comparator arm
-42.2 score @ 36wk40 mg or 80 mg every other weekb,c,d
NCT00603993 · Phase 3 · registry result, not featured evidence
2 other source trials
-37.3 score @ 36wk40 mg every other week
NCT00235872 · Phase 3 · registry result, not featured evidence
-34.3 score @ 36wk40 mg Eow
NCT00235833 · Phase 2 · registry result, not featured evidence
-2.57 score @ 36wk50 mgb,c,d
NCT00565409 · Phase 4 · registry result, not featured evidence · combination
RAMRIS Synovitis
absolute change · score
-3.38 vs -3.88 placebo score @ 78wka,c,d,s
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
-3.25 vs -3.88 placebo score @ 78wk
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
-0.16 vs -0.29 placebo score @ 12wk50 mga,c,d,s
NCT00858780 · Phase 4 · registry result, not featured evidence
show 1 more dose
1.36 vs -0.29 placebo score @ 12wk25 mg
NCT00858780 · Phase 4 · registry result, not featured evidence
SDAI
absolute change · score
-27.42 vs -28.5 ABBV-3373 score @ 12wke,c
NCT03823391 · Phase 2 · registry result, not featured evidence
3.14 vs 5.67 Methotrexate score @ 12wka,e,c
NCT02373813 · Phase 3 · registry result, not featured evidence · monotherapy
show 1 more dose
3.21 vs 5.67 Methotrexate score @ 12wk
NCT02373813 · Phase 3 · registry result, not featured evidence · combination
SDAI Remission
responder rate · % of participants
52.4% (n=105) vs 45.5% (n=112) placebo @ 78wk*a,t,c,u
NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 55 Participants as posted
show 1 more dose
15.1% (n=259) vs 45.5% (n=112) placebo @ 78wk*
NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 39 Participants as posted
49.5% (n=101) vs 28.7% (n=101) Methotrexate @ 48wka,t,c,u
NCT02373813 · Phase 3 · registry result, not featured evidence · monotherapy
show 5 more doses
52.1% (n=101) vs 30.5% (n=101) Methotrexate @ 48wk
NCT02373813 · Phase 3 · registry result, not featured evidence · monotherapy
55.9% (n=34) vs 54.2% (n=48) Methotrexate @ 48wk
NCT02373813 · Phase 3 · registry result, not featured evidence · monotherapy
52.9% (n=51) vs 28.7% (n=101) Methotrexate @ 48wk
NCT02373813 · Phase 3 · registry result, not featured evidence · combination
56.3% (n=51) vs 30.5% (n=101) Methotrexate @ 48wk
NCT02373813 · Phase 3 · registry result, not featured evidence · combination
66.7% (n=15) vs 54.2% (n=48) Methotrexate @ 48wk
NCT02373813 · Phase 3 · registry result, not featured evidence · combination
SF-36 MCS
absolute change · score
7.1 vs 6.5 Methotrexate score @ 52wka,b,c,v
NCT00195663 · Phase 3 · registry result, not featured evidence
show 1 more dose
7.2 vs 6.5 Methotrexate score @ 52wk
NCT00195663 · Phase 3 · registry result, not featured evidence · combination
7.32 vs 6.42 DMARD + Methotrexate score @ 128wkb,c,v
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
SF-36 PCS
absolute change · score
12.6 vs 12.5 Methotrexate score @ 52wka,b,c,v
NCT00195663 · Phase 3 · registry result, not featured evidence
show 1 more dose
16.7 vs 12.5 Methotrexate score @ 52wk
NCT00195663 · Phase 3 · registry result, not featured evidence · combination
13.47 vs 12.1 DMARD + Methotrexate score @ 128wkb,c,v
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
Swollen Joint Count
absolute change · swollen joints
-10.6 vs -10.1 Standard of Care swollen joints @ 104wkc,d,h
NCT01162421 · Phase 4 · registry result, not featured evidence
0 vs 0.5 placebo swollen joints @ 48wk50 mga,c,d,h
NCT00858780 · Phase 4 · registry result, not featured evidence
show 1 more dose
0 vs 0.5 placebo swollen joints @ 48wk25 mg
NCT00858780 · Phase 4 · registry result, not featured evidence
Dropout rate
23.2%40 mg every other weekw
NCT00195702 · Phase 3
show 50 more results
—40 mg every other week
NCT00195702 · Phase 3
20.8%20 mg weekly
NCT00195702 · Phase 3
—20 mg weekly, then 40 mg every other week
NCT00195702 · Phase 3
—maximum tolerated dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
—reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
24.8%40 mg Eow
NCT02198651 · Phase 4 · registry result, not featured evidence
—40 mg Eow
NCT02198651 · Phase 4 · registry result, not featured evidence
—Adalimumab Tapering
NCT02198651 · Phase 4 · registry result, not featured evidence
66.7%
NCT02451748 · Phase 4 · registry result, not featured evidence · combination
—
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
32.5%
NCT01162421 · Phase 4 · registry result, not featured evidence
10.3%high dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
12.3%low dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
—ADA+MTX/ADA+MTX (Arm 2)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
—ADA+MTX/OL ADA+MTX (Arm 3)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
5.9%
NCT03172325 · Phase 3 · registry result, not featured evidence
9.2%20 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
6.1%10 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
7%5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
15.3%2.5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
39.4%Adalimumab
NCT00195663 · Phase 3 · registry result, not featured evidence
26.9%Adalimumab + Methotrexate
NCT00195663 · Phase 3 · registry result, not featured evidence · combination
36%
NCT00690573 · Phase 3 · registry result, not featured evidence
9.4%DB Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
—DB Adalimumab/OL Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
—DB Adalimumab/RE OL Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
62.1%
NCT00195650 · Phase 3 · registry result, not featured evidence
5%40 mg/0.8 mL
NCT01231321 · Phase 3 · registry result, not featured evidence
8.2%40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
—40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
—40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
11.2%80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
—80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
—80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
22.7%40 mg or 80 mg every other week
NCT00603993 · Phase 3 · registry result, not featured evidence
47.6%40 mg every other week
NCT00235872 · Phase 3 · registry result, not featured evidence
1.7%40 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—40 mg EOW
NCT00538902 · Phase 2/3 · registry result, not featured evidence
4.1%80 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—80 mg EOW
NCT00538902 · Phase 2/3 · registry result, not featured evidence
0%Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
—Period 1: Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
—Period 2: Adalimumab / Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
2%40 mg
NCT02565810 · Phase 2 · registry result, not featured evidence
9.1%Current Formulation for 24 Weeks,
NCT01752855 · Phase 2 · registry result, not featured evidence
2.3%New Formulation for 48 Weeks
NCT01752855 · Phase 2 · registry result, not featured evidence
2%40 mg every other week
NCT01712178 · Phase 2 · registry result, not featured evidence
—Current Formulation Adalimumab
NCT01561313 · Phase 2 · registry result, not featured evidence
—New Formulation of Adalimumab
NCT01561313 · Phase 2 · registry result, not featured evidence
64%40 mg Eow
NCT00235833 · Phase 2 · registry result, not featured evidence
—0.4 mg/kgx
NCT03780959 · Phase 2/3 · monotherapy · Rheumatoid Arthritis · phase 2/3
show 44 more results
62.5%Adult Participants
NCT00357903 · Phase 3 · monotherapy
74.1%Pediatric Participants
NCT00357903 · Phase 3 · monotherapy
—Pediatric Subjects
NCT00357903 · Phase 3 · monotherapy
—Total Adults
NCT00357903 · Phase 3 · monotherapy
16.4%
NCT03649061 · Phase 4 · registry result, not featured evidence · combination
—
NCT01578850 · Phase 4 · registry result, not featured evidence
4.7%Etanercept
NCT01313208 · Phase 4 · registry result, not featured evidence
—Etanercept-Etanercept
NCT01313208 · Phase 4 · registry result, not featured evidence
—Placebo-Etanercept
NCT01313208 · Phase 4 · registry result, not featured evidence
4.3%Etanercept + Methotrexate
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
—Etanercept + Methotrexate Phase 1
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
—Etanercept + Methotrexate Phase 2
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
—Etanercept + Methotrexate Phase 2
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
29.9%Etanercept + Methotrexate
NCT00654368 · Phase 4 · registry result, not featured evidence · combination
49%Etanercept Alone
NCT00654368 · Phase 4 · registry result, not featured evidence · monotherapy
36.6%50 mg QW
NCT00913458 · Phase 4 · registry result, not featured evidence · combination
—E25 + MTX (Phase 2)
NCT00913458 · Phase 4 · registry result, not featured evidence · combination
—E25+MTX (Phase 3)
NCT00913458 · Phase 4 · registry result, not featured evidence · combination
—50 mg
NCT00858780 · Phase 4 · registry result, not featured evidence
—25 mg
NCT00858780 · Phase 4 · registry result, not featured evidence
9.4%50 mg
NCT00565409 · Phase 4 · registry result, not featured evidence · combination
—50 mg
NCT00565409 · Phase 4 · registry result, not featured evidence · combination
—25 mg
NCT00565409 · Phase 4 · registry result, not featured evidence · combination
9.5%
NCT00443430 · Phase 4 · registry result, not featured evidence · combination
40.5%ETN Alone
NCT00688103 · Phase 4 · registry result, not featured evidence · monotherapy
16.9%ETN+MTX
NCT00688103 · Phase 4 · registry result, not featured evidence · combination
31.1%
NCT00259610 · Phase 4 · registry result, not featured evidence · combination
2%
NCT00422227 · Phase 4 · registry result, not featured evidence
19.3%Year 1 E+M
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
—Year 1 E+M / Year 2 E
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
—Year 1 E+M / Year 2 E+M
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
—Year 1 M / Year 2 E+M
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
—Double-Blind Treatment: Etanercept
NCT02373813 · Phase 3 · registry result, not featured evidence · monotherapy
—Double-Blind Treatment: Etanercept
NCT02373813 · Phase 3 · registry result, not featured evidence · combination
—Open Label Rescue: Etanercept Plus
NCT02373813 · Phase 3 · registry result, not featured evidence · combination
31.3%Open Label Run-In: Etanercept Plus
NCT02373813 · Phase 3 · registry result, not featured evidence · combination
—
NCT02986139 · Phase 3 · registry result, not featured evidence
13.3%
NCT02378506 · Phase 3 · registry result, not featured evidence
17%25 mg
NCT00445770 · Phase 3 · registry result, not featured evidence
18.2%10 mg
NCT00445770 · Phase 3 · registry result, not featured evidence
8%50 mg
NCT00459706 · Phase 3 · registry result, not featured evidence
6.7%50 mg
NCT00459706 · Phase 3 · registry result, not featured evidence
2.4%50 mg once weekly
NCT00418717 · Phase 3 · registry result, not featured evidence
14.3%
NCT00361634 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—40 mg every other weekw
NCT00195702 · Phase 3
show 50 more results
—40 mg every other week
NCT00195702 · Phase 3
—20 mg weekly
NCT00195702 · Phase 3
—20 mg weekly, then 40 mg every other week
NCT00195702 · Phase 3
—maximum tolerated dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
—reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
1.3%40 mg Eow
NCT02198651 · Phase 4 · registry result, not featured evidence
—40 mg Eow
NCT02198651 · Phase 4 · registry result, not featured evidence
—Adalimumab Tapering
NCT02198651 · Phase 4 · registry result, not featured evidence
—
NCT02451748 · Phase 4 · registry result, not featured evidence · combination
—
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
12.5%
NCT01162421 · Phase 4 · registry result, not featured evidence
3.9%high dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
4.5%low dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
—ADA+MTX/ADA+MTX (Arm 2)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
—ADA+MTX/OL ADA+MTX (Arm 3)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
2.9%
NCT03172325 · Phase 3 · registry result, not featured evidence
3.1%20 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
2%10 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
0%5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
3.1%2.5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
9.9%Adalimumab
NCT00195663 · Phase 3 · registry result, not featured evidence
11.9%Adalimumab + Methotrexate
NCT00195663 · Phase 3 · registry result, not featured evidence · combination
—
NCT00690573 · Phase 3 · registry result, not featured evidence
—DB Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
—DB Adalimumab/OL Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
—DB Adalimumab/RE OL Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
22.9%
NCT00195650 · Phase 3 · registry result, not featured evidence
3%40 mg/0.8 mL
NCT01231321 · Phase 3 · registry result, not featured evidence
4.4%40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
—40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
—40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
3.4%80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
—80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
—80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
—40 mg or 80 mg every other week
NCT00603993 · Phase 3 · registry result, not featured evidence
11%40 mg every other week
NCT00235872 · Phase 3 · registry result, not featured evidence
1.7%40 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—40 mg EOW
NCT00538902 · Phase 2/3 · registry result, not featured evidence
2.5%80 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—80 mg EOW
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
—Period 1: Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
—Period 2: Adalimumab / Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
—40 mg
NCT02565810 · Phase 2 · registry result, not featured evidence
0%Current Formulation for 24 Weeks,
NCT01752855 · Phase 2 · registry result, not featured evidence
2.3%New Formulation for 48 Weeks
NCT01752855 · Phase 2 · registry result, not featured evidence
2%40 mg every other week
NCT01712178 · Phase 2 · registry result, not featured evidence
—Current Formulation Adalimumab
NCT01561313 · Phase 2 · registry result, not featured evidence
—New Formulation of Adalimumab
NCT01561313 · Phase 2 · registry result, not featured evidence
—40 mg Eow
NCT00235833 · Phase 2 · registry result, not featured evidence
—0.4 mg/kgx
NCT03780959 · Phase 2/3 · monotherapy · Rheumatoid Arthritis · phase 2/3
show 44 more results
15%Adult Participants
NCT00357903 · Phase 3 · monotherapy
6.9%Pediatric Participants
NCT00357903 · Phase 3 · monotherapy
—Pediatric Subjects
NCT00357903 · Phase 3 · monotherapy
—Total Adults
NCT00357903 · Phase 3 · monotherapy
—
NCT03649061 · Phase 4 · registry result, not featured evidence · combination
—
NCT01578850 · Phase 4 · registry result, not featured evidence
1.9%Etanercept
NCT01313208 · Phase 4 · registry result, not featured evidence
—Etanercept-Etanercept
NCT01313208 · Phase 4 · registry result, not featured evidence
—Placebo-Etanercept
NCT01313208 · Phase 4 · registry result, not featured evidence
1.8%Etanercept + Methotrexate
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
—Etanercept + Methotrexate Phase 1
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
—Etanercept + Methotrexate Phase 2
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
—Etanercept + Methotrexate Phase 2
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
5.6%Etanercept + Methotrexate
NCT00654368 · Phase 4 · registry result, not featured evidence · combination
9.2%Etanercept Alone
NCT00654368 · Phase 4 · registry result, not featured evidence · monotherapy
6.5%50 mg QW
NCT00913458 · Phase 4 · registry result, not featured evidence · combination
—E25 + MTX (Phase 2)
NCT00913458 · Phase 4 · registry result, not featured evidence · combination
—E25+MTX (Phase 3)
NCT00913458 · Phase 4 · registry result, not featured evidence · combination
—50 mg
NCT00858780 · Phase 4 · registry result, not featured evidence
—25 mg
NCT00858780 · Phase 4 · registry result, not featured evidence
2%50 mg
NCT00565409 · Phase 4 · registry result, not featured evidence · combination
—50 mg
NCT00565409 · Phase 4 · registry result, not featured evidence · combination
—25 mg
NCT00565409 · Phase 4 · registry result, not featured evidence · combination
2.4%
NCT00443430 · Phase 4 · registry result, not featured evidence · combination
5.4%ETN Alone
NCT00688103 · Phase 4 · registry result, not featured evidence · monotherapy
1.3%ETN+MTX
NCT00688103 · Phase 4 · registry result, not featured evidence · combination
4.5%
NCT00259610 · Phase 4 · registry result, not featured evidence · combination
1.5%
NCT00422227 · Phase 4 · registry result, not featured evidence
9.9%Year 1 E+M
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
—Year 1 E+M / Year 2 E
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
—Year 1 E+M / Year 2 E+M
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
—Year 1 M / Year 2 E+M
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
—Double-Blind Treatment: Etanercept
NCT02373813 · Phase 3 · registry result, not featured evidence · monotherapy
—Double-Blind Treatment: Etanercept
NCT02373813 · Phase 3 · registry result, not featured evidence · combination
—Open Label Rescue: Etanercept Plus
NCT02373813 · Phase 3 · registry result, not featured evidence · combination
0.8%Open Label Run-In: Etanercept Plus
NCT02373813 · Phase 3 · registry result, not featured evidence · combination
—
NCT02986139 · Phase 3 · registry result, not featured evidence
7.4%
NCT02378506 · Phase 3 · registry result, not featured evidence
10.4%25 mg
NCT00445770 · Phase 3 · registry result, not featured evidence
7.8%10 mg
NCT00445770 · Phase 3 · registry result, not featured evidence
5.8%50 mg
NCT00459706 · Phase 3 · registry result, not featured evidence
4.1%50 mg
NCT00459706 · Phase 3 · registry result, not featured evidence
—50 mg once weekly
NCT00418717 · Phase 3 · registry result, not featured evidence
—
NCT00361634 · Phase 1 · registry result, not featured evidence
Serious AEs
13%40 mg every other weekw
NCT00195702 · Phase 3
show 50 more results
—40 mg every other week
NCT00195702 · Phase 3
16%20 mg weekly
NCT00195702 · Phase 3
—20 mg weekly, then 40 mg every other week
NCT00195702 · Phase 3
7.4%maximum tolerated dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
4.5%reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
2.7%40 mg Eow
NCT02198651 · Phase 4 · registry result, not featured evidence
7.7%40 mg Eow
NCT02198651 · Phase 4 · registry result, not featured evidence
1%Adalimumab Tapering
NCT02198651 · Phase 4 · registry result, not featured evidence
0%
NCT02451748 · Phase 4 · registry result, not featured evidence · combination
13%
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
10.3%
NCT01162421 · Phase 4 · registry result, not featured evidence
7.1%high dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
3.9%low dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
11.4%ADA+MTX/ADA+MTX (Arm 2)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
6.9%ADA+MTX/OL ADA+MTX (Arm 3)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
2.9%
NCT03172325 · Phase 3 · registry result, not featured evidence
7.1%20 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
3%10 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
2%5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
5.1%2.5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
23.7%Adalimumab
NCT00195663 · Phase 3 · registry result, not featured evidence
20.9%Adalimumab + Methotrexate
NCT00195663 · Phase 3 · registry result, not featured evidence · combination
24%
NCT00690573 · Phase 3 · registry result, not featured evidence
4.1%DB Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
—DB Adalimumab/OL Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
—DB Adalimumab/RE OL Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
51.1%
NCT00195650 · Phase 3 · registry result, not featured evidence
1%40 mg/0.8 mL
NCT01231321 · Phase 3 · registry result, not featured evidence
—40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
4.9%40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
3.3%40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
—80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
6.4%80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
1.9%80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
22.7%40 mg or 80 mg every other week
NCT00603993 · Phase 3 · registry result, not featured evidence
35.9%40 mg every other week
NCT00235872 · Phase 3 · registry result, not featured evidence
—40 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
0%40 mg EOW
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—80 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
2.5%80 mg EOW
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
0%Period 1: Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
12.5%Period 2: Adalimumab / Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
0%40 mg
NCT02565810 · Phase 2 · registry result, not featured evidence
2.3%Current Formulation for 24 Weeks,
NCT01752855 · Phase 2 · registry result, not featured evidence
4.5%New Formulation for 48 Weeks
NCT01752855 · Phase 2 · registry result, not featured evidence
0%40 mg every other week
NCT01712178 · Phase 2 · registry result, not featured evidence
0%Current Formulation Adalimumab
NCT01561313 · Phase 2 · registry result, not featured evidence
0%New Formulation of Adalimumab
NCT01561313 · Phase 2 · registry result, not featured evidence
40%40 mg Eow
NCT00235833 · Phase 2 · registry result, not featured evidence
4%0.4 mg/kgx
NCT03780959 · Phase 2/3 · monotherapy · Rheumatoid Arthritis · phase 2/3
show 44 more results
—Adult Participants
NCT00357903 · Phase 3 · monotherapy
—Pediatric Participants
NCT00357903 · Phase 3 · monotherapy
27.6%Pediatric Subjects
NCT00357903 · Phase 3 · monotherapy
50.4%Total Adults
NCT00357903 · Phase 3 · monotherapy
9.1%
NCT03649061 · Phase 4 · registry result, not featured evidence · combination
0%
NCT01578850 · Phase 4 · registry result, not featured evidence
—Etanercept
NCT01313208 · Phase 4 · registry result, not featured evidence
3.8%Etanercept-Etanercept
NCT01313208 · Phase 4 · registry result, not featured evidence
2.9%Placebo-Etanercept
NCT01313208 · Phase 4 · registry result, not featured evidence
—Etanercept + Methotrexate
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
3.6%Etanercept + Methotrexate Phase 1
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
6.5%Etanercept + Methotrexate Phase 2
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
4.6%Etanercept + Methotrexate Phase 2
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
15.9%Etanercept + Methotrexate
NCT00654368 · Phase 4 · registry result, not featured evidence · combination
11.2%Etanercept Alone
NCT00654368 · Phase 4 · registry result, not featured evidence · monotherapy
9.2%50 mg QW
NCT00913458 · Phase 4 · registry result, not featured evidence · combination
4.8%E25 + MTX (Phase 2)
NCT00913458 · Phase 4 · registry result, not featured evidence · combination
0%E25+MTX (Phase 3)
NCT00913458 · Phase 4 · registry result, not featured evidence · combination
4.3%50 mg
NCT00858780 · Phase 4 · registry result, not featured evidence
3.7%25 mg
NCT00858780 · Phase 4 · registry result, not featured evidence
4.6%50 mg
NCT00565409 · Phase 4 · registry result, not featured evidence · combination
6.4%50 mg
NCT00565409 · Phase 4 · registry result, not featured evidence · combination
3.5%25 mg
NCT00565409 · Phase 4 · registry result, not featured evidence · combination
4.8%
NCT00443430 · Phase 4 · registry result, not featured evidence · combination
2.8%ETN Alone
NCT00688103 · Phase 4 · registry result, not featured evidence · monotherapy
11.8%ETN+MTX
NCT00688103 · Phase 4 · registry result, not featured evidence · combination
14.3%
NCT00259610 · Phase 4 · registry result, not featured evidence · combination
3%
NCT00422227 · Phase 4 · registry result, not featured evidence
—Year 1 E+M
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
—Year 1 E+M / Year 2 E
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
—Year 1 E+M / Year 2 E+M
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
—Year 1 M / Year 2 E+M
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
3%Double-Blind Treatment: Etanercept
NCT02373813 · Phase 3 · registry result, not featured evidence · monotherapy
3.8%Double-Blind Treatment: Etanercept
NCT02373813 · Phase 3 · registry result, not featured evidence · combination
3.9%Open Label Rescue: Etanercept Plus
NCT02373813 · Phase 3 · registry result, not featured evidence · combination
3.8%Open Label Run-In: Etanercept Plus
NCT02373813 · Phase 3 · registry result, not featured evidence · combination
0.9%
NCT02986139 · Phase 3 · registry result, not featured evidence
4.8%
NCT02378506 · Phase 3 · registry result, not featured evidence
6%25 mg
NCT00445770 · Phase 3 · registry result, not featured evidence
4.2%10 mg
NCT00445770 · Phase 3 · registry result, not featured evidence
5.5%50 mg
NCT00459706 · Phase 3 · registry result, not featured evidence
2.9%50 mg
NCT00459706 · Phase 3 · registry result, not featured evidence
—50 mg once weekly
NCT00418717 · Phase 3 · registry result, not featured evidence
0%
NCT00361634 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
40 mg every other weekw
injection site pain 17.9% (placebo 21.5%)
upper respiratory tract infection 16.9% (placebo 11%)
headache 11.6% (placebo 5%)
NCT00195702 · Phase 3
show 40 more results
20 mg weekly
injection site pain 17.5% (placebo 21.5%)
upper respiratory tract infection 16.5% (placebo 11%)
headache 13.2% (placebo 5%)
NCT00195702 · Phase 3
maximum tolerated dose
liver function test abnormal 8.8%
abdominal pain upper 2.9%
dry mouth 1.5%
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
reduced dose
dry mouth 3%
alanine aminotransferase increased 1.5%
cough 1.5%
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
40 mg Eow
cough 2.7% (placebo 5%)
nasopharyngitis 2.7% (placebo 20%)
urinary tract infection 1.4% (placebo 0%)
NCT02198651 · Phase 4 · registry result, not featured evidence
40 mg Eow
nasopharyngitis 10.3% (placebo 20%)
upper respiratory tract infection 7.7% (placebo 0%)
hepatic enzyme increased 5.1% (placebo 0%)
NCT02198651 · Phase 4 · registry result, not featured evidence
nasopharyngitis 15.7% (placebo 20%)
arthralgia 5.9% (placebo 0%)
influenza 4.9% (placebo 10%)
NCT02198651 · Phase 4 · registry result, not featured evidence
nasopharyngitis 15.3%
headache 10.7%
upper respiratory tract infection 10.3%
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
rheumatoid arthritis 25.6%
nasopharyngitis 20.5%
alanine aminotransferase increased 15.4%
NCT01162421 · Phase 4 · registry result, not featured evidence
high dose
nausea 10.3%
upper respiratory tract infection 7.7%
urinary tract infection 7.1%
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
low dose
nausea 9.7%
fatigue 9.1%
upper respiratory tract infection 9.1%
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
cough 6.7% (placebo 3.6%)
influenza 5.7% (placebo 2.7%)
nasopharyngitis 5.7% (placebo 3.6%)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
upper respiratory tract infection 11.2% (placebo 6.3%)
nasopharyngitis 8.9% (placebo 3.6%)
alanine aminotransferase increased 6.2% (placebo 2.7%)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
injection site reaction 8.8%
headache 5.9%
nausea 5.9%
NCT03172325 · Phase 3 · registry result, not featured evidence
20 mg MTX
nasopharyngitis 11.2%
headache 9.2%
alopecia 8.2%
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
10 mg MTX
nausea 13.1%
alopecia 6.1%
diarrhoea 6.1%
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
5 mg MTX
diarrhoea 6%
headache 6%
nasopharyngitis 6%
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
2.5 mg MTX
nausea 7.1%
arthralgia 6.1%
abdominal pain upper 4.1%
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 22.6%
headache 21.5%
nausea 17.5%
NCT00195663 · Phase 3 · registry result, not featured evidence
nasopharyngitis 30.2%
headache 20.5%
upper respiratory tract infection 18.7%
NCT00195663 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 56%
upper respiratory tract infection 56%
influenza 32%
NCT00690573 · Phase 3 · registry result, not featured evidence
nasopharyngitis 15.2% (placebo 16.6%)
hepatic function abnormal 8.2% (placebo 5.5%)
alanine aminotransferase increased 7.6% (placebo 3.7%)
NCT00870467 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 46.3%
rheumatoid arthritis 25.4%
sinusitis 24.9%
NCT00195650 · Phase 3 · registry result, not featured evidence
40 mg/0.8 mL
nasopharyngitis 4%
respiratory disorder 4%
headache 3%
NCT01231321 · Phase 3 · registry result, not featured evidence
40 mg every other week
nausea 5.5% (placebo 5.3%)
headache 4.9% (placebo 5.3%)
nasopharyngitis 4.9% (placebo 5.3%)
NCT00647270 · Phase 3 · registry result, not featured evidence
40 mg every other week
nasopharyngitis 6.6% (placebo 5.3%)
upper respiratory tract infection 2.6% (placebo 7%)
cough 0% (placebo 5.3%)
NCT00647270 · Phase 3 · registry result, not featured evidence
80 mg monthly
upper respiratory tract infection 3.2% (placebo 7%)
nasopharyngitis 2.7% (placebo 5.3%)
cough 0% (placebo 5.3%)
NCT00647270 · Phase 3 · registry result, not featured evidence
80 mg monthly
nausea 6.2% (placebo 5.3%)
upper respiratory tract infection 5.2% (placebo 7%)
headache 4.7% (placebo 5.3%)
NCT00647270 · Phase 3 · registry result, not featured evidence
40 mg or 80 mg every other week
nasopharyngitis 60.2%
adverse drug reaction 29.5%
antinuclear antibody positive 15.9%
NCT00603993 · Phase 3 · registry result, not featured evidence
40 mg every other week
nasopharyngitis 45%
adverse drug reaction 23.6%
dna antibody positive 16.2%
NCT00235872 · Phase 3 · registry result, not featured evidence
40 mg EOW
upper respiratory tract infection 14% (placebo 11.7%)
injection site pruritus 5.8% (placebo 0%)
nasopharyngitis 5.8% (placebo 6.7%)
NCT00538902 · Phase 2/3 · registry result, not featured evidence
80 mg EOW
upper respiratory tract infection 12.4% (placebo 11.7%)
nasopharyngitis 7.4% (placebo 6.7%)
injection site pruritus 4.1% (placebo 0%)
NCT00538902 · Phase 2/3 · registry result, not featured evidence
urinary tract infection 11.8%
abdominal discomfort 5.9%
arthralgia 5.9%
NCT03823391 · Phase 2 · registry result, not featured evidence
nasopharyngitis 12.5%
bronchitis 6.3%
drug hypersensitivity 6.3%
NCT03823391 · Phase 2 · registry result, not featured evidence
40 mg
nasopharyngitis 8.2%
NCT02565810 · Phase 2 · registry result, not featured evidence
nasopharyngitis 15.9%
rheumatoid arthritis 9.1%
upper respiratory tract infection 9.1%
NCT01752855 · Phase 2 · registry result, not featured evidence
nasopharyngitis 13.6%
cystitis 9.1%
upper respiratory tract infection 9.1%
NCT01752855 · Phase 2 · registry result, not featured evidence
40 mg every other week
nasopharyngitis 10%
cystitis 8%
nausea 8%
NCT01712178 · Phase 2 · registry result, not featured evidence
pharyngitis 1.6%
rash erythematous 1.6%
protein urine present 0%
NCT01561313 · Phase 2 · registry result, not featured evidence
protein urine present 1.6%
pharyngitis 0%
rash erythematous 0%
NCT01561313 · Phase 2 · registry result, not featured evidence
40 mg Eow
nasopharyngitis 60%
diarrhoea 24%
pruritus 20%
NCT00235833 · Phase 2 · registry result, not featured evidence
0.4 mg/kgx
upper respiratory tract infection 40% (placebo 15.4%)
headache 20% (placebo 11.5%)
gastroenteritis 12% (placebo 3.8%)
NCT03780959 · Phase 2/3 · monotherapy · Rheumatoid Arthritis · phase 2/3
show 40 more results
upper respiratory tract infection 62.1%
headache 34.5%
pharyngitis 22.4%
NCT00357903 · Phase 3 · monotherapy
upper respiratory tract infection 35.6%
sinusitis 20.8%
bronchitis 15.3%
NCT00357903 · Phase 3 · monotherapy
nausea 25.5%
fatigue 23.6%
hepatic function abnormal 16.4%
NCT03649061 · Phase 4 · registry result, not featured evidence · combination
upper respiratory tract infection 2.4% (placebo 5.1%)
NCT01578850 · Phase 4 · registry result, not featured evidence
injection site erythema 12.3%
rheumatoid arthritis 11.3%
headache 8.5%
NCT01313208 · Phase 4 · registry result, not featured evidence
headache 15.4%
upper respiratory tract infection 12.5%
nasopharyngitis 11.5%
NCT01313208 · Phase 4 · registry result, not featured evidence
bronchitis 6.4%
influenza 5.3%
nasopharyngitis 5%
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
bronchitis 4.2%
influenza 4.2%
nasopharyngitis 4.2%
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
bronchitis 7.1%
nasopharyngitis 4.6%
urinary tract infection 4.6%
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
upper respiratory tract infection 17.8%
nasopharyngitis 11.2%
sinusitis 10.3%
NCT00654368 · Phase 4 · registry result, not featured evidence · combination
upper respiratory tract infection 13.3%
nasopharyngitis 10.2%
headache 9.2%
NCT00654368 · Phase 4 · registry result, not featured evidence · monotherapy
50 mg QW
nasopharyngitis 12.7% (placebo 4.6%)
nausea 12.7% (placebo 0%)
headache 6.5% (placebo 0%)
NCT00913458 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 7.9% (placebo 4.6%)
upper respiratory tract infection 6.3% (placebo 4.6%)
rheumatoid arthritis 3.2% (placebo 9.2%)
NCT00913458 · Phase 4 · registry result, not featured evidence · combination
rheumatoid arthritis 18.9% (placebo 9.2%)
nasopharyngitis 5.7% (placebo 4.6%)
alanine aminotransferase increased 0% (placebo 0%)
NCT00913458 · Phase 4 · registry result, not featured evidence · combination
50 mg
nasopharyngitis 26.1% (placebo 8.7%)
upper respiratory tract infection 26.1% (placebo 8.7%)
back pain 13% (placebo 0%)
NCT00858780 · Phase 4 · registry result, not featured evidence
25 mg
nasopharyngitis 29.6% (placebo 8.7%)
arthralgia 11.1% (placebo 0%)
gastroenteritis 11.1% (placebo 0%)
NCT00858780 · Phase 4 · registry result, not featured evidence
50 mg
headache 6.1% (placebo 0%)
nasopharyngitis 5.8% (placebo 5%)
bronchitis 0% (placebo 3%)
NCT00565409 · Phase 4 · registry result, not featured evidence · combination
50 mg
nasopharyngitis 8.9% (placebo 5%)
bronchitis 5.9% (placebo 3%)
pharyngitis 1.5% (placebo 5.5%)
NCT00565409 · Phase 4 · registry result, not featured evidence · combination
25 mg
bronchitis 5.4% (placebo 3%)
nasopharyngitis 5% (placebo 5%)
pharyngitis 2.5% (placebo 5.5%)
NCT00565409 · Phase 4 · registry result, not featured evidence · combination
liver function test elevation 7.1%
NCT00443430 · Phase 4 · registry result, not featured evidence · combination
upper airway viral infection 40.8%
rash 26.8%
injection site reaction 22.5%
NCT00688103 · Phase 4 · registry result, not featured evidence · monotherapy
upper airway viral infection 43.4%
injection site reaction 11.8%
gastroentelitis 10.5%
NCT00688103 · Phase 4 · registry result, not featured evidence · combination
upper respiratory tract infection 53.7% (placebo 57.3%)
joint pain 27% (placebo 22.4%)
dermatalogic eruption 14.8% (placebo 14.5%)
NCT00259610 · Phase 4 · registry result, not featured evidence · combination
upper respiratory tract infection 13.7%
alanine aminotransferase increased 5.6%
aspartate aminotransferase increased 3.6%
NCT00422227 · Phase 4 · registry result, not featured evidence
administration site conditions 24.5%
nausea 19.3%
investigations 17.9%
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
infections and infestations 44.1%
injury, poisoning and procedural complications 13.5%
nasopharyngitis 9%
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
infections and infestations 42.3%
injury, poisoning and procedural complications 11.7%
nasopharyngitis 9%
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
infections and infestations 36.7%
injury, poisoning and procedural complications 12.2%
nasopharyngitis 11.1%
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
rheumatoid arthritis 7.1%
bronchitis 3%
upper respiratory tract infection 3%
NCT02373813 · Phase 3 · registry result, not featured evidence · monotherapy
bronchitis 7.5%
rheumatoid arthritis 5.7%
upper respiratory tract infection 1.9%
NCT02373813 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 6.8%
rheumatoid arthritis 1.9%
bronchitis 0%
NCT02373813 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 5.4%
bronchitis 1.6%
rheumatoid arthritis 0.8%
NCT02373813 · Phase 3 · registry result, not featured evidence · combination
hypoaesthesia 1.9%
pain in extremity 1.9%
cellulitis 0.9%
NCT02986139 · Phase 3 · registry result, not featured evidence
injection site erythema 10.7%
nasopharyngitis 7%
upper respiratory tract infection 7%
NCT02378506 · Phase 3 · registry result, not featured evidence
25 mg
nasopharyngitis 20.3%
upper respiratory tract infection 11.5%
pharyngitis 8.2%
NCT00445770 · Phase 3 · registry result, not featured evidence
10 mg
nasopharyngitis 23.4%
upper respiratory tract infection 10.4%
pharyngitis 9.4%
NCT00445770 · Phase 3 · registry result, not featured evidence
50 mg
injection site reaction 14.2%
injection site erythema 7.7%
nasopharyngitis 6.8%
NCT00459706 · Phase 3 · registry result, not featured evidence
50 mg
injection site reaction 17.6%
injection site erythema 9.3%
nasopharyngitis 8.3%
NCT00459706 · Phase 3 · registry result, not featured evidence
50 mg once weekly
infections and infestations 28.6%
dizziness 7.1%
headache 4.8%
NCT00418717 · Phase 3 · registry result, not featured evidence
dry skin 23.1%
injection site reaction 23.1%
cough 15.4%
NCT00361634 · Phase 1 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 3 versus Phase 4.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. eTrial phases differ: Phase 2 versus Phase 3.
  6. fAssessment timepoints differ: 78 weeks versus 24 weeks.
  7. gThe assessment timepoint is not available for both results.
  8. hAssessment timepoints differ: 104 weeks versus 48 weeks.
  9. iAssessment timepoints differ: 520 weeks versus 52 weeks.
  10. jAssessment timepoints differ: 78 weeks versus 128 weeks.
  11. kTrial phases differ: Phase 2 versus Phase 4.
  12. lAssessment timepoints differ: 24 weeks versus 36 weeks.
  13. mAssessment timepoints differ: 52 weeks versus 24 weeks.
  14. nAssessment timepoints differ: 104 weeks versus 52 weeks.
  15. oAssessment timepoints differ: 26 weeks versus 52 weeks.
  16. pTrial phases differ: Phase 4 versus Phase 2/3.
  17. qAssessment timepoints differ: 104 weeks versus 128 weeks.
  18. rAssessment timepoints differ: 78 weeks versus 52 weeks.
  19. sAssessment timepoints differ: 78 weeks versus 12 weeks.
  20. tTrial phases differ: Phase 4 versus Phase 3.
  21. uAssessment timepoints differ: 78 weeks versus 48 weeks.
  22. vAssessment timepoints differ: 52 weeks versus 128 weeks.
  23. wPopulation comparability has not been reviewed for these studies.
  24. xPopulation comparability has not been reviewed for 44 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab

Sustained 8.7% (n=207) vs 1.5% (n=200) placebo40 mg every other week
responder rate · % of participants
NCT00195702 · Phase 3 · converted to % from 18 Participants as posted
show 1 more result
9.4% (n=212) vs 1.5% (n=200) placebo*20 mg weekly
NCT00195702 · Phase 3 · converted to % from 20 Participants as posted
Modified Sharp 0.09 vs 2.66 placebo score @ 52wk40 mg every other week
absolute change · score
Actual progression during study
NCT00195702 · Phase 3
show 1 more result
0.77 vs 2.66 placebo score @ 52wk20 mg weekly
Actual progression during study
NCT00195702 · Phase 3
SDAI Remission 29.6% (n=98) @ 26wk20 mg MTX
responder rate · % of participants
No placebo or comparator arm
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
show 7 more results
28.3% (n=99) @ 26wk10 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
22% (n=100) @ 26wk5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
11.2% (n=98) @ 26wk2.5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
37.9% (n=66) @ 48wk*maximum tolerated dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 25 Participants as posted
44.3% (n=61) @ 48wk*reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 27 Participants as posted
39.7% (n=58) @ 48wk*maximum tolerated dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 23 Participants as posted
44.3% (n=61) @ 48wk*reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 27 Participants as posted
HAQ-DI Less Than 0.5 58.8% (n=68) @ 48wkmaximum tolerated dose
event count · % of participants
No placebo or comparator arm
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 40 Participants as posted
show 1 more result
62.1% (n=66) @ 48wk*reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 41 Participants as posted
mTSS no Progression 66.2% (n=68) @ 48wkmaximum tolerated dose
event count · % of participants
No placebo or comparator arm
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 45 Participants as posted
show 1 more result
62.1% (n=66) @ 48wk*reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 41 Participants as posted
Time to Flare NA vs NA placebo months
time to event · months
NCT02198651 · Phase 4 · registry result, not featured evidence
Time to Clinical Remission 1.41 vs 4.15 placebo months
time to event · months
NCT02198651 · Phase 4 · registry result, not featured evidence · converted to months from 6.1 weeks as posted
All-Cause Discontinuation 0% (n=353) vs 0.0028% (n=361) ADA+MTX @ 13wk
event count · % of participants
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
show 7 more results
0.0198% (n=353) vs 0.0332% (n=361) ADA+MTX @ 26wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
0.0453% (n=353) vs 0.0609% (n=361) ADA+MTX @ 39wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
0.0963% (n=353) vs 0.0886% (n=361) ADA+MTX @ 52wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
0.1643% (n=353) vs 0.1607% (n=361) ADA+MTX @ 65wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
0.2181% (n=353) vs 0.1967% (n=361) ADA+MTX @ 78wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
0.2408% (n=353) vs 0.2105% (n=361) ADA+MTX @ 91wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
0.2635% (n=353) vs 0.2247% (n=361) ADA+MTX @ 104wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
mTSS no Progression 61.5% (n=39) vs 62.9% (n=35) Standard of Care @ 52wk
responder rate · % of participants
NCT01162421 · Phase 4 · registry result, not featured evidence
show 2 more results
71.8% (n=39) vs 68.6% (n=35) Standard of Care @ 26wk
NCT01162421 · Phase 4 · registry result, not featured evidence
46.2% (n=39) vs 51.4% (n=35) Standard of Care @ 104wk
NCT01162421 · Phase 4 · registry result, not featured evidence
Rapid Radiographic Progression 2.6% (n=39) vs 14.3% (n=34) Standard of Care @ 52wk
responder rate · % of participants
NCT01162421 · Phase 4 · registry result, not featured evidence
SJC28 -6.5 vs -4.6 Standard of Care swollen joints @ 13wk
absolute change · swollen joints
NCT01162421 · Phase 4 · registry result, not featured evidence
show 5 more results
-7.9 vs -4.5 Standard of Care swollen joints @ 26wk
NCT01162421 · Phase 4 · registry result, not featured evidence
-8.3 vs -6.1 Standard of Care swollen joints @ 39wk
NCT01162421 · Phase 4 · registry result, not featured evidence
-8.5 vs -6.9 Standard of Care swollen joints @ 52wk
NCT01162421 · Phase 4 · registry result, not featured evidence
-8.1 vs -7.4 Standard of Care swollen joints @ 78wk
NCT01162421 · Phase 4 · registry result, not featured evidence
-8.4 vs -7.6 Standard of Care swollen joints @ 104wk
NCT01162421 · Phase 4 · registry result, not featured evidence
Tender Joint Count -12.1 vs -9.3 Standard of Care tender joints @ 13wk
absolute change · tender joints
NCT01162421 · Phase 4 · registry result, not featured evidence
show 5 more results
-15.5 vs -8.3 Standard of Care tender joints @ 26wk
NCT01162421 · Phase 4 · registry result, not featured evidence
-15 vs -11.2 Standard of Care tender joints @ 39wk
NCT01162421 · Phase 4 · registry result, not featured evidence
-14.1 vs -13.4 Standard of Care tender joints @ 52wk
NCT01162421 · Phase 4 · registry result, not featured evidence
-13.9 vs -13.4 Standard of Care tender joints @ 78wk
NCT01162421 · Phase 4 · registry result, not featured evidence
-15.8 vs -15 Standard of Care tender joints @ 104wk
NCT01162421 · Phase 4 · registry result, not featured evidence

+ 193 further endpoints in the CSV export.

etanercept

Time to Flare Median 3.81 vs 0.92 placebo months0.4 mg/kg
time to event · months
NCT03780959 · Phase 2/3 · monotherapy · Rheumatoid Arthritis · phase 2/3 · converted to months from 116 days as posted
Tender Joint 9.55 Joints @ 52wk
event count · Joints
Extension (open-label)
No placebo or comparator arm
NCT00357903 · Phase 3 · monotherapy
show 1 more result
11.6 Joints @ 52wk
NCT00357903 · Phase 3 · monotherapy
Swollen Joint 9.14 Joints @ 52wk
event count · Joints
Extension (open-label)
No placebo or comparator arm
NCT00357903 · Phase 3 · monotherapy
show 1 more result
11.93 Joints @ 52wk
NCT00357903 · Phase 3 · monotherapy
HAQ-DI 0.96 score @ 52wk
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT00357903 · Phase 3 · monotherapy
CHAQ 1.08 score @ 52wk
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT00357903 · Phase 3 · monotherapy
ACR20 66.4% (n=560) @ 12wk
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT00357903 · Phase 3 · monotherapy · converted to % from 372 Participants as posted
JRA DOI 30 86.8% (n=53) @ 12wk
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT00357903 · Phase 3 · monotherapy · converted to % from 46 Participants as posted
DAS28-CRP AUC 300.7 vs 297.4 Standard COBRA-Slim Induction score @ 104wk
absolute value · score
NCT03649061 · Phase 4 · registry result, not featured evidence · combination
EULAR Good 45.5% (n=55) vs 47.3% (n=55) Standard COBRA-Slim Induction @ 28wk
responder rate · % of participants
Good Response
NCT03649061 · Phase 4 · registry result, not featured evidence · combination · converted to % from 25 participants as posted
show 1 more result
61.8% (n=55) vs 76.4% (n=55) Standard COBRA-Slim Induction @ 104wk*
Good Response
NCT03649061 · Phase 4 · registry result, not featured evidence · combination · converted to % from 34 participants as posted
EULAR Moderate 72.7% (n=55) vs 74.5% (n=55) Standard COBRA-Slim Induction @ 28wk
responder rate · % of participants
Moderate Response
NCT03649061 · Phase 4 · registry result, not featured evidence · combination · converted to % from 40 participants as posted
show 1 more result
89.1% (n=55) vs 94.5% (n=55) Standard COBRA-Slim Induction @ 104wk*
Moderate Response
NCT03649061 · Phase 4 · registry result, not featured evidence · combination · converted to % from 49 participants as posted
DAS28-ESR LDAS 100% (n=163) vs 100% (n=168) placebo @ 24wk
responder rate · % of participants
DAS28-ESR Week 24 (N= 163, 168)
NCT01578850 · Phase 4 · registry result, not featured evidence
DAS28-CRP LDAS 87.7% (n=163) vs 85.1% (n=168) placebo @ 24wk
responder rate · % of participants
DAS28-CRP Week 24 (N= 163, 168)
NCT01578850 · Phase 4 · registry result, not featured evidence

+ 195 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab's landscape · etanercept's landscape